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1  Preamble 273 
Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, 274 
with the aim of assisting health professionals in selecting the best management strategies for an individual 275 
patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of 276 
particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to 277 
make decisions in their daily practice. However, the final decisions concerning an individual patient must be 278 
made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate. 279 
A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) 280 
and by the European Association for Cardio-Thoracic Surgery (EACTS), as well as by other societies and 281 
organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have 282 
been established in order to make all decisions transparent to the user. The recommendations for formulating 283 
and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/Guidelines-&-284 
Education/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). ESC Guidelines 285 
represent the official position of the ESC on a given topic and are regularly updated. 286 
Members of this Task Force were selected by the ESC, including representation from the European Heart 287 
Rhythm Association (EHRA), and EACTS as well as by the European Stroke Organisation (ESO) to represent 288 
professionals involved with the medical care of patients with this pathology. Selected experts in the field 289 
undertook a comprehensive review of the published evidence for management (including diagnosis, treatment, 290 
prevention and rehabilitation) of a given condition according to ESC Committee for Practice Guidelines (CPG) 291 
policy and approved by the EACTS and ESO. A critical evaluation of diagnostic and therapeutic procedures was 292 
performed, including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger 293 
populations were included, where data exist. The level of evidence and the strength of the recommendation of 294 
particular management options were weighed and graded according to predefined scales, as outlined in Tables 1 295 
and 2. 296 
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that 297 
might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file 298 
and can be found on the ESC website (http://www.escardio.org/guidelines). Any changes in declarations of 299 
interest that arise during the writing period must be notified to the ESC and EACTS and updated. The Task 300 
Force received its entire financial support from the ESC and EACTS without any involvement from the 301 
healthcare industry. 302 
The ESC CPG supervises and coordinates the preparation of new Guidelines produced by task forces, expert 303 
groups or consensus panels. The Committee is also responsible for the endorsement process of these Guidelines. 304 
The ESC Guidelines undergo extensive review by the CPG and external experts, and in this case by EACTS and 305 
ESO-appointed experts. After appropriate revisions the Guidelines are approved by all the experts involved in 306 
the Task Force. The finalized document is approved by the CPG, EACTS and ESO for publication in the 307 
European Heart Journal, Europace, and in the European Journal of Cardio-Thoracic Surgery as well as in the 308 
International Journal of Stroke (TBC). The Guidelines were developed after careful consideration of the 309 
scientific and medical knowledge and the evidence available at the time of their dating. 310 
The task of developing ESC and EACTS Guidelines covers not only integration of the most recent research, but 311 
also the creation of educational tools and implementation programmes for the recommendations. To implement 312 
the guidelines, condensed pocket guideline versions, summary slides, booklets with essential messages, 313 
summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.) are 314 
produced. These versions are abridged and thus, if needed, one should always refer to the full text version, 315 
which is freely available on the ESC website. The National Societies of the ESC are encouraged to endorse, 316 
translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown 317 
that the outcome of disease may be favourably influenced by the thorough application of clinical 318 
recommendations. 319 
Surveys and registries are needed to verify that real-life daily practice is in keeping with what is recommended 320 
in the guidelines, thus completing the loop between clinical research, writing of guidelines, disseminating them 321 
and implementing them into clinical practice. 322 
Health professionals are encouraged to take the ESC and EACTS Guidelines fully into account when exercising 323 
their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or 324 
therapeutic medical strategies. However, the ESC and EACTS Guidelines do not override in any way 325 
whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in 326 
consideration of each patient’s health condition and in consultation with that patient and the patient’s caregiver 327 
where appropriate and/or necessary. It is also the health professional's responsibility to verify the rules and 328 
regulations applicable to drugs and devices at the time of prescription. 329 
 330 
 331 
 332 
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Table 1 Classes of recommendations 333 
 334 
 335 
Table 2 Levels of evidence 336 
 337 
 338 
 339 
2 Introduction 340 
Despite good progress in the management of patients with atrial fibrillation (AF), this arrhythmia remains one of 341 
the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world. Furthermore, 342 
the number of patients with AF is predicted to rise steeply in the coming years. To meet the growing demand for 343 
effective care of patients with AF, new information is continually generated and published, and the last few 344 
years have seen substantial progress. It therefore seems timely to publish this 2nd edition of the ESC guidelines 345 
on AF.  346 
 347 
Reflecting the multidisciplinary input into the management of patients with AF, the Task Force includes 348 
cardiologists with varying subspecialty expertise, cardiac surgeons, stroke neurologists, and specialist nurses 349 
amongst its members. Supplementing the evidence review as outlined in the preamble, this task force identified 350 
three PICOT questions on relevant topics for the guideline. The ESC commissioned external systematic reviews 351 
to answer these three questions. These reviews informed specific recommendations. 352 
 353 
Further to adhering to the standards for generating recommendations that is common to all ESC guidelines (see 354 
preamble), this task force discussed each draft recommendation during web-based conference calls dedicated to 355 
specific chapters, followed by consensus modifications and an online vote on each recommendation. Only 356 
recommendations that were supported by at least 75% of the task force members were included in the guideline.  357 
 358 
We hope that this guideline will help to deliver good care to all patients with AF based on the current state-of-359 
the-art evidence in 2016.   360 
 361 
3 Epidemiology and impact for patients 362 
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3.1. Incidence and prevalence of atrial fibrillation 363 
In 2010, the estimated numbers of men and women with atrial fibrillation (AF) worldwide were 20.9 million 364 
and 12.6 million, respectively, with higher incidence and prevalence rates in developed countries.1, 2 One in four 365 
middle-aged adults in Europe and the United States (US) will develop AF.3-5 By 2030, 14–17 million AF 366 
patients are anticipated in the European Union, with 120,000–215,000 newly diagnosed patients per year.2, 6, 7 367 
Estimates suggest an AF prevalence of approximately 3% in adults age 20 years or older,8, 9 with more AF in 368 
elderly persons1 and in patients with conditions such as hypertension, heart failure, coronary artery disease 369 
(CAD), valvular heart disease, diabetes mellitus, and chronic kidney disease (CKD).7, 10-15 The increase in AF 370 
prevalence can be attributed to better detection of silent AF16-18 and increasing age and conditions predisposing 371 
to AF.19  372 
 373 
3.2. Morbidity, mortality, and healthcare burden of atrial fibrillation 374 
AF is independently associated with a twofold increased risk of all-cause mortality in women and a 1.5-fold 375 
increase in men20-22 (Table 3). Death due to stroke can largely be mitigated by anticoagulation, while other 376 
cardiovascular deaths, for example due to heart failure and sudden death, remain common even in AF patients 377 
treated according to the current evidence-base.23 AF is also associated with increased morbidity, such as heart 378 
failure and stroke.21, 24, 25 Contemporary studies show that 20–30% of patients with an ischaemic stroke have AF 379 
diagnosed before, during, or after the initial event.17, 26, 27 White matter lesions in the brain, cognitive 380 
impairment,28-30 decreased quality of life,31, 32 and depressed mood33 are common in AF patients, and between 381 
10% and 40% of AF patients are hospitalized each year.23, 34, 35 382 
 The direct costs of AF already amount to approximately 1% of total healthcare spending in the UK, and 383 
between $6.0 and $26.0 billion in the US for 2008,36, 37 driven by AF-related complications (e.g. stroke) and AF-384 
related treatment costs (e.g. hospitalizations). These costs will increase dramatically unless AF is prevented and 385 
treated in a timely and effective manner.  386 
 387 
Table 3 Cardiovascular morbidity and mortality associated with AF 388 
Event Association with AF 
Death Increased mortality, especially cardiovascular mortality due to sudden death, heart 
failure, or stroke 
Stroke 20–30% of all strokes are due to AF. A growing number of patients with stroke are 
diagnosed with ‘silent’, paroxysmal AF 
Hospitalizations 10–40% of AF patients are hospitalized every year 
Quality of life Quality of life is impaired in AF patients independent of other cardiovascular 
conditions 
LV dysfunction and 
heart failure 
LV dysfunction is found in 20–30% of all AF patients. AF causes or aggravates LV 
dysfunction in many AF patients, while others have completely preserved LV 
function despite long-standing AF 
Cognitive decline and 
vascular dementia 
Cognitive decline and vascular dementia increase even in anticoagulated patients. 
Brain white matter lesions are more common in AF patients than in patients without 
AF 
AF = atrial fibrillation; LV = left ventricular. 389 
 390 
3.3. Impact of evidence-based management on outcomes in atrial fibrillation 391 
patients 392 
Figure 1 depicts the major milestones in the management of AF. Despite these advances, substantial morbidity 393 
remains. Oral anticoagulation (OAC) with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants 394 
(NOACs) markedly reduces stroke and mortality in AF patients.38, 39 Other interventions such as rhythm control 395 
and rate control improve AF-related symptoms and may preserve cardiac function, but have not demonstrated a 396 
reduction in long-term morbidity or mortality.40, 41  397 
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 399 
Figure 1 Timeline of major landmarks in AF management, including treatment of concomitant conditions and 400 
prevention (green), anticoagulation (blue), rate and rhythm control (orange and red), and surgical therapy 401 
(purple). 402 
ACEi = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker; 403 
HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LVH = left ventricular hypertrophy; 404 
NOAC = non-vitamin K antagonist oral anticoagulant; PUFA = polyunsaturated fatty acid; PVI = pulmonary 405 
vein isolation; QoL = quality of life; RACE = Rate Control Efficacy in Permanent Atrial Fibrillation; RF = 406 
radiofrequency; SR = sinus rhythm; VKA = vitamin K antagonist. 407 
 408 
In contemporary, well-controlled, randomized clinical trials in AF, the average annual stroke rate is about 1.5% 409 
and the annualized death rate is around 3%.40 In real life, the annual mortality can be different (both higher and 410 
lower).42 A minority of these deaths are related to stroke, while sudden cardiac death and death from progressive 411 
heart failure are more frequent, emphasizing the need for interventions beyond anticoagulation.43, 44 412 
Furthermore, AF is also associated with high rates of hospitalization, commonly for AF management, but often 413 
also for heart failure, myocardial infarction, and treatment-associated bleeding.34, 45  414 
 415 
3.4. Gender 416 
In both developed and developing countries, the age-adjusted incidence and prevalence of AF are lower in 417 
women, while the risk of death in women with AF is similar to or higher than that in men with AF.1, 46, 47 Female 418 
AF patients who have additional stroke risk factors (particularly older age) are also at greater risk than men of 419 
having a stroke,48, 49 even those anticoagulated with warfarin50 (see Chapter 8 for details). Women with 420 
diagnosed AF can be more symptomatic than men and are typically older with more comorbidities.51, 52 421 
Bleeding risk on anticoagulation is similar in both sexes,49, 50, 53 but women appear less likely to receive 422 
specialist care and rhythm control therapy,54 while the outcomes of catheter ablation or AF surgery are 423 
comparable to those in men.55, 56 These observations highlight the need to offer effective diagnostic tools and 424 
therapeutic management equally in women and men. 425 
 426 
Recommendations relating to gender 427 
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Recommendations Class a Level b Refs c 
AF clinicians must offer effective diagnostic tools and therapeutic 
management to women and men equally to prevent stroke and 
death 
I A 39, 46, 57 
Catheter or surgical ablation techniques should be regarded as 
equally effective in women and men 
IIa B 55, 56 
AF = atrial fibrillation 428 
aClass of recommendation. 429 
bLevel of evidence. 430 
cReference(s) supporting recommendations. 431 
 432 
4 Pathophysiological and genetic aspects that guide management 433 
4.1. Genetic predisposition 434 
AF, especially early-onset AF, has a strong heritable component, independent of concomitant cardiovascular 435 
conditions.58, 59 A few young AF patients suffer from inherited cardiomyopathies or channelopathies mediated 436 
by disease-causing mutations. These monogenic diseases also convey a risk for sudden death (see Chapter 5). 437 
Up to one-third of AF patients carry common genetic variants that predispose to AF, albeit with a relatively low 438 
added risk. At least 14 of these common variants, often single nucleotide polymorphisms, are known to increase 439 
the risk of prevalent AF in populations.60-62 The most important variants are located close to the paired-like 440 
homeodomain transcription factor 2 gene on chromosome 4q25.63, 64 These variants modify the risk of AF up to 441 
sevenfold.64 Several of the AF risk variants are also associated with cardioembolic or ischaemic stroke, possibly 442 
due to silent AF (see section 4.1).62, 65, 66 Changes in atrial action potential characteristics,67-70 atrial remodelling, 443 
and modified penetration of rare gene defects61 have been suggested as potential mechanisms mediating 444 
increased AF risk in carriers of common gene variants. Genetic variants could in the future become useful for 445 
patient selection of rhythm control strategies,71-73 but it is currently unknown whether common gene variants 446 
differentially affect the efficacy of antiarrhythmic drugs or rate control medication.74 While genomic analysis 447 
may provide an opportunity to improve diagnosis and management of AF in the future,75, 76 routine genetic 448 
testing for common gene variants associated with AF cannot be recommended at present.77  449 
 450 
4.2. Mechanisms leading to atrial fibrillation 451 
4.2.1. Remodelling of atrial structure and ion channel function  452 
External stressors such as structural heart disease, hypertension, possibly diabetes, but also AF itself induce a 453 
slow but progressive process of structural remodelling in the atria (Figure 2). Activation of fibroblasts, 454 
enhanced connective tissue deposition, and fibrosis are the hallmarks of this process.78-80 In addition, atrial fatty 455 
infiltration, inflammatory infiltrates, myocyte hypertrophy, necrosis, and amyloidosis are found in AF patients 456 
with concomitant conditions predisposing to AF.81-84 Structural remodelling results in electrical dissociation 457 
between muscle bundles and local conduction heterogeneities,85 favouring reentry and perpetuation of the 458 
arrhythmia.86 In many patients, the structural remodelling process occurs before the onset of AF.78 As some of 459 
the structural remodelling will be irreversible, early initiation of treatment seems desirable.87 Table 4 gives an 460 
overview of the most relevant pathophysiological alterations in atrial tissue associated with AF, and lists 461 
corresponding clinical conditions that can contribute to these changes. 462 
 The functional and structural changes in atrial myocardium and stasis of blood, especially in the left 463 
atrial appendage (LAA), generate a prothrombotic milieu. Furthermore, even short episodes of AF lead to 464 
myocardial damage and expression of prothrombotic factors on the atrial endothelial surface, and activation of 465 
platelets and inflammatory cells, and contribute to a generalized prothrombotic state.88, 89 The atrial and 466 
systemic activation of the coagulation system can partially explain why short episodes of AF convey a long-467 
term stroke risk. 468 
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Figure 2 Major mechanisms causing AF that can be considered when guiding therapy. The various aetiological 471 
factors (left) cause a complex array of pathophysiological changes in the atria, including stretch-induced atrial 472 
fibrosis, hypocontractility, fatty infiltration, inflammation, vascular remodelling, ischaemia, ion channel 473 
dysfunction, and Ca2+-instability. These changes enhance both ectopy and conduction disturbances, increasing 474 
the propensity of the atria to develop or maintain AF. At the same time, some of these alterations are involved in 475 
the occurrence of the hypercoagulable state associated with AF. For example, hypocontractility reduces local 476 
endothelial shear stress, which increases PAI-1 expression, and ischaemia-induced inflammation enhances the 477 
expression of endothelial adhesion molecules or promotes shedding of endothelial cells, resulting in tissue factor 478 
exposure to the blood stream. These changes contribute to the thrombogenic milieu in the atria of AF patients. 479 
AF in itself can aggravate many of the mechanisms shown, which may explain the progressive nature of the 480 
arrhythmia.  481 
AngII = angiotensin II; TF = tissue factor; FXII = factor XII; IL-6 = interleukin 6; PAI-1 = plasminogen 482 
activator inhibitor 1; VCAM-1 = vascular cell adhesion molecule 1. 483 
 484 
Table 4 Pathophysiological alterations in atrial tissue associated with AF and clinical conditions that 485 
could contribute to such alterations 486 
 487 
Pathophysiological 
alteration 
Clinical conditions contributing 
to the alteration 
Proarrhythmic mechanism/ 
functional consequence References 
 
Changes of the extracellular matrix, fibroblast function, and fat cells 
Interstitial and 
replacement fibrosis 
AF (especially forms with a high 
AF burden), hypertension, heart 
failure, valvular heart disease (via 
pressure and volume overload) 
Electrical dissociation, 
conduction block, enhanced AF 
complexity 
78, 79, 90, 91 
Inflammatory 
infiltration 
 Profibrotic responses, enhanced 
AF complexity 
81 
Fatty infiltration Obesity (fatty infiltration) Profibrotic/proinflammatory 
responses, localized conduction 
82, 92 
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block 
Amyloid deposition Ageing, heart failure, CAD (via 
atrial scarring), genetic factors 
Conduction disturbances 83, 93 
 
Ion channel alterations  
Ion channel 
remodelling 
AF (especially forms with a high 
AF burden), genetic 
predisposition to AF 
AF cycle shortening (if due to 
atrial tachycardia), AF cycle 
length prolongation (if due to 
heart failure), enhanced 
heterogeneity of atrial 
repolarization 
94-96 
Ca2+ handling 
instability 
AF (especially forms with a high 
AF burden), possibly heart failure 
and hypertension (possibly 
through increased sympathetic 
activation) 
Enhanced propensity to ectopy 97, 98 
Gap-junction 
redistribution 
AF Conduction disturbances 99 
 
Myocyte alterations 
Apoptosis and 
necrosis 
CAD, heart failure (through 
cardiomyocyte death and atrial 
scarring) 
May induce replacement 
fibrosis 
100 
Myocyte hypertrophy Atrial dilatation, AF Aggravates conduction 
disturbances 
84, 101 
 
Endothelial and vascular alterations 
Microvascular 
changes 
Atherosclerosis, CAD and 
peripheral artery disease, possibly 
AF 
Aggravation of atrial ischaemia, 
heterogeneity of electrical 
function, structural remodelling 
102 
Endocardial 
remodelling 
 Enhanced risk for thrombus 
formation 
103, 104 
 
Changes of the autonomic nervous system 
Sympathetic 
hyperinnervation 
Heart failure, hypertension Enhanced propensity to ectopy 80, 105 
AF = atrial fibrillation; CAD = coronary artery disease. 488 
 489 
3.2.1. Electrophysiological mechanisms of atrial fibrillation 490 
AF provokes a shortening of the atrial refractory period and AF cycle length during the first days of the 491 
arrhythmia, largely due to downregulation of the Ca2+-inward current and upregulation of inward rectifier K+ 492 
currents.94, 95 Structural heart disease, in contrast, tends to prolong the atrial refractory period, illustrating the 493 
heterogeneous nature of mechanisms that cause AF in different patients.96 Hyperphosphorylation of various 494 
Ca2+ handling proteins may contribute to enhanced spontaneous Ca2+ release events and triggered activity,97, 98 495 
thus causing ectopy and promoting AF. Although the concept of Ca2+ handling instability has been challenged 496 
recently,106, 107 it may mediate AF in structurally remodelled atria and explain how altered autonomic tone can 497 
generate AF.80, 105  498 
 499 
Focal initiation and maintenance of AF: The seminal observation by Haissaguerre et al108 was that a focal 500 
source in the pulmonary veins can trigger AF, and ablation of this source can extinguish the arrhythmia. The 501 
mechanism of focal activity might involve both triggered activity and localized reentry.109, 110 Hierarchic 502 
organization of AF with rapidly activated areas driving the arrhythmia has been documented in patients with 503 
paroxysmal AF,111, 112 but is more challenging in patients with persistent AF.113  504 
 505 
The multiple wavelet hypothesis and rotors as sources of AF: Moe and Abildskov114 proposed that AF can be 506 
perpetuated by continuous conduction of several independent wavelets propagating through the atrial 507 
musculature in a seemingly chaotic manner. As long as the number of wavefronts does not decline below a 508 
critical level, they will be capable of sustaining the arrhythmia. Numerous experimental and clinical 509 
observations can be reconciled with the multiple wavelet hypothesis.115 All localized sources of AF (ectopic 510 
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foci, rotors, or other stable reentry circuits) cause fibrillatory conduction remote from the source, which is 511 
difficult to distinguish from propagation sustaining AF by multiple wavelets, and either of these phenomena 512 
may generate ‘rotors’ picked up by intracardiac116, 117 or body surface117 recordings. 513 
 514 
 515 
5 Diagnosis and timely detection of atrial fibrillation 516 
5.1. Overt and silent atrial fibrillation 517 
The diagnosis of AF requires rhythm documentation using an electrocardiogram (ECG), with the typical pattern 518 
of AF. ECG-documented AF was the entry criterion in trials forming the evidence for these guidelines. By 519 
accepted convention, an episode lasting at least 30 seconds is diagnostic. Individuals with AF may be 520 
symptomatic or asymptomatic (‘silent AF’). Many AF patients have both symptomatic and asymptomatic 521 
episodes of AF.118-121  522 
 Silent, undetected AF is common,120, 122 with severe consequences such as stroke and death.123-125 523 
Prompt recording of an ECG is an effective and cost-effective method to document chronic forms of AF.126 The 524 
technology to detect paroxysmal, self-terminating AF episodes is rapidly evolving (see Chapter 5 for a 525 
definition of AF patterns). There is good evidence that prolonged ECG monitoring enhances the detection of 526 
undiagnosed AF, for 72 hours after a stroke,27, 127 for even longer periods,18, 128 or by daily short-term ECG 527 
recording in patients over 75 years of age129 (Web Addenda Figure 1). Ongoing studies will determine whether 528 
such early detection alters management (e.g. initiation of anticoagulation) and improves outcomes.  529 
 Once the ECG diagnosis of AF has been established, further ECG monitoring can inform management 530 
in the context of: (1) a change in symptoms or new symptoms; (2) suspected progression of AF; (3) monitoring 531 
of drug effects on ventricular rate; and (4) ECG monitoring of antiarrhythmic drug effects or catheter ablation 532 
for rhythm control. 533 
 534 
5.2. Screening for silent atrial fibrillation 535 
5.2.1. Screening for atrial fibrillation by electrocardiogram in the community 536 
Undiagnosed AF is common, especially in older populations and in patients with heart failure.130 Opportunistic 537 
screening for silent AF seems cost-effective in elderly populations (e.g. > 65 years),131 and similar effects have 538 
been reported using single-lead ECG screening in other at-risk populations.132, 133 Screening of elderly 539 
populations (mean age 64 years) yielded a prevalence of 2.3% for chronic forms of AF in 122,571 participants 540 
using either short-term ECG or pulse palpation (followed by ECG in those with an irregular pulse).134 541 
Previously undiagnosed AF was found in 1.4% of those aged > 65 years, suggesting a number needed to screen 542 
of 70. These findings encourage the further evaluation of systematic AF screening programmes in at-risk 543 
populations. 544 
 545 
5.2.2. Prolonged monitoring for paroxysmal atrial fibrillation 546 
Paroxysmal AF is often missed.120 Repeated daily ECG recordings increased the detection of silent, 547 
asymptomatic paroxysmal AF in an unselected Swedish population aged > 75 years.120, 135 Several patient-548 
operated devices136, 137 and extended continuous ECG monitoring using skin patch recorders138 have been 549 
validated for detection of paroxysmal AF.139 The detection rate of asymptomatic AF by new technologies such 550 
as smartphone cases with ECG electrodes, smart watches, and blood pressure machines with AF detection 551 
algorithms, has not yet been formally evaluated against an established arrhythmia detection method.140  552 
 553 
5.2.3. Patients with pacemakers and implanted devices 554 
Implanted pacemakers or defibrillators with an atrial lead allow continuous monitoring of atrial rhythm. Using 555 
this technology, patients with atrial high rate episodes (AHRE) can be identified. Depending on the risk profile 556 
of the population studied, such AHRE are detected in 10–15% of pacemaker patients.141 AHRE are associated 557 
with an increased risk of overt AF (hazard ratio [HR] 5.56; 95% confidence interval [CI] 3.78–8.17; P < 0.001) 558 
and ischaemic stroke or systemic embolism (HR 2.49; 95% CI 1.28–4.85; P = 0.007). The stroke risk in AHRE 559 
patients seems lower than the stroke risk in patients with diagnosed AF, and not all AHRE represent AF.142 560 
Strokes often occur without AHRE detected within 30 days before the event.143-147 Consequently, it is unclear 561 
whether AHRE imply the same therapeutic requirements as overt AF,148 and the benefit of OAC in patients with 562 
AHRE is being evaluation in ongoing clinical trials (e.g. ARTESiA [NCT01938248] and NOAH 563 
[NCT02618577]). At present, pacemakers and implanted devices should be interrogated on a regular basis for 564 
AHRE, and patients with AHRE should undergo further assessment of stroke risk factors and for overt AF, 565 
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including ECG monitoring (Figure 3).149566 
 567 
Figure 3 Management of AHRE detected on an implanted device. Adapted from the report of the 3rd 568 
AFNET/EHRA consensus conference.150 569 
AF = atrial fibrillation; AFNET = German Competence NETwork on Atrial Fibrillation; AHRE = atrial high 570 
rate episodes; bpm = beats per minute; CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 571 
(doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); ECG = 572 
electrocardiogram; EHRA = European Heart Rhythm Association. 573 
 574 
5.2.4. Detection of atrial fibrillation in stroke survivors 575 
Sequential stratified ECG monitoring detected AF in 24% (95% CI 17–31) of stroke survivors,151 and in 11.5% 576 
(95% CI 8.9%–14.3%) in another meta-analysis,17 with large variations depending on the timing, duration, and 577 
method of monitoring. AF detection is not uncommon in unselected stroke patients (6.2%, 95% CI 4.4–8.3),128 578 
but is more likely in patients with cryptogenic stroke implanted with loop recorders or who have had ECG 579 
monitors for several weeks.18, 128, 152 Cryptogenic stroke is defined as a stroke in which the cause could not be 580 
identified after extensive investigations.153 A broader definition is embolic stroke of undetermined source.154 581 
Several studies have also found AF in patients in whom another competing cause for stroke has been identified 582 
clinically (e.g. hypertension or carotid artery stenosis).27, 127 Hence, prolonged ECG monitoring seems 583 
reasonable in all survivors of an ischaemic stroke without an established diagnosis of AF. 584 
 585 
Recommendations for screening for AF  586 
Recommendations Class a Level b Refs c 
Opportunistic screening for AF is recommended by pulse taking 
or ECG rhythm strip in patients > 65 years of age 
I B 130, 134, 155 
In patients with TIA or ischaemic stroke, screening for AF is 
recommended by short-term ECG recording followed by 
continuous ECG monitoring for at least 72 hours 
I B 27, 127  
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It is recommended to interrogate pacemakers and ICDs on a 
regular basis for atrial high rate episodes (AHRE). Patients with 
AHRE should undergo further ECG monitoring to document AF 
before initiating AF therapy 
I B 141, 156 
In stroke patients, additional ECG monitoring by long-term non-
invasive ECG monitors or implanted loop recorders should be 
considered to document silent AF 
IIa B 18, 128 
Systematic ECG screening may be considered to detect AF in 
patients aged > 75 years, or those at high stroke risk 
IIb B 130, 135, 157 
AF = atrial fibrillation; AHRE = atrial high rate episodes; ECG = electrocardiogram; ICD = implantable 587 
cardioverter defibrillator; TIA = transient ischaemic attack. 588 
aClass of recommendation. 589 
bLevel of evidence. 590 
cReference(s) supporting recommendations. 591 
 592 
5.3. Electrocardiogram detection of atrial flutter 593 
Right atrial isthmus-dependent flutter has a typical ECG pattern and ventricular rate.158 The prevalence of atrial 594 
flutter is less than one-tenth of the prevalence of AF.159 Atrial flutter often coexists with or precedes AF.160 In 595 
typical, isthmus-dependent flutter, P waves will often show a ‘saw tooth’ morphology, especially in the inferior 596 
leads (II, III, aVF). The ventricular rate can be variable (usual ratio of atrial to ventricular contraction 4:1 to 2:1, 597 
in rare cases 1:1) and macro-reentrant tachycardias may be missed in stable 2:1 conduction. Vagal stimulation 598 
or intravenous adenosine may be helpful to unmask atrial flutter. The management of atrial flutter is discussed 599 
in Section 12.7. Left or right atrial macro-reentrant tachycardia is usually confined to patients after catheter 600 
ablation for AF, AF surgery, or after open heart surgery.158  601 
 602 
6 Classification of atrial fibrillation 603 
6.1. Atrial fibrillation pattern 604 
In many patients, AF progresses from short, infrequent episodes to longer and more frequent attacks. Over time, 605 
many patients will develop sustained forms of AF. In a small proportion of patients, AF will remain paroxysmal 606 
over several decades (2–3% of AF patients).161 The distribution of paroxysmal AF recurrences is not random, 607 
but clustered.162 AF may also regress from persistent to paroxysmal AF. Furthermore, asymptomatic recurrences 608 
of AF are common in patients with symptomatic AF.120  609 
 610 
 Based on presentation, duration, and spontaneous termination of AF episodes, five types of AF are 611 
traditionally distinguished: first diagnosed, paroxysmal, persistent, long-standing persistent, and permanent AF 612 
(Table 5). If patients suffer from both paroxysmal and persistent AF episodes, the more common type should be 613 
used for classification. Clinically determined AF patterns do not correspond well to the AF burden measured by 614 
long-term ECG monitoring.163 Even less is known about the response to therapy in patients with long-standing 615 
persistent AF or long-standing paroxysmal AF. Despite these inaccuracies, the distinction between paroxysmal 616 
and persistent AF has been used in many trials and therefore still forms the basis of some recommendations.  617 
 There is some evidence suggesting that AF burden may influence stroke risk44, 124, 164 and could modify 618 
the response to rhythm control therapy.76, 165 The evidence for this is weak. Therefore, AF burden should not be 619 
a major factor in deciding on the usefulness of an intervention that is deemed suitable for other reasons.  620 
 621 
Table 5 Patterns of AF  622 
AF pattern Definition 
First diagnosed AF AF that has not been diagnosed before, irrespective of the duration of 
the arrhythmia or the presence and severity of AF-related symptoms. 
Paroxysmal AF Self-terminating, in most cases within 48 hours. Some AF paroxysms 
may continue for up to 7 days.a Most AF episodes that are cardioverted 
within 24-48 hours should be considered paroxysmal.a 
Persistent AF AF that lasts longer than 7 days, including episodes that are terminated 
by cardioversion, either with drugs or by direct current cardioversion, 
after 7 days or more.  
Long-standing persistent 
AF 
Continuous AF lasting for ≥ 1 year when it is decided to adopt a rhythm 
control strategy. 
Permanent AF AF is accepted by the patient (and physician). Hence, rhythm control 
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interventions are, by definition, not pursued in patients with permanent 
AF. Should a rhythm control strategy be adopted, the arrhythmia would 
be re-classified as ‘long-standing persistent AF’. 
AF = atrial fibrillation. 623 
aThe distinction between paroxysmal and persistent AF is often not made correctly without access to long-term 624 
monitoring.163 Hence, this classification alone is often insufficient to select specific therapies. If both persistent 625 
and paroxysmal episodes are present, the predominant pattern should guide the classification. 626 
 627 
6.2. Atrial fibrillation types reflecting different causes of the arrhythmia  628 
The risk of developing AF is increased in a variety of physiological and disease states, and the historic term 629 
‘lone AF’ is probably misleading and should be avoided.166 Although the pattern of AF may be the same, the 630 
mechanisms underpinning AF vary substantially between patients167 (Table 6). This suggests that stratifying AF 631 
patients by underlying drivers of AF could inform management, for example, considering cardiac and systemic 632 
comorbidity (e.g. diabetes and obesity168), lifestyle factors (e.g. activity level, smoking, alcohol intake169, 170), 633 
markers of cardiac structural remodelling (e.g. fibrosis171-173 or electrocardiographic parameters of AF 634 
complexity174), or genetic background. Table 6 provides such a taxonomy, informed by expert consensus,76, 120, 635 
175 but without much evidence to underpin its clinical use.176 Systematic research defining the major drivers of 636 
AF is clearly needed to better define different types of AF.176 637 
 638 
Table 6 Clinical types of AF (modified from the report on the 4th AFNET/EHRA consensus conference76)a 639 
AF type Clinical presentation Possible pathophysiology 
AF secondary 
to structural 
heart disease 
AF in patients with LV systolic or diastolic 
dysfunction, long-standing hypertension with 
LVH, and/or other structural heart diseases. 
The onset of AF in these patients is a common 
cause of hospitalization and a predictor of poor 
outcome 
Increased atrial pressure and atrial 
structural remodelling, together with 
activation of the sympathetic and renin–
angiotensin system 
Focal AF Patients with repetitive atrial runs and frequent, 
short episodes of paroxysmal AF. Often highly 
symptomatic, younger patients with 
distinguishable atrial waves (coarse AF), atrial 
ectopy, and/or atrial tachycardia deteriorating 
in AF 
Localized triggers, in most cases 
originating from the pulmonary veins, 
initiate AF. AF due to one or a few 
reentrant drivers is also considered to be 
part of this type of AF 
Polygenic AF AF in carriers of common gene variants that 
have been associated with early onset AF 
Currently under study. The presence of 
some gene variants may also influence 
treatment outcomes 
Postoperative 
AF 
New onset of AF (usually self-terminating) 
after major (typically cardiac) surgery in 
patients who were in sinus rhythm before 
surgery and had no history of AF 
Acute factors: inflammation, atrial 
oxidative stress, high sympathetic tone, 
electrolyte changes, and volume overload, 
possibly interacting with a pre-existing 
substrate 
AF in patients 
with mitral 
stenosis or 
prosthetic 
heart valves  
AF in patients with mitral stenosis, after mitral 
valve surgery and in some cases other valvular 
disease 
Left atrial pressure (stenosis) and volume 
(regurgitation) load are the main drivers of 
atrial enlargement and structural atrial 
remodelling in these patients 
AF in athletes Usually paroxysmal, related to duration and 
intensity of training 
Increased vagal tone and atrial volume 
Monogenic AF AF in patients with inherited cardiomyopathies, 
including channelopathies 
The arrhythmogenic mechanisms 
responsible for sudden death are likely to 
contribute to the occurrence of AF in these 
patients 
AF = atrial fibrillation; LV = left ventricular; LVH = left ventricular hypertrophy. 640 
aIt is recognized that these types of AF will overlap in clinical practice, and that their impact for management 641 
needs to be evaluated systematically. 642 
 643 
6.3. Symptom burden in atrial fibrillation 644 
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Patients with AF have significantly poorer quality of life than healthy controls, experiencing a variety of 645 
symptoms including lethargy, palpitations, dyspnoea, chest tightness, sleeping difficulties, and psychosocial 646 
distress.32, 177-180 Improved quality of life has been noted with both pharmacological and interventional 647 
therapies,181-185 but there are limited data to compare the benefit of different treatments.32, 186 Assessment of 648 
quality of life is further constrained by a lack of cross-validation of the several AF-specific quality-of-life 649 
tools.187-191 With regard to symptom assessment, the European Heart Rhythm Association (EHRA) suggested 650 
the EHRA symptom scale (Table 7) to describe symptom severity in AF patients.192 A similar scale (the 651 
Canadian Cardiovascular Society Severity of Atrial Fibrillation Scale) is used in Canada.193 The EHRA scale 652 
has been used and validated.194-199 A modification was proposed in 2014, subdividing EHRA class 2 into mild 653 
(2a) or moderate (2b) impact.199 As symptoms in class 2b (‘troubling’ symptoms) identified patients with a 654 
health utility benefit of rhythm control in that study, this modification may provide a threshold for potential 655 
treatment decisions, but this remains to be tested. While some AF patients had no or minimal symptoms (25–656 
40%), many (15–30%) reported severe or disabling symptoms.194, 196 The EHRA scale should be used to guide 657 
symptom-orientated treatment decisions and for longitudinal patient profiling.  658 
  659 
Table 7 Modified EHRA symptom scale (modified from Wynn et al199) 660 
Modified EHRA 
score 
Symptoms Description 
1 None AF does not cause any symptoms 
2a Mild Normal daily activity not affected by symptoms related to AFa 
2b Moderate Normal daily activity not affecteda 
3 Severe Normal daily activity affected 
4 Disabling Normal daily activity discontinued 
AF = atrial fibrillation; EHRA = European Heart Rhythm Association. 661 
aEHRA class 2a and 2b can be differentiated by evaluating whether patients are functionally affected by their 662 
AF symptoms. AF-related symptoms are most commonly fatigue/tiredness and exertional shortness of breath, or 663 
less frequently palpitations and chest pain.42, 194, 200-202   664 
 665 
Recommendation on use of the modified EHRA symptom scale 666 
Recommendation Class a Level b Refs c 
Use of the modified EHRA symptom scale is recommended in 
clinical practice and research studies to quantify AF-related 
symptoms 
I C 192, 199 
AF = atrial fibrillation; EHRA = European Heart Rhythm Association.  667 
aClass of recommendation. 668 
bLevel of evidence. 669 
cReference(s) supporting recommendations. 670 
 671 
7 Detection and management of risk factors and concomitant 672 
cardiovascular diseases 673 
Many cardiovascular diseases and concomitant conditions increase the risk of developing AF (Table 8), 674 
recurrent AF, and AF-associated complications. Identification of such conditions, their prevention and treatment 675 
is an important leverage to prevent AF and its disease burden. Knowledge of these factors and their management 676 
is hence important for optimal management of AF patients.203, 204  677 
 678 
Table 8 Cardiovascular and other conditions independently associated with AF  679 
Characteristic/comorbidity Association with AF 
Genetic predisposition (based on multiple common gene 
variants associated with AF)64 
HR range 0.4–3.2 
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Older age19 
50–59 years 
60–69 years 
70–79 years 
80–89 years 
HR: 
1.00 (reference) 
4.98 (95% CI 3.49–7.10) 
7.35 (95% CI 5.28–10.2) 
9.33 (95% CI 6.68–13.0) 
Hypertension (treated) vs. none19 HR 1.32 (95% CI 1.08–1.60)  
Heart failure vs. none19 HR 1.43 (95% CI 0.85–2.40)  
Valvular heart disease vs. none205 RR 2.42 (95% CI 1.62–3.60) 
Myocardial infarction vs. none19 HR 1.46 (95% CI 1.07–1.98) 
Thyroid dysfunction206, 207 
hypothyroidism 
subclinical hyperthyroidism  
overt hyperthyroidism 
(reference: euthyroid) 
HR 1.23 (95% CI 0.77-1.97) 
RR 1.31 (95% CI 1.19–1.44) 
RR 1.42 (95% CI 1.22–1.63) 
Obesity19, 208 
none (BMI < 25 kg/m²) 
overweight (BMI 25–30 kg/m²) 
obese (BMI ≥ 31 kg/m²) 
HR: 
1.00 (reference) 
1.13 (95% CI 0.87–1.46) 
1.37 (95% CI 1.05–1.78) 
Diabetes mellitus vs. none19 HR 1.25 (95% CI 0.98–1.60)  
Chronic obstructive pulmonary disease209 
FEV1  
≥ 80% 
60–80% 
< 60% 
RR:  
 
1.00 (reference) 
1.28 (95% CI 0.79–2.06) 
2.53 (95% CI 1.45–4.42) 
Obstructive sleep apnoea vs. none210 HR 2.18 (95% CI 1.34–3.54) 
Chronic kidney disease211 
none 
stage 1 or 2  
stage 3  
stage 4 or 5 
OR: 
1.00 (reference) 
2.67 (95% CI 2.04–3.48) 
1.68 (95% CI 1.26–2.24)  
3.52 (95% CI 1.73–7.15) 
Smoking212 
never 
former 
current 
HR: 
1.00 (reference) 
1.32 (95% CI 1.10–1.57)  
2.05 (95% CI 1.71–2.47) 
Alcohol consumption213 
None 
1–6 drinks/week 
7–14 drinks/week 
15–21 drinks/week 
> 21 drinks/week 
RR: 
1.00 (reference) 
1.01 (95% CI 0.94–1.09)  
1.07 (95% CI 0.98–1.17) 
1.14 (95% CI 1.01–1.28)  
1.39 (95% CI 1.22–1.58)  
Habitual vigorous exercise214 
Non-exercisers 
< 1 day/week 
1−2 days/week 
3−4 days/week 
5−7 days/week 
RR: 
1.00 (reference) 
0.90 (95% CI 0.68−1.20) 
1.09 (95% CI 0.95−1.26) 
1.04 (95% CI 0.91−1.19) 
1.20 (95% CI 1.02−1.41) 
AF = atrial fibrillation; BMI = body mass index; CI = confidence interval; FEV1 = forced expiratory volume in 680 
1 second; HR = hazard ratio; OR = odds ratio; RR = risk ratio 681 
 682 
7.1. Heart failure 683 
Heart failure and AF coincide in many patients.215-217 They are linked by similar risk factors and share a 684 
common pathophysiology.218 Heart failure and AF can cause and exacerbate each other through mechanisms 685 
such as structural cardiac remodelling, activation of neurohormonal mechanisms, and rate-related impairment of 686 
left ventricular (LV) function. Patients with AF and concomitant heart failure, both with preserved ejection 687 
fraction (LV ejection fraction [LVEF] ≥ 50%) and reduced ejection fraction (LVEF < 40%),219, 220 suffer from a 688 
worse prognosis, including increased mortality.16, 221 The recent ESC Guidelines on heart failure222 have also 689 
introduced a new category of heart failure with mid-range ejection fraction (HFmrEF; LVEF 40–49%), although 690 
data on AF patients in this group are currently limited. Prevention of adverse outcomes and maintenance of a 691 
good quality of life are the aims of management in all patients with AF and concomitant heart failure, regardless 692 
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of LVEF.223 The general approach to AF management does not differ between heart failure patients and others, 693 
but a few considerations are worthwhile to consider. Of note, the only therapy with proven prognostic value in 694 
these patients is anticoagulation, and appropriate OAC should be prescribed in all patients at risk of stroke (see 695 
Chapter 8).  696 
 697 
7.1.1. Patients with atrial fibrillation and heart failure with reduced ejection 698 
fraction 699 
In addition to OAC, standard heart-failure therapy should be used in patients with heart failure with reduced 700 
ejection fraction (HFrEF), as detailed in the ESC Guidelines.222 This includes angiotensin-converting enzyme 701 
(ACE) inhibitors or angiotensin receptor blockers (ARBs), mineralocorticoid antagonists, defibrillators and 702 
cardiac resynchronization therapy,218 in addition to combined angiotensin receptor neprilysin inhibition (ARNI) 703 
in patients able to tolerate an ACE inhibitor or ARB with ongoing symptoms.224  704 
 Rate control of AF is discussed in detail in Chapter 9. In brief, only beta-blockers and digoxin are 705 
suitable in HFrEF because of the negative inotropic potential of verapamil and diltiazem. Beta-blockers are 706 
usually the first-line option in patients with clinically stable HFrEF, although a meta-analysis using individual 707 
patient data from randomized controlled trials (RCTs) found no reduction in mortality from beta-blockers versus 708 
placebo in those with AF at baseline (HR 0.97, 95% CI 0.83–1.14).23 Digoxin is commonly prescribed in 709 
clinical practice but no head-to-head RCTs in AF patients have been performed. In a meta-analysis of 710 
observational studies, digoxin had a neutral effect on mortality in patients with AF and concomitant heart failure 711 
(adjusted observational studies HR 0.90, 95% CI 0.70–1.16; propensity-matched observational studies RR 1.08, 712 
95% CI 0.93–1.26).225 Initial and combination rate-control therapy for AF in HFrEF should therefore take 713 
account of individual patient characteristics and symptoms; beta-blocker initiation should be delayed in patients 714 
with acute decompensated heart failure, and digoxin has more adverse effects in patients with renal impairment 715 
(see Chapter 9).  716 
 Patients with AF and HFrEF who present with severe symptoms may require rhythm control therapy in 717 
addition to rate control therapy. For patients who develop HFrEF as a result of rapid AF (tachycardiomyopathy), 718 
a rhythm control strategy is preferred, based on several relatively small patient cohorts and trials reporting 719 
improved LV function after restoration of sinus rhythm.185, 226-228 The diagnosis of tachycardiomyopathy can be 720 
challenging, and at times requires restoration of sinus rhythm.229 Catheter ablation may be a useful method to 721 
restore LV function and quality of life in AF patients with HFrEF,185, 226-228 but further data are needed. Figure 4 722 
summarizes the approach to patients with AF and heart failure.  723 
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 724 
Figure 4 Initial management of newly diagnosed with AF and heart failure. Adapted from Kotecha and 725 
Piccini.218 726 
ACE = angiotensin-converting enzyme; AF = atrial fibrillation; ARB = angiotensin receptor blocker; ARNI = 727 
angiotensin receptor neprilysin inhibition; bpm = beats per minute; HF = heart failure. 728 
aIn patients with heart failure and reduced ejection fraction; also consider combined ARNI in patients able to 729 
tolerate an ACE inhibitor or ARB with ongoing symptoms.  730 
 731 
7.1.2. Atrial fibrillation patients with heart failure with preserved ejection fraction  732 
The diagnosis of heart failure with preserved ejection fraction (HFpEF) in patients with AF is problematic 733 
because of the difficulty in separating symptoms that are due to HF from those due to AF. Although diagnostic 734 
differentiation can be achieved by cardioversion and clinical reassessment, this option is often not appropriate in 735 
this group, particularly as a specific therapy that improves prognosis in HFpEF is currently lacking. 736 
Echocardiography can support detection of HFpEF in patients with symptomatic AF by providing evidence of 737 
relevant structural heart disease (e.g. LV hypertrophy [LVH]) and/or measurement of diastolic dysfunction. 738 
Reduced early diastolic myocardial velocity e’ by tissue Doppler reflects impaired LV relaxation, while the ratio 739 
of E/e’ has demonstrated a significant correlation with invasive measurement of LV filling pressures.230-234 740 
Natriuretic peptide levels are part of the diagnostic assessment of HFpEF,222 although natriuretic peptide levels 741 
are elevated in AF patients and the optimum diagnostic cut-off is still unknown.235 The management of patients 742 
with AF and concomitant HFpEF should focus on control of fluid balance and concomitant conditions such as 743 
hypertension and ischaemia.  744 
 745 
7.1.3. Atrial fibrillation patients with heart failure with mid-range ejection 746 
fraction 747 
HFmrEF is a recently defined entity, describing patients with symptoms and signs of heart failure, LVEF 40–748 
49%, elevated levels of natriuretic peptides, and either LV hypertrophy, left atrial (LA) enlargement, or 749 
evidence of diastolic dysfunction.222 However, diagnosis is more difficult in patients with AF, as natriuretic 750 
peptides are elevated in AF and LA dilatation is common, regardless of concomitant heart failure. LVEF is also 751 
variable and difficult to assess in AF patients because of AF-induced reduction in systolic LV function and 752 
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variable cardiac cycle length. Further study of this group is required before particular treatment strategies in AF 753 
patients with HFmrEF can be recommended. 754 
 755 
7.1.4. Prevention of atrial fibrillation in heart failure 756 
Retrospective analyses from large randomized trials have reported a lower incidence of new-onset AF in 757 
patients treated with ACE inhibitors/ARBs compared with placebo.236-238 The reduced incidence of AF with 758 
ACE inhibitors/ARBs is less evident in patients with HFpEF239 and is lost in patients without heart failure.240-242 759 
Neprilysin inhibition does not seem to add to this effect.224 Beta-blocker therapy was associated with a 33% 760 
reduction in the adjusted odds of incident AF in HFrEF patients pretreated with ACE inhibitors/ARBs, 761 
reinforcing the importance of beta-blocker therapy in HFrEF patients in sinus rhythm.23 Eplerenone, a 762 
mineralocorticoid receptor antagonist, also reduced the risk of new-onset AF in patients with LVEF ≤ 35%, 763 
New York Heart Association (NYHA) Class II, and pretreatment with ACE inhibitors/ARBs and beta-764 
blockers.243 765 
 766 
7.2. Hypertension 767 
7.2.1. Treatment of hypertension to prevent incident atrial fibrillation 768 
Inhibition of the renin–angiotensin–aldosterone system can prevent structural remodelling and recurrent AF.236, 769 
244 A recent analysis of the Danish healthcare database with long-term monitoring of the effect of different 770 
antihypertensive agents on the occurrence of overt AF suggests a beneficial effect of ACE inhibitors or 771 
ARBs.245 Secondary analyses of ACE inhibitors or ARBs in patients with heart failure or LVH show a lower 772 
incidence of new-onset AF.238, 246  773 
 774 
7.2.2. Blood pressure control in patients with atrial fibrillation 775 
Hypertension is a stroke risk factor in AF, and uncontrolled high blood pressure enhances the risk of stroke and 776 
bleeding events and may lead to recurrent AF. Good blood-pressure control should therefore form an integral 777 
part of the management of AF patients.247 In patients with established AF, but without LV dysfunction or heart 778 
failure, ARBs do not prevent recurrent AF better than placebo.240, 241 ACE inhibitors or ARBs may reduce 779 
recurrent AF after cardioversion when coadministered with antiarrhythmic drug therapy compared with an 780 
antiarrhythmic drug alone.248, 249 Meta-analyses driven by these studies suggested a lower risk of recurrent 781 
AF,236-238, 250 but at least one controlled trial failed to demonstrate benefit.240, 251  782 
 783 
7.3. Valvular heart disease 784 
Valvular heart disease is independently associated with incident AF.252 Approximately 30% of patients with AF 785 
have some form of valvular heart disease, often detected only by echocardiography.201, 253-255 AF worsens 786 
prognosis in patients with severe valvular heart disease,256 including those undergoing surgery or transcatheter 787 
interventions for aortic or mitral valve disease.257-262 Valvular heart disease can be associated with an increased 788 
thromboembolic risk, which probably also adds to the stroke risk in AF patients.263 Similar to heart failure, 789 
valvular disease and AF interact and sustain each other through volume and pressure overload, 790 
tachycardiomyopathy, and neurohumoral factors.264-270 When valve dysfunction is severe, AF can be regarded as 791 
a marker for progressive disease, thus favouring valve repair or replacement.271  792 
 Traditionally, patients with AF have been dichotomized into ‘valvular’ and ‘non-valvular’ AF.272 793 
Although slightly different definitions have been used, valvular AF mainly refers to AF patients that have either 794 
rheumatic valvular disease (predominantly mitral stenosis) or mechanical heart valves. In fact, while AF implies 795 
an incremental risk for thromboembolism in patients with mitral valve stenosis,263, 273, 274 there is no clear 796 
evidence that other valvular diseases, including mitral regurgitation or aortic valve disease, need to be 797 
considered when choosing an anticoagulant or indeed to estimate stroke risk.275 We have therefore decided to 798 
replace the historic term ‘non-valvular’ AF with reference to the specific underlying conditions. 799 
 800 
Recommendations for patients with valvular heart disease and AF 801 
Recommendations Class a Level b Refs c 
Early mitral valve surgery should be considered in severe mitral 
regurgitation, preserved LV function, and new-onset AF, even in 
the absence of symptoms, particularly when valve repair is 
feasible 
 
IIa 
 
C 
276 
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Mitral valvotomy should be considered for asymptomatic patients 
with severe mitral stenosis and suitable valve anatomy who have 
new-onset AF 
IIa C  
AF = atrial fibrillation; LV = left ventricular. 802 
aClass of recommendation. 803 
bLevel of evidence. 804 
cReference(s) supporting recommendations. 805 
 806 
 807 
7.4. Diabetes mellitus 808 
Diabetes and AF frequently coexist because of associations with other risk factors.277-283 Diabetes is a risk factor 809 
for stroke and other complications in AF.284 In patients with AF, a longer duration of diabetes appears to confer 810 
a higher risk of thromboembolism, albeit without greater risk of OAC-related bleeding.285 Unfortunately, 811 
intensive glycaemic control does not affect the rate of new-onset AF,284 while treatment with metformin seems 812 
to be associated with a decreased long-term risk of AF in diabetic patients286 and may even lower long-term 813 
stroke risk.13 Diabetic retinopathy, a measure of disease severity, does not increase the risk of ocular bleeding in 814 
anticoagulated patients.287  815 
 816 
7.5. Obesity and weight loss 817 
7.5.1. Obesity as a risk factor 818 
Obesity increases the risk for AF (risk ratio 1.5–1.8),288-291 with a progressive increase according to body mass 819 
index.288, 290-292 Obese patients may have more LV diastolic dysfunction, increased sympathetic activity and 820 
inflammation, and increased fatty infiltration of the atria.293-295 Obesity may also be a risk factor for ischaemic 821 
stroke, thromboembolism, and death in AF patients.292 822 
  823 
7.5.2. Weight reduction in obese patients with atrial fibrillation  824 
Intensive weight-reduction management in addition to management of other cardiovascular risk factors (in the 825 
range of 10–15 kg weight loss achieved) led to fewer AF recurrences and symptoms compared with an approach 826 
based on general advice in obese patients with AF.203, 204, 296 Improved cardiorespiratory fitness can further 827 
decrease AF burden in obese patients with AF.297 Although the findings in these studies have to be confirmed, 828 
they underpin the positive effect of weight reduction in obese patients.  829 
 830 
7.5.3. Catheter ablation in obese patients 831 
Obesity may increase the rate of AF recurrence after catheter ablation,298-301 with obstructive sleep apnoea as an 832 
important potential confounder. Obesity has also been linked to a higher radiation dose and complication rate 833 
during AF ablation.302, 303 Notably, the symptomatic improvement after catheter ablation of AF in obese patients 834 
seems comparable to the improvement in normal-weight patients.298 In view of the potential to reduce AF 835 
episodes by weight reduction (see Section 6.5.2.), AF ablation should be offered to obese patients in conjunction 836 
with lifestyle modifications that lead to weight reduction. 837 
 838 
Recommendation for obese patients with AF 839 
 840 
AF = atrial fibrillation. 841 
 842 
a Class of recommendation 843 
b Level of evidence 844 
c Reference(s) supporting recommendation(s) 845 
 846 
7.6. Chronic obstructive pulmonary disease, sleep apnoea, and other respiratory 847 
diseases 848 
Recommendation Class a Level b Refsc 
In obese patients with AF, weight loss together with management of 
other risk factors should be considered to reduce AF burden and 
symptoms 
IIa B 204, 288, 296 
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AF has been associated with obstructive sleep apnoea.304, 305 Multiple pathophysiological mechanisms can 849 
contribute to AF in obstructive sleep apnoea, including autonomic dysfunction, hypoxia, hypercapnia, and 850 
inflammation.96, 304-307 Obstructive sleep apnoea exaggerates intrathoracic pressure changes, which in itself and 851 
via vagal activation can provoke shortening of the atrial action potential and induce AF. Risk factor reduction 852 
and continuous positive airway pressure ventilation can reduce AF recurrence.308-312 It seems reasonable to 853 
consider obstructive sleep apnoea screening in AF patients with risk factors. Obstructive sleep apnoea treatment 854 
should be optimized to improve AF treatment results in appropriate patients. Servo-controlled pressure support 855 
therapy should not be used in HFrEF patients with predominantly central sleep apnoea (of which 25% had 856 
concomitant AF).313  857 
 Patients with chronic obstructive pulmonary disease often suffer from atrial tachycardias, which need 858 
to be differentiated from AF by ECG. Agents used to relieve bronchospasm, notably theophyllines and beta-859 
adrenergic agonists, may precipitate AF and make control of the ventricular response rate difficult. Non-860 
selective beta-blockers, sotalol, propafenone, and adenosine should be used with caution in patients with 861 
significant bronchospasm, while they can safely be used in patients with chronic obstructive pulmonary disease. 862 
Beta-1 selective blockers (e.g. bisoprolol, metoprolol, and nebivolol), diltiazem, and verapamil are often 863 
tolerated and effective (see Chapter 9).  864 
 865 
Recommendations for patients with AF and respiratory diseases 866 
Recommendations Class a Level b Refs c 
Correction of hypoxaemia and acidosis should be considered as initial 
management for patients who develop AF during an acute pulmonary 
illness or exacerbation of chronic pulmonary disease 
IIa C  
Interrogation for clinical signs of obstructive sleep apnoea in all AF 
patients should be considered IIa B 
304, 305, 314, 
315 
Obstructive sleep apnoea treatment should be optimized to reduce AF 
recurrences and improve AF treatment results IIa B 
307-311 
AF = atrial fibrillation. 867 
aClass of recommendation. 868 
bLevel of evidence. 869 
cReference(s) supporting recommendations. 870 
 871 
7.7. Chronic kidney disease 872 
AF is present in 15–20% of patients with CKD.316 The definition of CKD in most AF trials is relatively strict. 873 
Although an estimated creatinine clearance (CrCl) rate of < 60 mL/min is indicative of CKD, a number of trials 874 
in AF patients have used CrCl < 50 mL/min to adapt NOAC dosage, usually estimated using the Cockroft–Gault 875 
formula. CrCl in AF patients can deteriorate over time.317 The management of OAC in patients with CKD is 876 
discussed in Section 8.2.4.  877 
 878 
Recommendations for patients with kidney disease and AF 879 
 880 
AF = atrial fibrillation. 881 
aClass of recommendation. 882 
bLevel of evidence. 883 
cReference(s) supporting recommendations. 884 
Recommendations Class a Level b Refs c 
The assessment of kidney function by serum creatinine or 
creatinine clearance is recommended in all AF patients to 
detect kidney disease and to support correct dosing of AF 
therapy 
I A 316, 318-321 
All AF patients treated with oral anticoagulation should be 
considered for at least yearly renal function evaluation to 
detect kidney disease 
IIa B  
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 885 
8 Integrated management of patients with atrial fibrillation 886 
Most patients access the healthcare system initially through pharmacists, community health workers, or primary 887 
care physicians. As AF is often asymptomatic, these healthcare professionals are important stakeholders to 888 
enable adequate detection of AF and to ensure consistent management. The initial assessment should be 889 
performed at the point of first contact with the healthcare system, and is feasible in most healthcare settings 890 
(when an ECG is available). We propose to consider five domains in the initial assessment of patients presenting 891 
with newly diagnosed AF (Figure 5). These domains are: 892 
1. Haemodynamic instability or limiting, severe symptoms 893 
2. Presence of precipitating factors (e.g. thyrotoxicosis, sepsis, or postoperative AF) and 894 
underlying cardiovascular conditions 895 
3. Stroke risk and need for anticoagulation 896 
4. Heart rate and need for rate control 897 
5. Symptom assessment and decision for rhythm control 898 
 899 
Figure 5 Acute and chronic management of AF patients, desired cardiovascular outcomes, and patient benefits. 900 
Adapted from the report on the 4th AFNET/EHRA consensus conference.76 901 
AF = atrial fibrillation; AFNET = German Competence NETwork on Atrial Fibrillation; EHRA = European 902 
Heart Rhythm Association. 903 
 904 
An integrated, structured approach to AF care, as applied successfully to other domains of medicine,322-324 will 905 
facilitate consistent, guideline-adherent AF management for all patients325 (Figure 6), with the potential to 906 
improve outcomes.42, 326, 327 Such approaches are consistent with the Innovative Care for Chronic Conditions 907 
Framework proposal put forward by the World Health Organization.328 Review by an AF service, or at least 908 
referral to a cardiologist, will usually be required after the initial assessment to fully evaluate the effect of AF on 909 
cardiovascular health.329 There may also be reasons for early or urgent referral (Table 9). Integrated care of all 910 
patients with newly diagnosed AF should help to overcome the current shortcomings of AF management, such 911 
as underuse of anticoagulation, access to rate and rhythm control therapy, and inconsistent approaches to 912 
cardiovascular risk reduction. Integrated AF care requires the cooperation of primary care physicians, 913 
cardiologists, cardiac surgeons, AF specialists, stroke specialists, allied health practitioners and patients, 914 
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encompassing lifestyle interventions, treatment of underlying cardiovascular diseases and AF-specific therapy 915 
(Figure 7). 916 
 917 
Figure 6 Achieving optimal management of AF patients. 918 
AF = atrial fibrillation. 919 
aOn-site or through institutionalized cooperation. 920 
bSafety outcomes should be collected in published and monitored central databases. 921 
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 922 
Figure 7 Fundamentals of integrated care in AF patients. 923 
AF = atrial fibrillation; LAA = left atrial appendage. 924 
 925 
Table 9 Clinical signs calling for urgent involvement of a specialized AF service.a  926 
Haemodynamic instability 
Uncontrollable rate 
Symptomatic bradycardia not amenable to reduced dosing of rate control agents 
Severe angina or worsening left ventricular function 
Transient ischemic attack or stroke 
AF = atrial fibrillation 927 
aAnticoagulation should be initiated early in all suitable patients and will not routinely require specialist input.  928 
 929 
8.1. Evidence supporting integrated atrial fibrillation care 930 
Several structured approaches to AF care have been developed. Some evidence underpins their use, while more 931 
research is needed into the best way of delivering integrated AF care. Integrated AF management in an RCT 932 
increased the use of evidence-base care and reduced by approximately one-third the composite outcome of 933 
cardiovascular hospitalization and cardiovascular death over a mean follow-up of 22 months (14.3% vs. 20.8%, 934 
HR 0.65; 95% CI 0.45–0.93; P = 0.017) compared with usual care in a large tertiary care centre.330 Integrated 935 
AF management appeared cost-effective in that study.331 However, an Australian RCT showed only a marginal 936 
effect on unplanned admissions and death using integrated AF care limited to the initial care period, possibly 937 
emphasizing the need for sustained integration of AF care.332 Two observational studies of integrated AF care 938 
found fewer hospitalizations,333, 334 one study showed fewer cases of stroke,333 and a further non-randomized 939 
study identified a trend for a lower rate of the composite outcome of death, cardiovascular hospitalization, and 940 
AF-related emergency visits.335 More research is needed, and integrated AF care is likely to require different 941 
designs in different healthcare settings. 942 
 943 
8.2. Components of integrated atrial fibrillation care 944 
8.2.1. Patient involvement 945 
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Patients should have a central role in the care process. As treatment of AF requires patients to change their 946 
lifestyles and adhere to chronic therapy, at times without an immediately tangible benefit, they need to 947 
understand their responsibilities in the care process. Physicians and healthcare professionals are responsible for 948 
providing access to evidence-based therapy, but adherence to therapy is ultimately the responsibility of 949 
informed and autonomous patients, best described as ‘shared accountability’.336 Hence, information and 950 
education of patients and often of their partners and relatives is indispensable to encourage a self-management 951 
role and to empower patients to participate in shared decision-making,326, 328 and to support their understanding 952 
of the disease and the suggested treatments.337 953 
 954 
8.2.2. Multidisciplinary atrial fibrillation teams 955 
Delegation of tasks from specialists to general physicians and from physicians to allied health professionals is a 956 
fundamental concept of integrated care models. A multidisciplinary AF team approach includes an efficient mix 957 
of interpersonal and communication skills, education and expertise in AF management, as well as the use of 958 
dedicated technology. This approach underlines the importance of redesigning daily practice in a way that 959 
encourages non-specialists and allied professionals to have an important role in educating patients and 960 
coordinating care, while the specialist remains medically responsible. Cultural and regional differences will 961 
determine the composition of AF teams. 962 
 963 
8.2.3. Role of non-specialists 964 
AF patients often initially present to general practitioners or pharmacists. Some physicians in primary care have 965 
extensive expertise in stroke prevention and initial management of AF patients. Others may seek training to 966 
acquire such knowledge. Other components of AF management (e.g. assessment of concomitant cardiovascular 967 
conditions, antiarrhythmic drug therapy, or interventional treatment) often require specialist input. Integrated 968 
AF care structures should support treatment initiation by non-specialists where appropriate, and provide ready 969 
access to specialist knowledge to optimize AF care.  970 
 971 
8.2.4. Technology use to support atrial fibrillation care 972 
Technology, such as decision support software, has the potential to enhance the implementation of evidence-973 
based care and improve outcomes, when used to enhance expert advice.338 Electronic tools can also ensure 974 
coherent communication within the AF team. With a view to support the wider use of such technology, this 975 
Task Force is providing tools free of charge, in the form of smartphone apps, to AF healthcare professionals and 976 
to AF patients. 977 
 978 
Recommendations for an integrated approach to care 979 
Recommendations Class a Level b Refs c 
An integrated approach with structured organization of care and follow-
up should be considered in all patients with AF, aiming to improve 
guideline adherence and reduce hospitalization and mortality 
IIa B 330-332 
Placing patients in a central role in the decision-making should be 
considered in order to tailor management to patient preferences and 
improve adherence to chronic therapy 
IIa C 330, 332, 334 
AF = atrial fibrillation 980 
aClass of recommendation. 981 
bLevel of evidence. 982 
cReference(s) supporting recommendations. 983 
 984 
8.3. Diagnostic workup of atrial fibrillation patients 985 
AF is often found in patients with other, at times undiagnosed, cardiovascular conditions. Thus, all AF patients 986 
will benefit from a comprehensive cardiovascular assessment.339  987 
 988 
8.3.1.  Recommended evaluation in all atrial fibrillation patients 989 
A complete medical history should be taken and all patients should undergo clinical evaluation that includes 990 
thorough assessment for concomitant conditions, establishing the AF pattern, estimation of stroke risk and AF-991 
related symptoms, and assessment of arrhythmia-related complications such as thromboembolism or LV 992 
dysfunction. A 12-lead ECG is recommended to establish a suspected diagnosis of AF, to determine rate in AF, 993 
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and to screen for conduction defects, ischaemia, and signs of structural heart disease. Initial blood tests should 994 
evaluate thyroid and kidney function as well as serum electrolytes and full blood count. Transthoracic 995 
echocardiography is recommended in all AF patients to guide treatment decisions. Transthoracic 996 
echocardiography should be used to identify structural disease (e.g. valvular disease) and assess LV size and 997 
function (systolic and diastolic), atrial size, and right heart function.339, 340 Although biomarkers such as 998 
natriuretic peptides are elevated in AF patients, there is insufficient data to suggest that blood-based parameters 999 
are independent markers for AF.341-343 1000 
 1001 
8.3.2. Additional investigations in selected patients with atrial fibrillation 1002 
Ambulatory ECG monitoring in AF patients can assess the adequacy of rate control, relate symptoms with AF 1003 
recurrences, and detect focal induction of bouts of paroxysmal AF. Transoesophageal echocardiography (TOE) 1004 
is useful to further assess valvular heart disease and to exclude intracardiac thrombi, especially in the LAA, to 1005 
facilitate early cardioversion or catheter ablation.344 Patients with symptoms or signs of myocardial ischaemia 1006 
should undergo coronary angiography or stress testing as appropriate. In patients with AF and signs of cerebral 1007 
ischaemia or stroke, computed tomography (CT) or magnetic resonance imaging (MRI) of the brain is 1008 
recommended to detect stroke and support decisions regarding acute management and long-term 1009 
anticoagulation. Delayed-enhancement MRI of the left atrium using gadolinium contrast,345-347 T1 mapping 1010 
using cardiac MRI,347 and intracardiac echo348 may help to guide treatment decisions in AF, but require external 1011 
validation in multicentre studies.  1012 
 1013 
8.4. Structured follow-up 1014 
Most AF patients need regular follow-up to ensure continued optimal management. Follow-up may be 1015 
undertaken in primary care, by specially trained nurses, by cardiologists, or by AF specialists.325, 330 A specialist 1016 
should coordinate care and follow-up. Follow-up should ensure implementation of the management plan, 1017 
continued engagement of the patient, and therapy adaptation where needed.  1018 
 1019 
Recommendations for diagnostic workup of AF patients 1020 
AF = atrial fibrillation; ECG = electrocardiogram. 1021 
aClass of recommendation. 1022 
bLevel of evidence. 1023 
cReference(s) supporting recommendations. 1024 
 1025 
8.5. Defining goals of atrial fibrillation management 1026 
AF management comprises therapies with prognostic impact (anticoagulation and treatment of cardiovascular 1027 
conditions) and therapies predominantly providing symptomatic benefit (rate control, rhythm control, Table 10). 1028 
Therapies with prognostic benefit need careful explanation to patients when their benefits are not directly felt. 1029 
Rhythm control therapy can be successful if symptoms are controlled, even when AF recurs. Explaining the 1030 
expected benefits to each patient at the start of AF management will prevent unfounded expectations and has the 1031 
potential to optimize quality of life.  1032 
 1033 
Table 10 Goal-based follow-up 1034 
Category Intervention Follow-up aspects Performance indicator 
(examples) 
Recommendations Class a Level b Refs c 
ECG documentation is required to establish the diagnosis of AF I B 349 
A full cardiovascular evaluation, including an accurate history, 
careful clinical examination, and assessment of concomitant 
conditions, is recommended in all AF patients 
I C  
Transthoracic echocardiography is recommended in all AF 
patients to guide management 
I C 339 
Long-term ECG monitoring should be considered in selected 
patients to assess the adequacy of rate control in symptomatic 
patients and to relate symptoms with AF episodes 
IIa C  
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Prognostic  Comorbidity control 
(relevant examples 
given) 
Obesity Weight loss 
Arterial hypertension Blood pressure control 
Heart failure Heart failure therapy 
Coronary artery disease 
 
Statin and antiplatelet therapy  
Revascularization 
Diabetes Glycaemic control 
Valvular Heart Disease Valve repair or replacement 
Prognostic  Anticoagulation Indication (risk profile; timing, 
e.g. post-cardioversion); 
Adherence (NOAC or VKA) 
and INR (if VKA); 
NOAC dosing (co-
medications, age, weight, renal 
function) 
Stroke  
Bleeding 
Mortality 
Mainly symptomatic 
Partly prognostic  
Rate control Symptoms 
Average resting heart rate 
< 110 bpm 
 
EHRA score 
Heart failure status  
LV function 
Exercise capacity 
Hospitalization 
Therapy complications 
Symptomatic at present Rhythm control Symptoms vs. side-effects 
Exclusion of proarrhythmia 
(PR; QRS; QTc interval) 
Relevant for 
implementation of and 
adherence to therapy 
Patient education and 
self-care capabilities 
Knowledge (about disease; 
about treatment; about 
management goals) 
Capabilities (what to do if…) 
Adherence to therapy 
Directed evaluation, preferably 
based on systematic checklists 
Relevant for chronic 
care management 
Caregiver 
involvement 
Who? (spouse; GP; home 
nurse; pharmacist) 
Clearly spelling out 
participation roles 
Knowledge and capabilities 
Directed evaluation of task 
performance (e.g. via patient 
card) 
Dispensed medication 
GP log of follow-up visits 
bpm = beats per minute; EHRA = European Heart Rhythm Association; GP = general practitioner; INR = 1035 
international normalized ratio; LV = left ventricular; NOAC = non-vitamin K antagonist oral anticoagulant; 1036 
VKA = vitamin K antagonist. 1037 
 1038 
9 Stroke prevention therapy in atrial fibrillation patients 1039 
OAC therapy can prevent the majority of ischaemic strokes in AF patients and can prolong life.38, 39, 42, 194, 201, 329, 1040 
350-352 It is superior to no treatment or aspirin in patients with different profiles for stroke risk.353, 354 The net 1041 
clinical benefit is almost universal, with the exception of patients at very low stroke risk, and OAC should 1042 
therefore be used in most patients with AF (Figure 8). Despite this evidence, underuse or premature termination 1043 
of OAC therapy is still common. Bleeding events, both severe and nuisance bleeds, a perceived ‘high risk of 1044 
bleeding’ on anticoagulation, and the efforts required to monitor and dose-adjust VKA therapy are among the 1045 
most common reasons for withholding or ending OAC.352, 355-359 However, the considerable stroke risk without 1046 
OAC often exceeds the bleeding risk on OAC, even in the elderly, in patients with cognitive dysfunction, or in 1047 
patients with frequent falls or frailty.360, 361 The bleeding risk on aspirin is not different to the bleeding risk on 1048 
VKA362 or NOAC therapy,354, 363 while VKA and NOACs, but not aspirin, effectively prevent strokes in AF 1049 
patients.38, 354, 362, 363  1050 
 1051 
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 1052 
Figure 8 Stroke prevention in AF. 1053 
AF = atrial fibrillation; CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), 1054 
Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); LAA = left atrial appendage; 1055 
NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; VKA = vitamin K 1056 
antagonist.  1057 
aCongestive heart failure, hypertension, age ≥75 years (2 points), diabetes, prior stroke/TIA/embolus (2 points), 1058 
vascular disease, age 65–74, female sex. 1059 
bIncludes women without other stroke risk factors.  1060 
cIIaB for women with only one additional stroke risk factor,  1061 
dIB for patients with mechanical heart valves or mitral stenosis 1062 
 1063 
9.1. Prediction of stroke and bleeding risk  1064 
9.1.1. Clinical risk scores for stroke and systemic embolism 1065 
Simple, clinically applicable stroke risk-stratification schemes in AF patients were developed in the late 1990s 1066 
in small cohort studies and have later been refined and validated in larger populations.364-368 The introduction of 1067 
the CHA2DS2-VASc score (Table 11) has clearly simplified the initial decision for OAC in AF patients. Since 1068 
its first incorporation in the ESC guidelines in 2010,369 it has been widely used.370 We recommend estimating 1069 
stroke risk in AF patients based on the CHA2DS2-VASc score.368 In general, patients without clinical stroke risk 1070 
factors do not need antithrombotic therapy, while patients with stroke risk factors (i.e. CHA2DS2-VASc score of 1071 
1 or more for men, and 2 or more for women) are likely to benefit from OAC.  1072 
 1073 
Table 11 Clinical risk factors for stroke, transient ischemic attack, and systemic embolism in the 1074 
CHA2DS2-VASc score. 1075 
CHA2DS2-VASc risk factor Points 
Congestive heart failure  
Signs/symptoms of heart failure or objective evidence of reduced left-ventricular ejection 
fraction 
+1  
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Hypertension  
Resting blood pressure > 140/90 mmHg on at least two occasions or current antihypertensive 
treatment 
+1  
Age 75 years or older  +2  
Diabetes mellitus  
Fasting glucose > 125 mg/dL or treatment with oral hypoglycaemic agent and/or insulin 
+1  
Previous stroke, transient ischemic attack, or thromboembolism  +2  
Vascular disease  
Previous myocardial infarction, peripheral artery disease, or aortic plaque 
+1  
Age 65 to 74 years  +1  
Sex category (female)  +1  
CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled), 1076 
Vascular disease, Age 65–74, and Sex (female). 1077 
 1078 
Other, less established risk factors for stroke include unstable international normalized ratio (INR) and low time 1079 
in therapeutic range (TTR) in patients treated with VKAs; previous bleed or anaemia; alcohol excess and other 1080 
markers for decreased therapy adherence; CKD; elevated high-sensitivity troponin T; and elevated N-terminal 1081 
pro-B-type natriuretic peptide. 1082 
 1083 
9.1.2. Anticoagulation in patients with a CHA2DS2-VASc score of 1 in men and 2 1084 
in women 1085 
Controlled trials studying OAC in AF patients have been enriched for patients at high risk of stroke,38, 39, 42, 194, 1086 
201, 329, 351, 352 and hence there is strong evidence that patients with a CHA2DS2-VASc risk score of 2 or more in 1087 
men, and 3 or more in women benefit from OAC. Fortunately, we now have a growing evidence-base regarding 1088 
stroke risk in patients with one clinical risk factor (i.e. CHA2DS2-VASc score of 1 for men, and 2 for women), 1089 
although this relies largely on observed stroke rates in patients not receiving OAC. In many of these patients, 1090 
anticoagulation seems to provide a clinical benefit.371-375 The rates of stroke and thromboembolism vary 1091 
considerably in patients with CHA2DS2-VASc scores of 1 or 2 due to differences in outcomes, populations, and 1092 
anticoagulation status (Web Addenda Table 1).371, 376, 377, 1041 OAC should be considered for men with a 1093 
CHA2DS2-VASc score of 1 and women with a score of 2, balancing the expected stroke reduction, bleeding 1094 
risk, and patient preference. Importantly, age (65 years and older) conveys a relatively high and continuously 1095 
increasing stroke risk that also potentiates other risk factors (such as heart failure and sex). Hence, an 1096 
individualized weighing of risk, as well as patient preferences, should inform the decision to anticoagulate 1097 
patients with only one CHA2DS2-VASc risk factor, apart from female sex. Female sex does not appear to 1098 
increase stroke risk in the absence of other stroke risk factors (Web Addenda Table 1).378, 379 1099 
 Measurement of cardiac troponin (high-sensitivity troponin T or I) and N-terminal pro-B-type 1100 
natriuretic peptide may provide additional prognostic information in selected AF patients.380-382 Biomarker-1101 
based risk scores may in the future prove helpful to better stratify patients (e.g. those at a truly low risk of 1102 
stroke).75, 382  1103 
 1104 
9.1.3. Clinical risk scores for bleeding 1105 
Several bleeding risk scores have been developed, mainly in patients on VKAs. These include HAS-BLED 1106 
(hypertension, abnormal renal/liver function [1 point each], stroke, bleeding history or predisposition, labile 1107 
INR, elderly [>65 years], drugs/alcohol concomitantly [1 point each]), ORBIT (Outcomes Registry for Better 1108 
Informed Treatment of Atrial Fibrillation), and more recently, the ABC (age, biomarkers, clinical history) 1109 
bleeding score, which also makes use of selected biomarkers.383-385 Stroke and bleeding risk factors overlap 1110 
(compare Table 11 and Table 12). For example, older age is one of the most important predictors of both 1111 
ischaemic stroke and bleeding in AF patients.386, 387 A high bleeding risk score should generally not result in 1112 
withholding OAC. Rather, bleeding risk factors should be identified and treatable factors corrected (see Section 1113 
8.5). Table 12 provides details of modifiable bleeding risk factors.  1114 
 1115 
Table 12 Modifiable and non-modifiable risk factors for bleeding in anticoagulated patients based on 1116 
bleeding risk scores. 1117 
Modifiable bleeding risk factors 
Hypertension (especially when systolic blood pressure is > 160 mmHg)a,b,c 
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Labile INR (in patients on vitamin K antagonists) or time in therapeutic range < 60%a 
Medication predisposing to bleeding, such as antiplatelet drugs and non-steroidal anti-inflammatory drugsa,d 
Excess alcohol (≥ 8 drinks/week)a,b 
Potentially modifiable bleeding risk factors 
Anaemiab,c,d 
Impaired renal functiona,b,c,d 
Impaired liver functiona,b 
Reduced platelet count or functionb 
Non-modifiable bleeding risk factors 
Agee (> 65 years)a (≥ 75 years)b,c,d 
History of major bleedinga,b,c,d 
Previous strokea,b 
Dialysis-dependent CKD or renal transplanta,c 
Cirrhotic liver diseasea 
Malignancyb 
Genetic factorsb 
Biomarker-based bleeding risk factors 
High-sensitivity troponin Te 
Growth differentiation factor-15e 
Serum creatinine/estimated CrCLe 
ABC = age, biomarkers, clinical history; ATRIA = AnTicoagulation and Risk factors In Atrial fibrillation; CKD 1118 
= chronic kidney disease; CrCl = creatinine clearance; HAS-BLED = hypertension, abnormal renal/liver 1119 
function (1 point each), stroke, bleeding history or predisposition, labile INR, elderly (>65 years), drugs/alcohol 1120 
concomitantly (1 point each); INR = international normalized ratio; ORBIT = Outcomes Registry for Better 1121 
Informed Treatment of Atrial Fibrillation; TTR = time in therapeutic range; VKA = vitamin K antagonist. 1122 
aDerived from the HAS-BLED score.384 1123 
bDerived from the HEMORR2HAGES score.383 1124 
cDerived from the ATRIA score.385 1125 
dDerived from the ORBIT score.388 1126 
eDerived from the ABC bleeding score.387 1127 
 1128 
 Recommendations for prediction of stroke and bleeding risk  1129 
Recommendations Class a Level b Refs c 
The CHA2DS2-VASc score is recommended for stroke risk 
prediction in patients with AF 
I A 368, 371, 
386 
Bleeding risk scores should be considered in AF patients on oral 
anticoagulation to identify modifiable factors for major bleeding 
IIa B 384, 386, 
387, 389-392 
Biomarkers such as high-sensitivity troponin and N-terminal pro-
B-type natriuretic peptide may be considered to further refine 
stroke and bleeding risk in AF patients 
IIb B 380-382, 
387, 393 
AF = atrial fibrillation; CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), 1130 
Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); OAC = oral anticoagulation. 1131 
aClass of recommendation. 1132 
bLevel of evidence. 1133 
cReference(s) supporting recommendations. 1134 
 1135 
9.2. Stroke prevention 1136 
9.2.1. Vitamin K antagonists 1137 
Warfarin and other VKAs were the first anticoagulants used in AF patients. VKA therapy reduces risk of stroke 1138 
by two-thirds and mortality by one-quarter compared with control (aspirin or no therapy).38 VKAs have been 1139 
used in many patients throughout the world with good outcomes,394-396 and this is reflected in the warfarin arms 1140 
of the NOAC trials (see Section 8.2.2.). The use of VKAs is limited by the narrow therapeutic interval, 1141 
necessitating frequent monitoring and dose adjustments, but VKAs, when delivered with adequate TTR, are 1142 
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effective for stroke prevention in AF patients. Clinical parameters can help to identify patients who are likely to 1143 
achieve a decent TTR on VKA therapy.397 These have been summarized in the SAMe-TT2R2 score. Patients who 1144 
fare well on this score, when treated with a VKA, have on average a higher TTR than patients who do not fare 1145 
well on the score.398, 399 VKAs are currently the only treatment with established safety in AF patients with 1146 
rheumatic mitral valve disease and/or a mechanical heart valve prosthesis.400  1147 
 1148 
9.2.2. Non-vitamin K antagonist oral anticoagulants 1149 
NOACs, including the direct thrombin inhibitor dabigatran and the factor Xa inhibitors apixaban, edoxaban, and 1150 
rivaroxaban, are suitable alternatives to VKAs for stroke prevention in AF (Table 13). Their use in clinical 1151 
practice is increasing rapidly.401 All NOACs have a predictable effect (onset and offset) without need for regular 1152 
anticoagulation monitoring. The phase III trials have been conducted with carefully selected doses of the 1153 
NOACs, including clear rules for dose reduction that should be followed in clinical practice (Table 13). 1154 
 1155 
Apixaban 1156 
In the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial 1157 
Fibrillation) trial,319 apixaban reduced stroke or systemic embolism by 21% compared with warfarin, combined 1158 
with a 31% reduction in major bleeding and an 11% reduction in all-cause mortality (all statistically significant). 1159 
Rates of haemorrhagic stroke and intracranial haemorrhage, but not of ischaemic stroke, were lower on 1160 
apixaban. Rates of gastrointestinal bleeding were similar between the two treatment arms.402  1161 
 Apixaban is the only NOAC that has been compared with aspirin in AF patients: apixaban significantly 1162 
reduced stroke or systemic embolism by 55% compared with aspirin, with no significant difference in rates of 1163 
major bleeding or intracranial haemorrhage.354, 403  1164 
 1165 
Dabigatran 1166 
In the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study,318, 404 dabigatran 150 mg 1167 
twice daily reduced stroke and systemic embolism by 35% compared with warfarin without a significant 1168 
difference in major bleeding events. Dabigatran 110 mg twice daily was non-inferior to warfarin for prevention 1169 
of stroke and systemic embolism, with 20% fewer major bleeding events. Both dabigatran doses significantly 1170 
reduced haemorrhagic stroke and intracranial haemorrhage. Dabigatran 150 mg twice daily significantly 1171 
reduced ischaemic stroke by 24% and vascular mortality by 12%, while gastrointestinal bleeding was 1172 
significantly increased by 50%. There was a non-significant numerical increase in the rate of myocardial 1173 
infarction with both dabigatran doses,318, 404 which has not been replicated in large post-authorization 1174 
analyses.396 These data have also replicated the benefit of dabigatran over VKAs found in the RE-LY trial in 1175 
patients enriched for the higher dabigatran dose (150 mg twice daily).396  1176 
  1177 
Edoxaban 1178 
In the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–1179 
Thrombolysis in Myocardial Infarction 48) trial,321 edoxaban 60 mg once daily and edoxaban 30 mg once daily 1180 
(with dose reductions in certain patients according to Table 13), were compared with adjusted-dose warfarin.405 1181 
Edoxaban 60 mg once daily was non-inferior to warfarin (primary outcome, HR 0.87; 97.5% CI 0.73–1.04; P = 1182 
0.08). In an on-treatment analysis, edoxaban 60 mg once daily significantly reduced stroke or systemic 1183 
embolism by 21% and significantly reduced major bleeding events by 20% compared with warfarin, while 1184 
edoxaban 30 mg once daily was non-inferior to warfarin for prevention of stroke and systemic embolism but 1185 
significantly reduced major bleeding events by 53%. Cardiovascular death was reduced in patients randomized 1186 
to edoxaban 60 mg once daily or edoxaban 30 mg once daily compared with warfarin. Only the higher dose 1187 
regimen has been approved for stroke prevention in AF. 1188 
 1189 
Rivaroxaban 1190 
In the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K 1191 
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial,320 patients were 1192 
randomized to rivaroxaban 20 mg once daily or VKA, with a dose adjustment to 15 mg daily for those with 1193 
estimated CrCl 30–49 mL/min by the Cockroft–Gault formula. Rivaroxaban was non-inferior to warfarin for the 1194 
prevention of stroke and systemic embolism in the intent-to-treat analysis, while the per-protocol on-treatment 1195 
analysis achieved statistical superiority with a 21% reduction in stroke or systemic embolism compared with 1196 
warfarin. Rivaroxaban did not reduce the rates of mortality, ischaemic stroke, or major bleeding events 1197 
compared to VKA. There was an increase in gastrointestinal bleeding events, but a significant reduction in 1198 
haemorrhagic stroke and intracranial haemorrhage with rivaroxaban compared with warfarin. Comparable event 1199 
rates have been reported in post-authorization analyses, which are part of the post-approval risk-management 1200 
process.406, 4071201 
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Table 13 NOACs compared with warfarin in controlled trials 1202 
  Dabigatran (RE-LY) 
Rivaroxaban 
(ROCKET-AF) 
Apixaban 
(ARISTOTLE) 
Edoxaban 
(ENGAGE AF-TIMI 48) 
Mechanism Oral direct thrombin inhibitor Oral direct factor Xa inhibitor Oral direct factor Xa inhibitor Oral direct factor Xa inhibitor 
Bioavailability, % 6 66 fasting, 80–100 with food 50 62 
Time to peak levels, h 3 2–4 3 1–2 
Half-life, h 12–17 5–13 9–14 10–14 
Excretion 80% renal 66% liver, 33% renal 27% renal 50% renal 
Dose 150 mg or 110 mg twice daily 20 mg once daily 5 mg twice daily 60 mg or 30 mg once daily 
Dose reduction in selected 
patients   
Rivaroxaban 15 mg once daily if 
CrCl 30–49 mL/min 
Apixaban 2.5 mg twice daily if at least 
2 of age ≥ 80 years, body weight ≤ 60 
kg or serum creatinine level ≥ 1.5 
mg/dL (133 µmol/L) 
Edoxaban 60 mg reduced to 30 mg once 
daily, and edoxaban 30 mg reduced to 15 mg 
once daily, if any of the following: CrCl 30–
50 mL/min, body weight ≤ 60 kg, 
concomitant use of verapamil or quinidine or 
dronedarone 
Study design Randomized, open-label Randomized, double-blind Randomized, double-blind Randomized, double-blind 
Number of patients 18,113 14,264 18,201 21,105 
Follow-up period, years 2 1.9 1.8 2.8 
Randomized groups 
Dose-adjusted warfarin vs. blinded 
doses of dabigatran (150 mg twice 
daily or 110 mg twice daily) 
Dose-adjusted warfarin vs. 
rivaroxaban 20 mg once daily 
Dose-adjusted warfarin vs. apixaban 5 
mg twice daily 
Dose-adjusted warfarin vs. edoxaban (60 mg 
once daily or 30 mg once daily)  
Age, years Mean ± SD 71.5 ± 8.7  Median 73; IQR 65–78 Median 70; IQR 63–76 Median 72; IQR 64–78 
Men, % 63.6 60.3 64.5 61.9 
CHADS2 score (mean) 2.1 3.5 2.1 2.8 
  1203 
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 Outcomes Warfarin Dabigatran 150 
Dabigatran 
110 Warfarin Rivaroxaban Warfarin Apixaban Warfarin Edoxaban 60 Edoxaban 30 
 
n = 6022 n = 6076 n = 6015 n = 7133 n = 7131 n = 9081 n = 9120 n = 7036 n = 7035 n = 7034 
Event 
rate, 
%/year 
Event rate, 
%/year (RR 
vs. warfarin)  
Event rate, 
%/year (RR 
vs. 
warfarin)  
Event rate, 
%/year 
Event rate, %/year 
(HR vs. warfarin)  
Event rate, 
%/year 
Event rate, %/year (HR 
vs. warfarin)  
Event rate, 
%/year 
Event rate, 
%/year (HR vs. 
warfarin)  
Event rate, 
%/year (HR 
vs. warfarin)  
Stroke/systemic embolism 1.72 
1.12 (0.65, 
0.52–0.81; 
P for non-
inferiority and 
superiority 
< 0.001) 
1.54 (0.89, 
0.73–1.09; 
P for non-
inferiority 
< 0.001) 
2.42 
2.12 (0.88, 0.75–1.03; 
P for non-inferiority 
< 0.001, P for 
superiority = 0.12) 
1.60 
1.27 (0.79, 0.66–0.95; 
P < 0.001 for non-
inferiority, 
P = 0.01 for superiority) 
1.80 
1.57 (0.87, 0.73–
1.04; 
P < 0.001 for 
non-inferiority, P 
= 0.08 for 
superiority) 
2.04 (1.13, 
0.96–1.34; 
P = 0.005 for 
non-
inferiority, P 
= 0.10 for 
superiority) 
Ischaemic stroke 1.22 
0.93 (0.76, 
0.59–0.97; 
P = 0.03) 
1.34 (1.10, 
0.88–1.37; 
P = 0.42) 
1.42 1.34 (0.94; 0.75–1.17; P = 0.581) 1.05 
0.97 (0.92, 0.74–1.13; 
P = 0.42) 1.25 
1.25 (1.00, 0.83–
1.19; 
P = 0.97) 
1.77 (1.41, 
1.19–1.67; 
P < 0.001) 
Haemorrhagic stroke 0.38 
0.10 (0.26, 
0.14–0.49; 
P < 0.001) 
0.12 (0.31, 
0.17–0.56; 
P < 0.001) 
0.44 0.26 (0.59; 0.37–0.93; P = 0.024) 0.47 
0.24 (0.51, 0.35–0.75; 
P < 0.001) 0.47 
0.26 (0.54, 0.38–
0.77; 
P < 0.001) 
0.16 (0.33, 
0.22–0.50; 
P < 0.001) 
Major bleeding 3.61 
3.40 (0.94, 
0.82–1.08; 
P = 0.41) 
2.92 (0.80, 
0.70–0.93; 
P = 0.003) 
3.45 3.60 (1.04; 0.90-2.30; P = 0.58) 3.09 
2.13 (0.69, 0.60–0.80; 
P < 0.001) 3.43 
2.75 (0.80, 0.71–
0.91; P < 0.001) 
1.61 (0.47, 
0.41–0.55; P 
< 0.001) 
Intracranial bleeding 0.77 
0.32 (0.42, 
0.29–0.61; 
P < 0.001) 
0.23 (0.29 
0.19–0.45; 
P < 0.001) 
0.74 0.49 (0.67; 0.47–0.93; P = 0.02) 0.80 
0.33 (0.42, 0.30–0.58; 
P < 0.001) 0.85 
0.39 (0.47, 0.34–
0.63; P < 0.001)  
0.26 (0.30, 
0.21–0.43; P 
< 0.001) 
Gastrointestinal major 
bleeding 1.09 
1.60 (1.48, 
1.19–1.86; 
P < 0.001) 
1.13 (1.04, 
0.82–1.33; 
P = 0.74) 
1.24 2.00 (1.61; 1.30-1.99; P < 0.001) 0.86 
0.76 (0.89, 0.70–1.15; 
P = 0.37) 1.23 
1.51 (1.23, 1.02–
1.50; P = 0.03) 
0.82 (0.67, 
0.53–0.83; P 
< 0.001) 
Myocardial infarction 0.64 
0.81 (1.27, 
0.94-1.71; 
P = 0.12) 
0.82 (1.29, 
0.96-1.75; 
P = 0.09) 
1.12 0.91 (0.81; 0.63–1.06; P = 0.12) 0.61 
0.53 (0.88, 0.66–1.17; 
P = 0.37) 0.75 
0.70 (0.94, 0.74–
1.19; P = 0.60) 
0.89 (1.19, 
0.95–1.49; P 
= 0.13) 
Death from any cause 4.13 
3.64 (0.88, 
0.77–1.00; 
P = 0.051) 
3.75 (0.91, 
0.80–1.03; 
P = 0.13) 
2.21 1.87 (0.85; 0.70–1.02; P = 0.07) 3.94 
3.52 (0.89, 0.80–0.99; 
P = 0.047) 4.35 
3.99 (0.92, 0.83–
1.01; P = 0.08) 
3.80 (0.87, 
0.79–0.96; P 
= 0.006) 
AF = atrial fibrillation; CHADS2 = Cardiac failure, Hypertension, Age, Diabetes, Stroke (Doubled); CrCl = creatinine clearance; HR = hazard ratio; IQR = interquartile range (25th to 1204 
75th quartiles); RR = risk ratio; SD = standard deviation.  1205 
RRs and HRs compared to warfarin therapy are presented with 95% confidence intervals and P-values.1206 
Page 40 of 148 ESC AF Guidelines 
 
 1207 
9.2.3. Non-vitamin K antagonist oral anticoagulants or vitamin K antagonists 1208 
Both VKAs and NOACs are effective for the prevention of stroke in AF. A meta-analysis39 based on the high-1209 
dose treatment groups of the pivotal studies of warfarin versus NOACs included 42,411 patients receiving a 1210 
NOAC and 29,272 receiving warfarin. NOACs in these dosages significantly reduced stroke or systemic 1211 
embolic events by 19% compared with warfarin (RR 0.81; 95% CI 0.73–0.91; P < 0.0001), mainly driven by a 1212 
reduction in haemorrhagic stroke (RR 0.49; 95% CI 0.38–0.64; P < 0.0001). Mortality was 10% lower in 1213 
patients randomized to NOAC therapy (RR 0.90; 95% CI 0.85–0.95; P = 0.0003) and intracranial haemorrhage 1214 
was halved (RR 0.48; 95% CI 0.39–0.59; P < 0.0001), while gastrointestinal bleeding events were more 1215 
frequent (RR 1.25; 95% CI 1.01–1.55; P = 0.04).39 The stroke reduction with NOACs was consistent in all 1216 
evaluated subgroups, while there was a suggestion of greater relative reduction in bleeding with NOACs at 1217 
centres with poor INR control (interaction P = 0.022). Notably, the substantial reduction in intracranial 1218 
haemorrhage by NOACs compared with warfarin seems unrelated to poor or good INR control.408, 409  1219 
 1220 
9.2.4. Oral anticoagulation in atrial fibrillation patients with chronic kidney 1221 
disease 1222 
CKD is associated with stroke and bleeding in large data sets.410, 411 Anticoagulation can be safely used in AF 1223 
patients with moderate or moderate-to-severe CKD (glomerular filtration rate [GFR] ≥ 15 mL/min): the SPAF 1224 
(Stroke Prevention in Atrial Fibrillation) III trial randomized 805/1936 participants with stage 3 CKD (estimated 1225 
GFR < 59 mL/min/1.73 m2), and reported good outcomes on warfarin (INR 2–3).412 This finding is supported by 1226 
a large Swedish database, in which stroke risk was lower in CKD patients with AF treated with warfarin 1227 
(adjusted HR 0.76; 95% CI 0.72–0.80),413 while bleeding was also slightly increased, especially during therapy 1228 
initiation.414 In a meta-analysis of the major NOAC trials, patients with mild or moderate CKD suffered fewer 1229 
strokes, systemic emboli, or major bleeding events on NOACs than on warfarin.415 Kidney function should be 1230 
regularly monitored in AF patients on OAC to allow dose adaptation for those on NOACs (Table 14) and to 1231 
refine risk estimation.416  1232 
 1233 
Table 14 Inclusion criteria, dose adjustments, and outcomes in patients with chronic kidney disease in the 1234 
four major randomized trials comparing NOACs with warfarin in patients with AF. Adapted from Hart 1235 
et al.316 1236 
 Dabigatran  
(RE-LY)318, 425 
Rivaroxaban  
(ROCKET-AF) 
320, 426 
Apixaban  
(ARISTOTLE)319, 427 
Edoxaban  
(ENGAGE AF-
TIMI 48)321 
Renal clearance 80% 35% 25% 50% 
Number of 
patients 
18,113 14,264 18,201 21,105 
Dose 150 mg or 110 
mg twice daily 
20 mg once daily 5 mg twice daily 60 mg or 30 mg 
once daily 
Exclusion criteria 
for CKD 
CrCl < 30 
mL/min 
CrCl < 30 
mL/min 
Serum creatinine > 
2.5 mg/dL or CrCl < 
25 mL/min 
CrCl < 30 mL/min 
Dose adjustment 
with CKD 
None 15 mg once daily 
if CrCl < 30–49 
mL/min 
2.5 mg twice daily if 
serum creatinine ≥ 
1.5 mg/dL plus age ≥ 
80 years or weight ≤ 
60 kg 
30 mg or 15 mg 
once daily if CrCl 
< 50 mL/min 
Per cent of 
patients with CKD 
20% with CrCl 
30–49 mL/min 
21% with CrCl 
30–49 mL/min 
15% with CrCl 30–50 
mL/dL 
19% with CrCl < 
50 mL/min 
Reduction of 
stroke and 
systemic 
embolism 
No interaction 
with CKD status 
No interaction 
with CKD status 
No interaction with 
CKD status 
NA 
Reduction of 
major 
haemorrhages 
compared with 
warfarin 
Reduction in 
major 
haemorrhage 
with dabigatran 
was greater in 
patients with 
Major 
haemorrhage 
similar 
Reduction in major 
haemorrhage with 
apixaban 
NA 
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estimated GFR 
> 80 mL/min 
with either dose 
AF = atrial fibrillation; CKD = chronic kidney disease; CrCl = creatinine clearance; GFR = glomerular filtration 1237 
rate; NA = not available; NOAC = non-vitamin K antagonist oral anticoagulant. 1238 
 1239 
9.2.5. Oral anticoagulation in atrial fibrillation patients on dialysis 1240 
Approximately one in eight dialysis patient suffers from AF, with an incidence rate of 2.7/100 patient-years.417 1241 
AF is associated with increased mortality in patients on dialysis.417 There are no randomized trials assessing 1242 
OAC in haemodialysis patients,418 and no controlled trials of NOACs in patients with severe CKD (CrCl < 25–1243 
30 mL/min).318-321 Warfarin use was associated either with a neutral or increased risk of stroke in database 1244 
analyses of patients on dialysis,419-421 including a population-based analysis in Canada (adjusted HR for stroke 1245 
1.14; 95% CI 0.78–1.67, adjusted HR for bleeding 1.44; 95% CI 1.13–1.85).422 In contrast, data from Denmark 1246 
suggest a benefit of OAC in patients on renal replacement therapy.423 Hence, controlled studies of 1247 
anticoagulants (both VKAs and NOACs) in AF patients on dialysis are needed.424  1248 
 1249 
9.2.6. Patients with atrial fibrillation requiring kidney transplantation 1250 
There are no randomized trials assessing OAC in patients after kidney transplantation. The prescription of 1251 
NOAC therapy should be guided by the estimated GFR of the transplanted kidney. Potential pharmacokinetic 1252 
interactions of OAC with immunosuppressive agents should be considered. 1253 
 1254 
 1255 
9.2.7. Antiplatelet therapy as an alternative to oral anticoagulants 1256 
The evidence supporting antiplatelet monotherapy for stroke prevention in AF is very limited.38, 428-430 VKA 1257 
therapy prevents stroke, non-central nervous system embolus, myocardial infarction, and vascular death better 1258 
than single or dual antiplatelet therapy with aspirin and clopidogrel (annual risk of 5.6% for aspirin and 1259 
clopidogrel vs. 3.9% with VKA therapy).431 Even greater benefits were seen in VKA-treated patients with a high 1260 
TTR.432 Antiplatelet therapy increases bleeding risk, especially dual antiplatelet therapy (2.0% vs. 1.3% with 1261 
antiplatelet monotherapy; P < 0.001),433 with bleeding rates that are similar to those on OAC.354, 362, 431, 434 Thus, 1262 
antiplatelet therapy cannot be recommended for stroke prevention in AF patients. 1263 
 1264 
Recommendations for stroke prevention in patients with AF 1265 
Recommendations Class a Level b Refs c 
Oral anticoagulation therapy to prevent thromboembolism is 
recommended for all male AF patients with a CHA2DS2-VASc 
score of 2 or more 
I A 38, 318-321, 354, 
404 
Oral anticoagulation therapy to prevent thromboembolism is 
recommended in all female AF patients with a CHA2DS2-
VASc score of 3 or more 
I 
 
A 38, 318-321, 354, 
404 
Oral anticoagulation therapy to prevent thromboembolism 
should be considered in male AF patients with a CHA2DS2-
VASc score of 1, considering individual characteristics and 
patient preferences 
IIa B 371, 375-377 
Oral anticoagulation therapy to prevent thromboembolism 
should be considered in female AF patients with a CHA2DS2-
VASc score of 2, considering individual characteristics and 
patient preferences 
IIa B 371, 376, 377 
Vitamin K antagonist therapy (INR 2.0–3.0 or higher) is 
recommended for stroke prevention in AF patients with 
moderate-to-severe mitral stenosis or mechanical heart 
valves 
I B 274, 435-440 
When oral anticoagulation is initiated in a patient with AF 
who is eligible for a NOAC (apixaban, dabigatran, edoxaban, 
or rivaroxaban), a NOAC is recommended in preference to a 
Vitamin K antagonist 
I A 39, 318-321, 404 
When patients are treated with a vitamin K antagonist, time I A 
395, 432, 441-444 
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AF = atrial fibrillation; CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), 1266 
Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); INR = international normalized 1267 
ratio; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; TTR = time in 1268 
therapeutic range; VKA = vitamin K antagonist. 1269 
aClass of recommendation. 1270 
bLevel of evidence. 1271 
cReference(s) supporting recommendations. 1272 
 1273 
9.3. Left atrial appendage occlusion and exclusion 1274 
9.3.1. Left atrial appendage occlusion devices 1275 
Interventional LAA occlusion,446-449 and limited experience with percutaneous LAA ligation, has mainly been 1276 
reported in observational studies and registries. Only one device (Watchman®) has been compared with VKA 1277 
therapy in randomized trials (PROTECT AF [Watchman Left Atrial Appendage System for Embolic Protection 1278 
in Patients With AF trial], see Web Addenda Table 2; and PREVAIL [Prospective Randomized Evaluation of 1279 
the Watchman LAA Closure Device In Patients with AF Versus Long Term Warfarin Therapy trial]).449-451 In 1280 
these data sets, LAA occlusion was non-inferior to VKA treatment for the prevention of stroke in AF patients 1281 
with moderate stroke risk, with a possibility of lower bleeding rates in the patients who continued follow-up.452, 1282 
453 These data were confirmed in a patient-level meta-analysis of the two trials and their associated registries.453 1283 
LAA occlusion may also reduce stroke risk in patients with contraindications to OAC.454, 455 The implantation 1284 
procedure can cause serious complications,446, 456-458 with high event rates reported in analyses from insurance 1285 
databases and systematic reviews, possibly identifying a certain degree of reporting bias.446, 456 A large recent 1286 
European registry reported a high rate of implantation success (98%), with an acceptable procedure-related 1287 
complication rate of 4% at 30 days.459 Most patients who historically would be considered unsuitable for OAC 1288 
therapy seem to do relatively well on contemporarily managed OAC.396, 407, 460 Adequately powered controlled 1289 
trials are urgently needed to inform the best use of these devices, including LAA occluders in patients who are 1290 
truly unsuitable for OAC or in patients who suffer a stroke on OAC, randomized comparisons of LAA occluders 1291 
with NOACs, and assessment of the minimal antiplatelet therapy acceptable after LAA occlusion. 1292 
 1293 
9.3.2. Surgical left atrial appendage occlusion or exclusion 1294 
Surgical LAA occlusion or exclusion concomitant to cardiac surgery has been performed for many decades and 1295 
with various techniques. Multiple observational studies indicate the feasibility and safety of surgical LAA 1296 
occlusion/exclusion, but only limited controlled trial data are available.461-464 Residual LAA flow or incomplete 1297 
LAA exclusion can increase stroke risk.465 In most studies, LAA occlusion/exclusion was performed during 1298 
other open heart surgery, and more recently in combination with surgical ablation of AF463 or as a stand-alone 1299 
thoracoscopic procedure. One randomized trial evaluating the role of concomitant AF surgery and LAA 1300 
occlusion reported in 2015, without a clear benefit of LAA exclusion for stroke prevention in the subgroup 1301 
undergoing AF surgery.466 A large randomized trial is currently underway.467  1302 
 1303 
Recommendations for occlusion or exclusion of the LAA 1304 
in therapeutic range (TTR) should be kept as high as 
possible and closely monitored 
AF patients already on treatment with a vitamin K antagonist 
may be considered for NOAC treatment if TTR is not well 
controlled despite good adherence, or if patient preference 
without contraindication (e.g. prosthetic valve) 
IIb A 39, 318, 319, 404, 
408 
Combinations of oral anticoagulants and platelet inhibitors 
increase bleeding risk and should be avoided in AF patients 
without another indication for platelet inhibition 
III (harm) B 429, 445 
In male or female AF patients without additional stroke risk 
factors, anticoagulant or antiplatelet therapy is not 
recommended for stroke prevention 
III (harm) B 368, 371, 376, 377 
Antiplatelet monotherapy is not recommended for stroke 
prevention in AF patients, regardless of stroke risk 
III (harm) A 38, 429, 430 
NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) 
are not recommended in patients with mechanical heart 
valves (Level of evidence B) or moderate-to-severe mitral 
stenosis (Level of evidence C) 
III (harm) B/C 318-321, 400, 404 
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Recommendations Class a Level b Refs c 
After surgical occlusion or exclusion of the LAA, it is recommended to 
continue anticoagulation in at-risk patients with AF for stroke 
prevention 
I B 461, 462 
LAA occlusion may be considered for stroke prevention in patients 
with AF and contraindications for long-term anticoagulant treatment 
(e.g. those with a previous life-threatening bleed without a reversible 
cause) 
IIb B 449, 453, 454 
Surgical occlusion or exclusion of the LAA may be considered for 
stroke prevention in patients with AF undergoing cardiac surgery 
IIb B 463 
Surgical occlusion or exclusion of the LAA may be considered for 
stroke prevention in patients undergoing thoracoscopic ablation surgery 
IIb B 468 
AF = atrial fibrillation; LAA = left atrial appendage. 1305 
aClass of recommendation. 1306 
bLevel of evidence. 1307 
cReference(s) supporting recommendations. 1308 
 1309 
9.4. Secondary stroke prevention 1310 
The most important risk factors for stroke in patients with AF are advanced age and previous cardioembolic 1311 
stroke or TIA,382 emphasizing the need for OAC in these patients. The highest risk of recurrent stroke is in the 1312 
early phase after a first stroke or TIA.469, 470 1313 
 1314 
9.4.1. Treatment of acute ischaemic stroke 1315 
Systemic thrombolysis with recombinant tissue plasminogen activator (rtPA)  is an effective and approved 1316 
medical treatment for acute ischaemic stroke in patients presenting within 4.5 hours of symptom onset.471 1317 
Systemic thrombolysis is contraindicated in patients on therapeutic OAC.472, 473 Recombinant tissue 1318 
plasminogen activator can be given in patients treated with a VKA if the INR is below 1.7,474 or in dabigatran-1319 
treated patients with a normal activated partial thromboplastin time and last intake of drug > 48 hours previously 1320 
(based on expert consensus).472 Whether specific NOAC antidotes475 could be used followed by systemic 1321 
thrombolysis needs to be investigated. Thrombectomy can be performed in anticoagulated patients with distal 1322 
occlusion of the internal carotid artery or middle cerebral artery in a 6-hour window.476 1323 
 1324 
9.4.2. Initiation of anticoagulation after transient ischaemic attack or ischaemic 1325 
stroke 1326 
Data on the optimal use of anticoagulants (heparin, low-molecular-weight heparin, heparinoid, VKA, NOAC) in 1327 
the first days after a stroke are scarce. Parenteral anticoagulants seem to be associated with a non-significant 1328 
reduction in recurrent ischaemic stroke when administered 7 to 14 days after the acute stroke (odds ratio [OR] 1329 
0.68; 95% CI 0.44–1.06), with a significant increase in symptomatic intracranial bleeding (OR 2.89; 95% CI 1330 
1.19–7.01), and a similar rate of death or disability at final follow-up.477 It seems likely that the bleeding risk on 1331 
parenteral anticoagulation exceeds the stroke prevention benefit in the first days after a large stroke, whereas 1332 
patients with a TIA or a small stroke may benefit from early (immediate) initiation or continuation of 1333 
anticoagulation. Therefore, we propose to initiate anticoagulation in AF patients between 1 and 12 days after an 1334 
ischaemic stroke, depending on its severity (Figure 9).478 We suggest repeat brain imaging to determine the 1335 
optimal initiation of anticoagulation in patients with a large stroke at risk for haemorrhagic transformation. 1336 
Long-term OAC with a VKA363, 479-481 or NOAC482 conveys benefits in AF patients who survived a stroke. 1337 
NOACs seem to convey slightly better outcomes, mainly driven by fewer intracranial haemorrhages and 1338 
haemorrhagic strokes (OR 0.44, 95% CI 0.32–0.62).482 Detailed data for edoxaban have not yet been 1339 
published.321 If a patient suffers a stroke or TIA whilst taking an anticoagulant, switching to another 1340 
anticoagulant should be considered. 1341 
 1342 
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Figure 9 Initiation or continuation of anticoagulation in AF patients after a stroke or TIA. This approach is 1343 
based on consensus rather than prospective data. 1344 
  1345 
AF = atrial fibrillation; CT = computed tomography; MRI = magnetic resonance imaging; NIHSS = National 1346 
Institutes of Health stroke severity scale (available at http://www.strokecenter.org/wp-1347 
content/uploads/2011/08/NIH_Stroke_Scale.pdf); OAC = oral anticoagulation; TIA = transient ischaemic 1348 
attack. 1349 
 1350 
9.4.3. Initiation of anticoagulation after intracranial haemorrhage 1351 
No prospective studies have investigated the benefit or risk of the initiation of OAC after intracranial 1352 
haemorrhage,483 and patients with a history of intracranial bleeding were excluded from the randomized trials 1353 
comparing NOACs with VKAs. The available evidence indicates that anticoagulation in patients with AF can be 1354 
reinitiated after 4–8 weeks, especially when the cause of bleeding or the relevant risk factor (e.g. uncontrolled 1355 
hypertension) has been treated, and that such treatment leads to fewer recurrent (ischaemic) strokes and lower 1356 
mortality.460, 484 If anticoagulation is resumed, it seems reasonable to consider anticoagulants with a low 1357 
bleeding risk.39 Figure 10 depicts a consensus opinion on the initiation or resumption of OAC after an 1358 
intracranial haemorrhage. We recommend a multidisciplinary decision with input from stroke 1359 
physicians/neurologists, cardiologists, neuroradiologists, and neurosurgeons.  1360 
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 1361 
Figure 10 Initiation or resumption of anticoagulation in AF patients after an intracranial bleed. This approach is 1362 
based on consensus and retrospective data. In all patients, evaluation by a multidisciplinary panel is required 1363 
before treatment (stroke physician/neurologist, cardiologist, neuroradiologist, and neurosurgeon).  1364 
AF = atrial fibrillation; LAA = left atrial appendage; NOAC = non-vitamin K antagonist oral anticoagulant; 1365 
OAC = oral anticoagulation; PCI = percutaneous coronary intervention; VKA = vitamin K antagonist. 1366 
 1367 
Recommendations for secondary stroke prevention 1368 
Recommendations Class a Level b Refs c 
Anticoagulation with heparin or low-molecular-weight heparin 
immediately after ischaemic stroke is not recommended in AF 
patients 
III (harm) A 477 
In patients who suffer a transient ischemic attack or stroke while 
on anticoagulation, adherence to therapy should be assessed and 
optimized 
IIa C  
In patients who suffer a moderate-to-severe ischaemic stroke 
while on anticoagulation, anticoagulation should be interrupted for 
3–12 days based on a multidisciplinary assessment of acute 
stroke and bleeding risk 
IIa C  
In AF patients who suffer a stroke, aspirin should be considered 
for prevention of secondary stroke until the initiation or resumption 
of oral anticoagulation. 
IIa B 485 
Systemic thrombolysis with a recombinant tissue plasminogen 
activator is not recommended if the INR is above 1.7 (or, for 
patients on dabigatran, if activated partial thromboplastin time is 
outside the normal range) 
III (harm) C 472, 474 
NOACs are recommended in preference to VKAs or aspirin in AF 
patients with a previous stroke 
I B 363, 482 
After TIA or stroke, combination therapy of OAC and an III (harm) B 486 
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 1369 
 1370 
AF = atrial fibrillation; INR = international normalized ratio; NOAC = non-vitamin K antagonist oral 1371 
anticoagulant; OAC = oral anticoagulation; TIA = transient ischaemic attack; VKA = vitamin K antagonist. 1372 
aClass of recommendation. 1373 
bLevel of evidence. 1374 
cReference(s) supporting recommendations. 1375 
 1376 
9.5. Strategies to minimize bleeding on anticoagulant therapy 1377 
In a meta-analysis of 47 studies, the overall incidence of major bleeding with VKAs was 2.1 (range 0.9–3.4) per 1378 
100 patient-years in controlled trials and 2.0 (range 0.2–7.6) per 100 patient-years for observational data sets.488 1379 
Minimizing treatable bleeding risk factors (see Table 12) seems paramount to reduce the bleeding rate on 1380 
anticoagulants.  1381 
 1382 
9.5.1. Uncontrolled hypertension 1383 
Uncontrolled blood pressure increases the risk of bleeding on OAC.53 Hence, keeping systolic blood pressure 1384 
well controlled is of particular relevance in anticoagulated patients with AF. Treatment according to current 1385 
guidelines is recommended in patients with known hypertension.489 1386 
 1387 
9.5.2. Previous bleeding event 1388 
History of bleeding events and the presence of anaemia are important parts of the assessment of all patients 1389 
receiving OAC. The majority of bleeding events are gastrointestinal. Compared with warfarin, the risk of 1390 
gastrointestinal bleeds was increased for dabigatran 150 mg twice daily,396, 490 rivaroxaban 20 mg once daily,491 1391 
and edoxaban 60 mg once daily.321 The risk of gastrointestinal bleeds was comparable to warfarin on dabigatran 1392 
110 mg twice daily490 and on apixaban 5 mg twice daily319 Recent observational analyses do not replicate these 1393 
findings, suggesting a smaller effect.396, 492, 493 In patients in whom the source of bleeding has been identified and 1394 
corrected, OAC can be reinitiated. This also appears true for patients who have had an intracranial haemorrhage, 1395 
once modifiable bleeding risk factors (e.g. uncontrolled hypertension) have been corrected.460, 484  1396 
 1397 
9.5.3. Labile international normalized ratio and adequate non-vitamin K 1398 
antagonist oral anticoagulant dosing  1399 
TTR on VKA therapy is an important predictor of major haemorrhage.432, 441, 494 Therefore we recommend 1400 
targeting the INR between 2.0 and 3.0 in patients on VKAs, maintaining a high TTR (e.g. ≥ 70%494), and to 1401 
consider switching to a NOAC when a high TTR cannot be sustained.444 NOAC dosing should follow the dose-1402 
reduction criteria evaluated in the clinical trials, considering renal function, age, and weight. Patient information 1403 
and empowerment, best delivered through integrated AF management, seem paramount to achieve this goal.  1404 
 1405 
9.5.4. Alcohol abuse 1406 
Alcohol excess is a risk factor for bleeding in anticoagulated patients,384 mediated by poor adherence, liver 1407 
disease, variceal bleeding, and risk of major trauma. Severe alcohol abuse and binge drinking habits should be 1408 
corrected in patients eligible for OAC.  1409 
 1410 
9.5.5. Falls and dementia 1411 
Falls and dementia are associated with increased mortality in AF patients,495 without evidence that these 1412 
conditions markedly increase the risk of intracranial haemorrhage.495, 496 Hence, anticoagulation should only be 1413 
withheld from patients with severe uncontrolled falls (e.g. epilepsy or advanced multisystem atrophy with 1414 
backwards falls), or in selected patients with dementia where compliance and adherence cannot be ensured by a 1415 
caregiver. 1416 
 1417 
9.5.6. Genetic testing 1418 
antiplatelet is not recommended 
After intracranial haemorrhage, oral anticoagulation in patients 
with AF may be reinitiated after 4–8 weeks provided the cause of 
bleeding or the relevant risk factor has been treated or controlled 
IIb B 483, 484, 487 
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In addition to food and drug interactions, multiple genetic variations affect the metabolism of VKAs.497 The 1419 
systematic use of genetic information for adjustment of VKA dosage has been evaluated in several controlled 1420 
clinical studies.498-500 Genetic testing has little effect on TTR or bleeding risk on warfarin, and is not 1421 
recommended for clinical use at present.501 1422 
 1423 
9.5.7. Bridging periods off oral anticoagulation 1424 
Most cardiovascular interventions (e.g. percutaneous coronary intervention or pacemaker implantation) can be 1425 
performed safely on continued OAC. When interruption of OAC is required, bridging does not seem to be 1426 
beneficial, except in patients with mechanical heart valves. In a randomized trial of 1884 patients with AF, 1427 
interruption of anticoagulation was non-inferior to heparin administration for the outcome of arterial 1428 
thromboembolism (incidence of 0.4% and 0.3%, respectively) and resulted in a lower risk of major bleeding 1429 
(1.3% and 3.2%, respectively).502 A short interruption or continued OAC should be considered in patients at 1430 
highest risk of stroke. 1431 
 1432 
9.6. Management of bleeding events in anticoagulated patients with atrial fibrillation 1433 
9.6.1. Management of minor, moderate, and severe bleeding 1434 
General assessment of an anticoagulated patient with AF experiencing a bleeding event should include 1435 
assessment of bleeding site, onset, and severity of the bleeding, the time-point of last intake of OAC and other 1436 
antithrombotic drugs, and other factors influencing bleeding risk such as CKD, alcohol abuse, and concurrent 1437 
medications. Laboratory tests should include haemoglobin, haematocrit, platelet count, renal function, and for 1438 
VKA patients, prothrombin time, activated partial thromboplastin time, and INR. Coagulation tests do not 1439 
provide much information in patients on NOACs, except for activated partial thromboplastin time in the case of 1440 
dabigatran. More specific coagulation tests do exist, including diluted thrombin time (HEMOCLOT) for 1441 
dabigatran and calibrated quantitative anti-factor Xa assays for factor Xa inhibitors.503 However, these tests are 1442 
not always readily available and are often unnecessary for bleeding management.504 1443 
 We propose a simple scheme to manage bleeding events in patients on OAC (Figure 11). Minor 1444 
bleeding events should be treated with supportive measures such as mechanical compression or minor surgery to 1445 
achieve haemostasis. In patients receiving VKAs, the next dose of VKA can be postponed. NOACs have a short 1446 
plasma half-life of approximately 12 hours and improved haemostasis is expected within 12–24 hours after a 1447 
delayed or omitted dose. Treatment of moderate bleeding events may require blood transfusions and fluid 1448 
replacement. Specific diagnostic and treatment interventions directed against the cause of the bleeding (e.g. 1449 
gastroscopy) should be performed promptly. If the intake of NOAC was recent (< 2–4 h), charcoal 1450 
administration and/or gastric lavage will reduce further exposure. Dialysis clears dabigatran but is not effective 1451 
for the other NOACs.  1452 
 Immediate reversal of the antithrombotic effect is indicated in severe or life-threatening bleeding 1453 
events. An agreed, the institutional procedure for the management of life-threatening bleeds should be 1454 
documented and accessible at all times to ensure adequate initial management. For VKAs, administration of 1455 
fresh frozen plasma restores coagulation more rapidly than vitamin K, and prothrombin complex concentrates 1456 
achieve even faster blood coagulation.505 Registry data suggest that the combination of plasma and prothrombin 1457 
complex concentrates is associated with the lowest case fatality following intracranial haemorrhage on VKA 1458 
treatment with an INR ≥ 1.3.506 In a multicentre randomized trial of 188 patients, four-factor prothrombin 1459 
complex concentrates achieved more rapid INR reversal and effective haemostasis than plasma in patients 1460 
undergoing urgent surgical or invasive procedures.507 Administration of prothrombin complex concentrates may 1461 
also be considered for severe bleeding on NOAC treatment if specific antidotes are not available.  1462 
 Several antidotes to NOACs are under development. Idarucizumab (approved in 2015 by the US Food 1463 
and Drug Administration and the European Medicines Agency) is a clinically available humanized antibody 1464 
fragment that binds dabigatran and rapidly and dose-dependently reverses the effects without over-correction or 1465 
thrombin generation.475 Andexanet alpha, a modified recombinant human factor Xa that lacks enzymatic 1466 
activity, reverses the anticoagulant activity of apixaban and rivaroxaban in healthy probands within minutes 1467 
after administration and for the duration of infusion, with a transient increase in markers of coagulation activity 1468 
of uncertain clinical relevance.508 Another agent under development is ciraparantag (PER977), an antidote 1469 
targeted to reverse both direct thrombin and factor Xa inhibitors as well as the indirect inhibitor enoxaparin.509 1470 
The clinical usefulness of these specific antidotes needs further evaluation. 1471 
 1472 
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Figure 11 Management of active bleeding in patients receiving anticoagulation.1473 
 1474 
INR = international normalized ratio; i.v. = intravenous; NOAC = non-vitamin K antagonist oral anticoagulant; 1475 
PCC = prothrombin complex concentrates; FFP = four-factor prothrombin complex concentrates; VKA = 1476 
vitamin K antagonist. 1477 
 1478 
9.6.2. Oral anticoagulation in atrial fibrillation patients at risk of or having a 1479 
bleeding event 1480 
While anticoagulation therapy should be paused to control active bleeding, absolute contraindications to long-1481 
term OAC after a bleeding episode are rare. When nuisance bleeds are the reason to stop OAC, a change from 1482 
one anticoagulant to another seems reasonable. Many causes or triggers of major bleeding events can be treated 1483 
and/or eliminated, including uncontrolled hypertension, gastrointestinal ulcers, and intracranial aneurysms. 1484 
Reinitiation of anticoagulation after a bleeding event is often clinically justified.460, 510 Difficult decisions, 1485 
including the discontinuation and recommencement of OAC, should be taken by a multidisciplinary team, 1486 
balancing estimated risk of recurrent stroke and bleeding, and considering the bleeding risk of different stroke 1487 
prevention therapies. LAA exclusion or occlusion might be an alternative in selected patients.  1488 
 1489 
Recommendations for management of bleeding 1490 
Recommendations  Class a Level b Refs c 
Blood pressure control in anticoagulated patients with 
hypertension should be considered to reduce the risk of 
bleeding 
IIa B 511 
When dabigatran is used, a reduced dose of dabigatran 
(110 mg twice daily) may be considered in patients > 75 
years to reduce the risk of bleeding 
IIb B 490 
In patients at high risk of gastrointestinal bleeding, a 
VKA or another NOAC should be preferred over 
dabigatran 150 mg twice daily, rivaroxaban 20 mg once 
daily, or edoxaban 60 mg once daily 
IIa B 321, 396, 402, 
405, 490, 492, 
493, 512 
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AF = atrial fibrillation; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; 1491 
VKA = vitamin K antagonist 1492 
aClass of recommendation. 1493 
bLevel of evidence. 1494 
cReference(s) supporting recommendations. 1495 
 1496 
9.7. Combination therapy with oral anticoagulants and antiplatelets  1497 
Approximately 15% of AF patients in contemporary trials513 and registries514-516 have a history of myocardial 1498 
infarction. Between 5% and 15% of AF patients will require stenting at some point in their lives. This scenario 1499 
requires careful consideration of antithrombotic therapy, balancing bleeding risk, stroke risk, and risk of acute 1500 
coronary syndromes (ACS).516 Co-prescription of OAC with antiplatelet therapy, in particular triple therapy, 1501 
increases the absolute risk of major haemorrhage.445, 517, 518 A recent meta-analysis involving 30,866 patients 1502 
with a recent ACS evaluated the effects of adding NOAC therapy to single (4135 patients) or dual (26,731 1503 
patients) antiplatelet therapy.519 The addition of a NOAC increased the bleeding risk by 79–134%, while 1504 
reducing recurrent ischaemic events only marginally in patients without AF. OAC monotherapy, and not 1505 
combination therapy with antiplatelets, is recommended in AF patients with stable CAD but without an ACS 1506 
and/or coronary intervention in the previous 12 months. In patients treated for ACS and in those receiving a 1507 
coronary stent, short-term triple combination therapy of OAC, clopidogrel, and aspirin seems warranted (Figure 1508 
12).  1509 
Advice and treatment to avoid alcohol excess should be 
considered in all AF patients considered for OAC 
IIa C  
Genetic testing before the initiation of VKA therapy is not 
recommended. 
III (no benefit) B 497 
Reinitiation of OAC after a bleeding event should be 
considered in all eligible patients by a multidisciplinary 
AF team, considering different anticoagulants and 
stroke-prevention interventions, improved management 
of factors that contributed to bleeding, and stroke risk 
IIa B 460 
In AF patients with severe active bleeding events, it is 
recommended to interrupt OAC therapy until the 
underlying cause is resolved 
I C  
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 1510 
Figure 12 Antithrombotic therapy after an ACS in AF patients requiring anticoagulation. 1511 
ACS = acute coronary syndrome; AF = atrial fibrillation; OAC = oral anticoagulation (using vitamin K 1512 
antagonists or non-vitamin K antagonist oral anticoagulants); PCI = percutaneous coronary intervention. 1513 
aDual therapy with OAC and aspirin or clopidogrel may be considered in selected patients, especially those not 1514 
receiving a stent or patients at a longer time from the index event.  1515 
bOAC plus single antiplatelet.  1516 
cDual therapy with OAC and an antiplatelet agent (aspirin or clopidogrel) may be considered in patients at high 1517 
risk of coronary events. 1518 
 1519 
 1520 
9.7.1. Antithrombotic therapy after acute coronary syndromes and percutaneous 1521 
coronary intervention in patients requiring oral anticoagulation 1522 
The optimal combination antithrombotic therapy or duration of combination therapy for AF patients undergoing 1523 
percutaneous coronary intervention is not known, but the continued bleeding risk suggests a short duration. 1524 
Expert consensus,520 reviewed and reconsidered by this Task Force, suggests the following principles: AF 1525 
patients at risk for stroke, patients with mechanical valves, and patients with recent or recurrent deep vein 1526 
thrombosis or pulmonary embolism should continue OAC during and after stenting. In general, a short period of 1527 
triple therapy (OAC, aspirin, clopidogrel) is recommended, followed by a period of dual therapy (OAC plus a 1528 
single antiplatelet) (Figure 13). When a NOAC is used, the consensus recommendation is that the lowest dose 1529 
effective for stroke prevention in AF should be considered. Dose reduction beyond the dosing regimens tested in 1530 
the phase III trials is not currently recommended, and awaits assessment in ongoing controlled trials. The 1531 
combination of aspirin, clopidogrel, and low-dose rivaroxaban (2.5 mg twice daily) is not recommended for 1532 
stroke prevention in AF.521 1533 
 The use of prasugrel or ticagrelor as part of triple therapy should be avoided unless there is a clear need 1534 
for these agents (e.g. stent thrombosis on aspirin plus clopidogrel), given the lack of evidence and the greater 1535 
risk of major bleeding compared with clopidogrel.522, 523 Ongoing trials will inform about such combination 1536 
therapies in the future. 1537 
 The omission of aspirin while maintaining clopidogrel and OAC has been evaluated in the WOEST 1538 
(What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary 1539 
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StenTing) trial, in which 573 anticoagulated patients undergoing percutaneous coronary intervention (70% with 1540 
AF) were randomized to either dual therapy with OAC and clopidogrel (75 mg once daily) or to triple therapy 1541 
with OAC, clopidogrel, and aspirin.524 Bleeding was lower in the dual versus triple therapy arm, driven by fewer 1542 
minor bleeding events. The rates of myocardial infarction, stroke, target vessel revascularization, and stent 1543 
thrombosis did not differ (albeit with low event numbers), but all-cause mortality was lower in the dual therapy 1544 
group at 1 year (2.5% vs. triple 6.4%). Although the trial was too small to assess ischaemic outcomes, dual 1545 
therapy with OAC and clopidogrel may emerge in the future as an alternative to triple therapy in patients with 1546 
AF and ACS and/or coronary intervention.525  1547 
 1548 
Figure 13 Antithrombotic therapy after percutaneous intervention in AF patients requiring anticoagulation. 1549 
ACS = acute coronary syndrome; AF = atrial fibrillation; OAC = oral anticoagulation (using vitamin K 1550 
antagonists or non-vitamin K antagonist oral anticoagulants); PCI = percutaneous coronary intervention. 1551 
aDual therapy with OAC and aspirin or clopidogrel may be considered in selected patients.  1552 
bOAC plus single antiplatelet.  1553 
cDual therapy with OAC and an antiplatelet agent (aspirin or clopidogrel) may be considered in patients at high 1554 
risk of coronary events. 1555 
 1556 
Recommendations for combination therapy with oral anticoagulants and antiplatelets 1557 
 1558 
Recommendations Class a Level b Refs c 
After elective coronary stenting for stable coronary artery disease in 
AF patients at risk of stroke, combination triple therapy with aspirin, 
clopidogrel and an oral anticoagulant should be considered for 1 month 
to prevent recurrent coronary and cerebral ischaemic events 
IIa B 522, 524 
After an ACS with stent implantation in AF patients at risk of stroke, 
combination triple therapy with aspirin, clopidogrel, and an oral 
anticoagulant should be considered for 1–6 months to prevent recurrent 
coronary and cerebral ischaemic events 
IIa C 520 
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After an ACS without stent implantation in AF patients at risk of 
stroke, dual therapy with an oral anticoagulant and aspirin or 
clopidogrel should be considered for up to 12 months to prevent 
recurrent coronary and cerebral ischaemic events 
IIa C  
The duration of combination antithrombotic therapy, especially triple 
therapy, should be kept to a limited period, balancing the estimated risk 
of recurrent coronary events and bleeding 
IIa B 520 
Dual therapy with any oral anticoagulant plus clopidogrel 75 mg/day 
may be considered as an alternative to initial triple therapy with aspirin 
in selected patients. 
IIb C 524, 525 
ACS = acute coronary syndromes; AF = atrial fibrillation 1559 
aClass of recommendation. 1560 
bLevel of evidence. 1561 
cReference(s) supporting recommendations. 1562 
 1563 
10 Rate control therapy in AF 1564 
Rate control is an integral part of the management of AF patients, and is often sufficient to improve AF-related 1565 
symptoms. Compared with stroke prevention and rhythm control, very little robust evidence exists to inform the 1566 
best type and intensity of rate control treatment, with the majority of data derived from short-term crossover 1567 
trials and observational studies.41, 526-528 Pharmacological rate control can be achieved for acute or long-term rate 1568 
control with beta-blockers, digoxin, the calcium channel blockers diltiazem and verapamil, or combination 1569 
therapy (Table 15). A number of antiarrhythmic drugs also have rate-limiting properties (amiodarone, 1570 
dronedarone, sotalol, and to some extent propafenone), but they should only be used in patients needing rhythm 1571 
control therapy (see Chapter 10). 1572 
 1573 
10.1. Acute rate control 1574 
In the setting of acute new-onset AF, patients are often in need of heart rate control. Physicians should evaluate 1575 
underlying causes of elevated heart rate, such as infection, endocrine imbalance, anaemia, and pulmonary 1576 
embolism. For acute rate control, beta-blockers and diltiazem/verapamil are preferred over digoxin because of 1577 
their rapid onset of action and effectiveness at high sympathetic tone.528-532 The choice of drug (Table 15) and 1578 
target heart rate will depend on patient characteristics, symptoms, LVEF and haemodynamics, but a lenient 1579 
initial approach to heart rate seems acceptable. Combination therapy may be required (Figure 14). In patients 1580 
with evidence of HFrEF, beta-blockers, digitalis (digoxin or digitoxin), or their combination should be used,218, 1581 
533 as diltiazem and verapamil can have negative inotropic effects in patients with LVEF < 40%.222, 534, 535 In 1582 
critically ill patients and those with severely impaired LV systolic function, intravenous amiodarone can be used 1583 
where excess heart rate is leading to haemodynamic instability.536-538 Urgent cardioversion should be considered 1584 
in unstable patients (see Chapter 10.2). 1585 
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 1586 
Figure 14 Acute heart rate control of AF.  1587 
See Table 15 for medication dosage. Digitoxin is a suitable alternative to digoxin, where available.  1588 
AF = atrial fibrillation; bpm = beats per minute; LVEF = left ventricular ejection fraction. 1589 
 1590 
10.2. Long-term pharmacological rate control  1591 
10.2.1. Beta-blockers 1592 
Beta-adrenoreceptor blocker monotherapy is often the first-line rate-controlling agent,539 largely based on 1593 
observations of better acute heart rate control than digoxin. Interestingly, the prognostic benefit of beta-blockers 1594 
seen in HFrEF patients with sinus rhythm is lost in those with AF. In an individual patient-level meta-analysis 1595 
of RCTs, beta-blockers did not reduce all-cause mortality compared to placebo in those with AF at baseline (HR 1596 
0.97; 95% CI 0.83–1.14; P = 0.73), whereas there was a clear benefit in patients with sinus rhythm (HR 0.73; 1597 
95% CI 0.67–0.80; P < 0.001).23 The study, which included 3066 participants with HFrEF and AF, showed 1598 
consistency across all subgroups and outcomes, with no heterogeneity between the 10 RCTs included (I2 = 0%). 1599 
Despite this lack of prognostic benefit in HFrEF, this Task Force still considers beta-blockers as a useful first-1600 
line rate control agent across all AF patients, based on the potential for symptomatic and cardiac function 1601 
improvement as a result of rate control, the lack of harm from published studies, and the good tolerability profile 1602 
across all ages in sinus rhythm and in AF.23, 540 1603 
 1604 
10.2.2. Non-dihydropyridine calcium channel blockers 1605 
Verapamil or diltiazem provides reasonable rate control in AF patients.541 They should be avoided in patients 1606 
with HFrEF because of their negative inotropic effects.222, 534, 535 Verapamil or diltiazem can improve 1607 
arrhythmia-related symptoms,526 in comparison with beta-blockers, which reduced exercise capacity and 1608 
increased B-type natriuretic peptide in one small trial of low-risk patients with preserved LVEF.542  1609 
 1610 
10.2.3. Digitalis 1611 
Cardiac glycosides such as digoxin and digitoxin have been in use for over two centuries, although prescriptions 1612 
have been declining steadily over the past 15 years.543 In the randomized Digitalis Investigation Group (DIG) 1613 
trial, digoxin had no effect on mortality compared to placebo in HFrEF patients in sinus rhythm (RR 0.99; 95% 1614 
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CI 0.91–1.07), but reduced hospital admissions (RR 0.72; 95% CI 0.66–0.79).544, 545 There have been no head-1615 
to-head RCTs of digoxin in AF patients.546 Observational studies have associated digoxin use with excess 1616 
mortality in AF patients,547-549 but this association is likely due to selection and prescription biases rather than 1617 
harm caused by digoxin,550-553 particularly as digoxin is commonly prescribed to sicker patients.225 In a 1618 
crossover mechanistic trial of 47 patients with HFrEF and AF, there were no differences in heart rate, blood 1619 
pressure, walking distance, or LVEF between carvedilol and digoxin, although beta-blockers did result in higher 1620 
B-type natriuretic peptide levels, combination carvedilol/digoxin improved LVEF, and digoxin withdrawal 1621 
reduced LVEF.554 Comparisons with other rate control therapies are based on small, short-duration studies that 1622 
identify no or marginal differences in exercise capacity, quality of life, or LVEF compared to digoxin.526, 554-558 1623 
Lower doses of digoxin (≤ 250 µg once daily), corresponding to serum digoxin levels of 0.5–0.9 ng/mL, may be 1624 
associated with better prognosis.225 1625 
 1626 
10.2.4. Amiodarone 1627 
Amiodarone can be useful for rate control as a last resort. The wide array of extracardiac adverse effects 1628 
associated with amiodarone renders it a reserve agent in patients whose heart rate cannot be controlled with 1629 
combination therapy (e.g. beta-blocker or verapamil/diltiazem combined with digoxin). 1630 
  1631 
In summary, there is equipoise for the use of different rate control agents in AF. The choice of beta-blocker, 1632 
diltiazem/verapamil, digoxin, or combination therapy should be made on an individual basis, after consideration 1633 
of patient characteristics and patient preference. All available therapies have the potential for adverse effects and 1634 
patients should initially be treated with a low dose and uptitrated to achieve symptom improvement. In practice, 1635 
achieving a heart rate < 110 bpm will often require combination therapy (Figure 15). The benefit of different 1636 
rate control strategies on symptoms, quality of life, and other intermediate outcomes is under investigation.559  1637 
 1638 
Figure 15 Long-term heart rate control of AF.  1639 
See Table 15 for medication dosage. Digitoxin is a suitable alternative to digoxin, where available.  1640 
AF = atrial fibrillation; bpm = beats per minute; LVEF = left ventricular ejection fraction. 1641 
 1642 
10.3. Heart rate targets in atrial fibrillation 1643 
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The optimal heart rate target in AF patients is unclear. The RACE (Rate Control Efficacy in Permanent Atrial 1644 
Fibrillation) II study randomized 614 patients with permanent AF to either a target heart rate < 80 bpm at rest 1645 
and < 110 bpm during moderate exercise, or to a lenient heart rate target of < 110 bpm. There was no difference 1646 
in a composite of clinical events (14.9% in the strict rate control group, 12.9% in the lenient group),560 NYHA 1647 
class, or hospitalizations.560, 561 Similar results were found in a pooled analysis of the AFFIRM (Atrial 1648 
Fibrillation Follow-up Investigation of Rhythm Management) and RACE trials (1091 participants), albeit with 1649 
smaller heart rate differences and without randomization.562 It is worthwhile to note that many ‘adequately rate-1650 
controlled’ patients (resting heart rate 60–100 bpm) are severely symptomatic, calling for additional 1651 
management.194 Nonetheless, lenient rate control is an acceptable initial approach, regardless of heart failure 1652 
status, unless symptoms call for stricter rate control.  1653 
 1654 
10.4. Atrioventricular node ablation and pacing  1655 
Ablation of the atrioventricular node/His bundle and implantation of a VVI pacemaker can control ventricular 1656 
rate when medications fail to control rate and symptoms. It is a relatively simple procedure with a low 1657 
complication rate and low long-term mortality risk,563, 564 especially when the pacemaker is implanted a few 1658 
weeks before the AV nodal ablation and the initial pacing rate after ablation is set at 70–90 bpm.565, 566 The 1659 
procedure does not worsen LV function567 and may even improve LVEF in selected patients.568-570 In some 1660 
patients in heart failure treated with biventricular pacing (cardiac resynchronization therapy), AF can 1661 
terminate,571 although such a ‘rhythm control’ effect of cardiac resynchronization therapy is likely to be small 1662 
and clearly needs confirmation.572 AV nodal ablation renders patients pacemaker-dependent for the rest of their 1663 
lives, limiting AV nodal ablation and pacing to patients whose symptoms cannot be managed by rate controlling 1664 
medication or by reasonable rhythm control interventions. The choice of pacing therapy (right ventricular or 1665 
biventricular pacing with or without an implantable defibrillator) will depend on individual patient 1666 
characteristics, including LVEF.573, 574  1667 
 1668 
Recommendations for rate control 1669 
Recommendations Class a Level b Refs c 
Beta-blocker, digoxin, diltiazem, or verapamil are recommended 
to control heart rate in AF patients with LVEF ≥ 40% I B 
225, 526, 
528, 531, 
532, 541, 
555, 575  
Beta-blocker and/or digoxin are recommended to control heart 
rate in AF patients with LVEF < 40%  I B 
23, 225, 526, 
533, 554, 
575, 576 
Combination therapy comprising different rate controlling agents 
should be considered if a single agent does not achieve the 
necessary heart rate target 
IIa C 23, 554, 577 
In cases of haemodynamic instability or severe depression in 
LVEF, amiodarone may be considered for acute control of heart 
rate 
Ilb B 536-538 
In patients with permanent AF (i.e. where no attempt to restore 
sinus rhythm is planned), antiarrhythmic drugs should not 
routinely be used for rate control 
III (harm) A 41, 578, 579 
A resting heart rate of < 110 bpm (i.e. lenient rate control) should 
be considered as the initial heart rate target for rate control 
therapy 
IIa B 560 
Rhythm rather than rate control strategies should be considered 
as the preferred management in pre-excited AF and AF during 
pregnancy 
IIa C  
Atrioventricular node ablation should be considered to control 
heart rate in patients unresponsive or intolerant to intensive rate 
and rhythm control therapy, accepting that these patients will 
become pacemaker dependent 
IIa B 
184, 564, 
569 
AF = atrial fibrillation; bpm = beats per minute; LVEF = left ventricular ejection fraction.  1670 
Digitoxin is a suitable alternative to digoxin, where available. In patients with heart failure with reduced ejection 1671 
fraction (LVEF < 40%), recommended beta-blockers are bisoprolol, carvedilol, long-acting metoprolol, and 1672 
nebivolol. 1673 
a Class of recommendation. 1674 
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b Level of evidence. 1675 
c Reference(s) supporting recommendations. 1676 
 1677 
Table 15 Rate control therapy in AF 1678 
Therapy Acute 
intravenous 
rate control 
Long-term oral 
rate control 
Side-effect profile Comments 
Beta-blockersa 
 Bisoprolol Not available 1.25–20 mg once 
daily or split 
Most common 
reported adverse 
symptoms are 
lethargy, headache, 
peripheral oedema, 
upper respiratory tract 
symptoms, 
gastrointestinal upset, 
and dizziness. 
Adverse effects 
include bradycardia, 
atrioventricular block, 
and hypotension 
Bronchospasm is 
rare – in cases of 
asthma, recommend 
beta-1 selective 
agents (avoid 
carvedilol). 
Contraindicated in 
acute cardiac failure 
and a history of 
severe 
bronchospasm 
 
 Carvedilol Not available 3.125–50 mg 
twice daily 
 Metoprolol 2.5–10 mg 
intravenous 
bolus (repeated 
as required) 
100–200 mg total 
daily dose 
(according to 
preparation) 
Nebivolol N/A 2.5–10 mg once 
daily or split 
Esmolol 0.5 mg 
intravenous 
bolus over 1 
min; then 0.05–
0.25 mcg/kg/min 
 
Calcium-channel blockers 
 Diltiazem 15–25 mg 
intravenous 
bolus (repeated 
as required) 
60 mg three 
times daily up to 
360 mg total daily 
dose (120–360 
mg once daily 
modified release) 
Most common 
reported adverse 
symptoms are 
dizziness, malaise, 
lethargy, headache, 
hot flushes, 
gastrointestinal upset, 
and oedema. Adverse 
effects include 
bradycardia, 
atrioventricular block, 
and hypotension 
(prolonged 
hypotension possible 
with verapamil) 
Use with caution in 
combination with 
beta-blockers. 
Reduce dose with 
hepatic impairment 
and start with smaller 
dose in renal 
impairment. 
Contraindicated in LV 
failure with 
pulmonary 
congestion or LVEF 
< 40% 
 Verapamil 2.5–10 mg 
intravenous 
bolus (repeated 
as required) 
40–120 mg three 
times daily (120–
480 mg once 
daily modified 
release) 
Cardiac glycosides 
 Digoxin 0.5 mg 
intravenous 
bolus (0.75–1.5 
mg over 24 h in 
divided doses) 
0.0625–0.25 mg 
daily dose 
Most common 
reported adverse 
symptoms are 
gastrointestinal upset, 
dizziness, blurred 
vision, headache, and 
rash. In toxic states 
(serum levels > 2 
ng/mL), digoxin is 
proarrhythmic and 
can aggravate heart 
failure, particularly 
with coexistent 
hypokalaemia 
High plasma levels 
associated with 
increased risk of 
death. Check renal 
function before 
starting and adapt 
dose in patients with 
CKD. 
Contraindicated in 
accessory 
conducting 
pathways, ventricular 
tachycardia, and 
hypertrophic 
cardiomyopathy with 
outflow tract 
obstruction 
 Digitoxin  
  
0.4–0.6 mg 
intravenous 
bolus 
0.05–0.3 mg 
daily dose 
Specific indications 
 Amiodarone 300 mg 200 mg daily Hypotension, Suggested as 
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intravenously 
diluted in 250 
mL 5% dextrose 
over 30–60 min 
(preferably via 
central venous 
cannula)b 
bradycardia, nausea, 
QT prolongation, 
pulmonary toxicity, 
skin discolouration, 
thyroid dysfunction, 
corneal deposits, and 
cutaneous reaction 
with extravasation 
adjunctive therapy in 
patients where heart 
rate control cannot 
be achieved using 
combination therapy 
AF = atrial fibrillation; CKD = chronic kidney disease; LV = left ventricular; LVEF = left ventricular ejection 1679 
fraction.  1680 
aA number of other beta-blockers are also available, but are not recommended as specific rate control therapy in 1681 
AF. These include atenolol (25–100 mg once daily with a short biological half-life), propranolol (non-selective, 1682 
1 mg over 1 min and repeat up to 3 mg at 2-min intervals [acute] or 10–40 mg three times daily [long-term]), or 1683 
labetalol (non-selective, 1–2 mg/min [acute]). 1684 
bIf ongoing requirement for amiodarone, follow with 900 mg intravenous over 24 hours diluted in 500–1000 mL 1685 
via a central venous cannula. 1686 
 1687 
11 Rhythm control therapy in atrial fibrillation 1688 
Restoring and maintaining sinus rhythm is an integral part of AF management. Antiarrhythmic drugs 1689 
approximately double the rate of sinus rhythm compared with placebo.580-584 Catheter ablation or combination 1690 
therapy is often effective when antiarrhythmic drugs fail.226, 585-587 Although many clinicians believe that 1691 
maintaining sinus rhythm can improve outcomes in AF patients,588 all trials that have compared rhythm control 1692 
to rate control (with appropriate anticoagulation) therapy have resulted in neutral outcomes.41, 578, 579, 582, 589-593 1693 
Whether modern rhythm control management involving catheter ablation, combination therapy, and early 1694 
therapy leads to a reduction in major cardiovascular events (e.g. stroke and cardiovascular death) is currently 1695 
under investigation (e.g. in the EAST [Early treatment of Atrial fibrillation for Stroke prevention Trial] – 1696 
AFNET 440 and CABANA [Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial]594 1697 
trials). For now, rhythm control therapy is indicated to improve symptoms in AF patients who remain 1698 
symptomatic on adequate rate control therapy. 1699 
 1700 
11.1. Acute restoration of sinus rhythm 1701 
11.1.1. Antiarrhythmic drugs for acute restoration of sinus rhythm 1702 
(‘pharmacological cardioversion’) 1703 
Antiarrhythmic drug can restore sinus rhythm in patients with AF (pharmacological cardioversion) as 1704 
shown in small controlled trials, meta-analyses,41, 584, 595, 596 and in a few larger controlled trials.597-605 1705 
Outside of Europe, dofetilide is available and can convert recent-onset AF.606 Pharmacological cardioversion 1706 
restores sinus rhythm in approximately 50% of patients with recent-onset AF (Table 16).607-609 In the short term, 1707 
electrical cardioversion restores sinus rhythm quicker and more effectively than pharmacological cardioversion 1708 
and is associated with shorter hospitalization.609-613 Pharmacological cardioversion, conversely, does not require 1709 
sedation or fasting (Figure 16).  1710 
 Flecainide and propafenone are effective for pharmacological cardioversion,595, 602-605, 614, 615 but their 1711 
use is restricted largely to patients without structural heart disease. Ibutilide is an alternative where available, 1712 
but carries a risk of torsades de pointes.615 Vernakalant602-605 can be given to patients with mild heart failure 1713 
(NYHA Class I or II), including those with ischaemic heart disease, provided they do not present with 1714 
hypotension or severe aortic stenosis.616-618 Amiodarone can be used in patients with heart failure and in patients 1715 
with ischaemic heart disease (although patients with severe heart failure were excluded in most of the AF 1716 
cardioversion trials).596 Amiodarone also slows heart rate by 10–12 bpm after 8–12 hours when given 1717 
intravenously.596 Both amiodarone and flecainide appear more effective than sotalol in restoring sinus 1718 
rhythm.600, 601, 619 1719 
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 1720 
Figure 16 Rhythm control management of acute AF. 1721 
AF = atrial fibrillation; HFmrEF = heart failure with mid-range ejection fraction; HFrEF = heart failure with 1722 
reduced ejection fraction. 1723 
aIbutilide should not be used in patients with long QT interval. 1724 
 1725 
11.1.2. ‘Pill in the pocket’ cardioversion performed by patients 1726 
In selected patients with infrequent symptomatic episodes of paroxysmal AF, a single bolus of oral flecainide 1727 
(200–300 mg) or propafenone (450–600 mg) can be self-administered by the patient at home (‘pill in the pocket’ 1728 
therapy) to restore sinus rhythm, after safety has been established in the hospital setting.620 This approach seems 1729 
marginally less effective than hospital-based cardioversion,621 but is practical and provides control and 1730 
reassurance to selected patients.  1731 
 1732 
Table 16 Antiarrhythmic drugs for pharmacological cardioversion 1733 
Drug Route First dose Follow-up 
dose 
Risks Referenc
es 
Flecainide Oral 
 
200–300 mg 
 
 
 
 
N/A 
Avoid in patients with IHD and/or 
significant structural heart disease. 
Hypotension, atrial flutter with 1:1 
conduction, QT prolongation 
595, 598 
IV 1.5–2 mg/kg 
over 10 min 
Amiodarone IVa 5–7 mg/kg over 
1–2 h 
50 mg/h to a 
maximum 
of 1.0 g 
over 24 h 
Phlebitis, hypotension, 
bradycardia/AV block. Will slow 
ventricular rate. 
Delayed conversion to sinus rhythm 
(8–12 h) 
596-601  
Propafenone IV 
 
1.5–2 mg/kg 
over 10 min 
 
 Avoid in patients with IHD and/or 
significant structural heart disease. 
Hypotension, atrial flutter with 1:1 
622-625 
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Oral 450–600 mg conduction, QRS prolongation (mild) 
Ibutilideb IV 1 mg over 10 
min 
1 mg over 
10 min after 
waiting for 
10 min 
Avoid in patients with QT 
prolongation, hypokalemia, severe 
LVH, or low ejection fraction. 
QT prolongation, polymorphic 
ventricular tachycardia/torsades de 
pointes (3–4% of patients). Will slow 
ventricular rate 
614, 615 
Vernakalant IV 3 mg/kg over 10 
min 
2 mg/kg 
over 10 min 
after 
waiting for 
15 min 
Avoid in patients with systolic blood 
pressure < 100 mmHg, recent (< 30 
days) ACS, NYHA Class III and IV 
heart failure, QT interval 
prolongation (uncorrected QT > 440 
ms), and severe aortic stenosis. 
Hypotension, non-sustained 
ventricular arrhythmias, QT and 
QRS prolongation 
602-605, 618 
ACS = acute coronary syndromes; IHD = ischaemic heart disease; IV = intravenous; LVH = left ventricular 1734 
hypertrophy; NYHA = New York Heart Association. 1735 
aUse a large peripheral vessel and change to oral amiodarone within 24 h of IV (central line) administration.  1736 
bIbutilide is only available in selected European countries. 1737 
 1738 
11.1.3. Electrical cardioversion 1739 
Synchronized direct current electrical cardioversion quickly and effectively converts AF to sinus rhythm and is 1740 
the method of choice in severely haemodynamically compromised patients with new-onset AF (Figure 16).626-1741 
628 Electrical cardioversion can be performed safely in sedated patients treated with intravenous midazolam 1742 
and/or propofol. Continuous monitoring of blood pressure and oximetry during the procedure is important.629 1743 
Skin burns may occasionally be observed. Intravenous atropine or isoproterenol or temporary transcutaneous 1744 
pacing should be available to mitigate post-cardioversion bradycardia. Biphasic defibrillators are more effective 1745 
than monophasic waveforms, and have become industry standard.626, 628 Anterior–posterior electrode positions 1746 
generate a stronger shock field in the left atrium than anterolaterally positioned electrodes, and restore sinus 1747 
rhythm more effectively. 626, 627, 630  1748 
 Pretreatment with amiodarone (requiring a few weeks of therapy),631, 632 sotalol,631 ibutilide,633 or 1749 
vernakalant634 can improve efficacy of electrical cardioversion, and similar effects are likely for flecainide584 1750 
and propafenone.635 Beta-blockers,636 verapamil, diltiazem,637-639 and digoxin640, 641 do not reliably terminate AF 1751 
or facilitate electrical cardioversion. When antiarrhythmic drug therapy is planned to maintain sinus rhythm 1752 
after cardioversion, it seems prudent to start therapy 1–3 days before cardioversion (amiodarone: a few weeks) 1753 
to promote pharmacological conversion and to achieve effective drug levels.584, 601 1754 
 1755 
11.1.4. Anticoagulation in patients undergoing cardioversion  1756 
Cardioversion carries an inherent risk of stroke in non-anticoagulated patients,642 which is reduced substantially 1757 
by the administration of anticoagulation.643 Immediate initiation of anticoagulation is important in all patients 1758 
scheduled for cardioversion.644-646 Patients who have been in AF for longer than 48 hours should start OAC at 1759 
least 3 weeks before cardioversion and continue it for 4 weeks afterwards (in patients without a need for long-1760 
term anticoagulation), and continue it indefinitely in patients at risk of stroke. This practice has never been 1761 
evaluated in controlled trials, but seemed safe in a large observational data set from Finland.647 When early 1762 
cardioversion is desired, TOE can exclude the majority of left atrial thrombi, allowing immediate 1763 
cardioversion.648, 649 Ongoing studies will inform about the safety and efficacy of newly initiated anticoagulation 1764 
using NOACs in patients scheduled for electrical cardioversion. 1765 
 1766 
11.2. Long-term antiarrhythmic drug therapy 1767 
The aim of antiarrhythmic drug therapy is improvement in AF-related symptoms.41, 580 Hence, the decision to 1768 
initiate long-term antiarrhythmic drug therapy needs to balance symptom burden, possible adverse drug 1769 
reactions, and patient preferences. The principles of antiarrhythmic drug therapy outlined in the 2010 ESC AF 1770 
guidelines369 are still relevant and should be observed: 1771 
1. Treatment is aimed at reducing AF-related symptoms; 1772 
2. Efficacy of antiarrhythmic drugs to maintain sinus rhythm is modest; 1773 
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3. Clinically successful antiarrhythmic drug therapy may reduce rather than eliminate the recurrence of 1774 
AF; 1775 
4. If one antiarrhythmic drug ‘fails’, a clinically acceptable response may be achieved with another agent; 1776 
5. Drug-induced proarrhythmia or extra-cardiac side-effects are frequent; 1777 
6. Safety rather than efficacy considerations should primarily guide the choice of antiarrhythmic drug. 1778 
 1779 
Antiarrhythmic drug therapy approximately doubles sinus rhythm maintenance compared with no therapy.580 1780 
There is no appreciable effect on mortality or cardiovascular complications, but rhythm control therapy can 1781 
slightly increase the risk of hospitalizations (often for AF).41, 578, 579, 582, 589-593 To reduce the risk of side-1782 
effects,201, 580 a shorter duration of antiarrhythmic drug therapy seems desirable. As an example, short-term 1783 
treatment (4 weeks) with flecainide for 4 weeks after cardioversion of AF was well-tolerated and prevented 1784 
most (80%) AF recurrences when compared with long-term treatment.584 Short-term antiarrhythmic drug 1785 
therapy is also used to avoid early AF recurrences after catheter ablation650 and may be reasonable in patients 1786 
deemed at increased risk of antiarrhythmic drug side-effects or in those with a low perceived risk of recurrent 1787 
AF.  1788 
 In addition to antiarrhythmic drug therapy and catheter ablation (see Section 10.3), management of 1789 
concomitant cardiovascular conditions can reduce symptom burden in AF and facilitate maintenance of sinus 1790 
rhythm.203, 204, 296, 312 This includes weight reduction, blood pressure control, heart failure treatment, increasing 1791 
cardiorespiratory fitness, and other measures (see Chapter 6). 1792 
 1793 
11.2.1. Selection of antiarrhythmic drugs for long-term therapy: Safety first!  1794 
Usually, the safety of antiarrhythmic drug therapy determines the initial choice of antiarrhythmic drugs (Figure 1795 
17). The following major antiarrhythmic drugs are available to prevent AF: 1796 
 1797 
Amiodarone is an effective multichannel blocker, reduces ventricular rate, and is safe in patients with heart 1798 
failure.582, 651 Torsades de pointes proarrhythmia can occur, and QT interval and TU waves should be monitored 1799 
on therapy (see Table 17).652 Amiodarone often causes extracardiac side-effects, especially on long-term 1800 
therapy,653, 654 rendering it a second-line treatment in patients who are suitable for other antiarrhythmic drugs. 1801 
Amiodarone appears less suitable to episodic short-term therapy (unless after catheter ablation),655 probably 1802 
because of its long biological half-life. 1803 
 1804 
Dronedarone maintains sinus rhythm, reduces ventricular rate, and prevents cardiovascular hospitalizations 1805 
(mostly due to AF) and cardiovascular death in patients with paroxysmal or persistent AF or flutter who had at 1806 
least one relevant cardiovascular comorbidity.583, 588, 656 Dronedarone increases mortality in patients with 1807 
recently decompensated heart failure (with or without AF)657 and in patients with permanent AF in whom sinus 1808 
rhythm is not restored.658 Dronedarone moderately increases serum creatinine, reflecting a reduction in 1809 
creatinine excretion rather than a decline in kidney function.659  1810 
 1811 
Flecainide and propafenone are effective in preventing recurrent AF.581, 584, 620 They should only be used in 1812 
patients without significant ischaemic heart disease or heart failure to avoid the risk of life-threatening 1813 
ventricular arrhythmias.660 High ventricular rates resulting from the conversion of AF into atrial flutter with 1:1 1814 
conduction by flecainide or propafenone can be prevented by preadministering a beta-blocker, verapamil, or 1815 
diltiazem. 1816 
 1817 
Quinidine and disopyramide have been associated with an increase in all-cause mortality (OR 2.39; 95% CI 1818 
1.03–5.59; number needed to harm 109; 95% CI 34–4985) at 1-year follow-up,580, 661 likely due to ventricular 1819 
arrhythmias (torsades de pointes).580, 661 Although this proarrhythmic effect is more common at higher doses, 1820 
they are less commonly used for rhythm control in AF. Disopyramide may be useful in ‘vagally mediated’ AF 1821 
(e.g. AF occurring in athletes and/or during sleep76), and has been shown to reduce LV outflow gradient and 1822 
improve symptoms in patients with hypertrophic cardiomyopathy.662-664  1823 
 1824 
Sotalol has a relevant risk of torsades de pointes (1% in the Prevention of Atrial Fibrillation After Cardioversion 1825 
[PAFAC] trial118). Its d-enantiomer is associated with an increased mortality compared to placebo in patients 1826 
with LV dysfunction post-myocardial infarction,665 probably due to ventricular arrhythmias (OR 2.47; 95% CI 1827 
1.2–5.05; number needed to harm 166; 95% CI 61–1159).580, 665 On the other hand, d,l sotalol has been used in 1828 
AF patients without safety signals in two controlled trials.581, 601  1829 
 1830 
Dofetilide is another potassium channel blocker that is mainly available outside of Europe. Dofetilide restores 1831 
and maintains sinus rhythm in heart failure patients666 and occasionally in patients refractory to other 1832 
antiarrhythmic drugs.667 1833 
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 1834 
Overall, it seems prudent to limit the use of quinidine, disopyramide, dofetilide, and sotalol to specific 1835 
situations. Similarly, combinations of QT-prolonging antiarrhythmic drugs should generally be avoided (Table 1836 
17). 1837 
 1838 
Figure 17 Initiation of rhythm control therapy in symptomatic patients. 1839 
AF = atrial fibrillation; HF = heart failure; LVH = left ventricular hypertrophy; 1840 
aSotalol requires careful evaluation of proarrhythmic risk. 1841 
bCatheter ablation should isolate pulmonary veins and can be performed using radiofrequency or cryoballoon 1842 
catheters.  1843 
cCatheter ablation as a first-line therapy is usually reserved for heart failure patients with tachycardiomyopathy. 1844 
dAmiodarone is a second-choice therapy in many patients because of its extracardiac side-effects. 1845 
 1846 
11.2.2. Twelve-lead electrocardiogram as a tool to identify patients at risk of 1847 
proarrhythmia 1848 
Identifying patients at risk of proarrhythmia can help to mitigate the proarrhythmic risk of antiarrhythmic 1849 
drugs.668 In addition to the clinical characteristics mentioned above, monitoring PR, QT, and QRS durations 1850 
during initiation of antiarrhythmic drug therapy can identify patients at higher risk of drug-induced 1851 
proarrhythmia on longer-term treatment.669-671 In addition, the presence of ‘abnormal TU waves’ is a sign of 1852 
imminent torsades de pointes.652 Periodic ECG analysis for proarrhythmia signs has been used successfully in 1853 
recent antiarrhythmic drug trials.118, 584, 672 Specifically, ECG monitoring was used systematically on days 1–3 in 1854 
patients receiving flecainide, propafenone, or sotalol to identify those at risk of proarrhythmia.118, 584, 601 Based 1855 
on this evaluated practice, we suggest to record an ECG in all patients before initiation of antiarrhythmic drugs. 1856 
Scheduled ECGs during the initiation period seem reasonable (Table 17).  1857 
 1858 
Table 17 Oral antiarrhythmic drugs used for maintaining sinus rhythm after cardioversion.  1859 
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Drug Dose Main contraindications and 
precautions 
Warning signs 
warranting 
discontinuation 
Atrioventricu
lar nodal 
slowing 
Suggested 
ECG 
monitoring 
during 
initiation 
Amiodarone 600 mg in 
divided 
doses for 4 
weeks, 400 
mg for 4 
weeks, then 
200 mg 
once daily 
Caution when using concomitant 
therapy with QT-prolonging drugs 
and in patients with sinoatrial node 
or atrioventricular node and 
conduction disease.  
The dose of VKAs and of digitalis 
should be reduced. Increased risk of 
myopathy with statins. 
Caution in patients with pre-
existing liver disease 
QT 
prolongation > 
500 ms 
10–12 bpm in 
AF 
Baseline, 1 
week, 4 
weeks 
Dronedarone 400 mg 
twice daily 
Contraindicated in NYHA class III 
or IV or unstable heart failure, 
during concomitant therapy with 
QT-prolonging drugs, or powerful 
CYP3A4 inhibitors (e.g. verapamil, 
diltiazem, azole antifungal agents), 
and when CrCl < 30 mg/mL. 
The dose of digitalis, beta-blockers, 
and of some statins should be 
reduced.  
Elevations in serum creatinine of 
0.1–0.2 mg/dL are common and do 
not reflect a decline in renal 
function. 
Caution in patients with pre-
existing liver disease 
QT 
prolongation > 
500 ms 
10–12 bpm in 
AF 
Baseline, 1 
week, 4 
weeks 
Flecainide 
 
100–150 mg 
twice daily 
 
Contraindicated if CrCl < 50 
mg/mL, liver disease, IHD, or 
reduced LVEF. 
Caution in the presence of sinoatrial 
node or atrioventricular node or 
conduction system disease. 
CYP2D6 inhibitors (e.g. fluoxetine, 
tricyclic) increase plasma 
concentration 
QRS duration 
increases > 25% 
above baseline 
None Baseline, 
day 1, day 
2–3 
Flecainide slow 
release 
200 mg 
once daily 
Propafenone 
 
150–300 mg 
three times 
daily 
 
Contraindicated in IHD or reduced 
LV ejection fraction. 
Caution in the presence of sinoatrial 
node or atrioventricular node and 
conduction system disease, renal or 
liver impairment, and asthma. 
Increases concentration of digitalis 
and warfarin 
QRS duration 
increase > 25% 
above baseline 
Slight Baseline, 
day 1, day 
2–3 
Propafenone 
SR 
225–425 mg 
twice daily 
d,l sotalol 80–160 mg 
twice daily 
Contraindicated in the presence of 
significant LV hypertrophy, systolic 
heart failure, asthma, pre-existing 
QT prolongation, hypokalaemia, 
CrCl < 50 mg/mL.  
Moderate renal dysfunction requires 
careful adaptation of dose 
QT interval 
> 500 ms, QT 
prolongation by 
> 60 ms upon 
therapy 
initiation 
Similar to 
high-dose 
blockers 
Baseline, 
day 1, day 
2–3 
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AF = atrial fibrillation; bpm = beats per minute; CrCl = creatinine clearance; ECG = electrocardiogram; IHD = 1860 
ischaemic heart disease; LV = left ventricular; LVEF = left ventricular ejection fraction; NYHA = New York 1861 
Heart Association; VKA = vitamin K antagonist. 1862 
 1863 
11.2.3. New antiarrhythmic drugs 1864 
Several compounds that inhibit the ultrarapid potassium current (IKur) and other inhibitors of atypical ion 1865 
channels are in clinical development.673-675 They are not available for clinical use at present. The antianginal 1866 
compound ranolazine inhibits potassium and sodium currents and increases glucose metabolism at the expense 1867 
of free fatty acid metabolism, thereby enhancing efficient use of oxygen.676, 677 Ranolazine was safe in patients 1868 
with non–ST-segment elevation myocardial infarction and unstable angina evaluated in the MERLIN 1869 
(Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome) 1870 
trial.678 In a post-hoc analysis of continuous ECG recordings obtained during the first 7 days after 1871 
randomization, patients assigned to ranolazine had a trend towards fewer episodes of AF than those on placebo 1872 
(75 [2.4%] vs. 55 [1.7%] patients; P = 0.08).679 In the HARMONY (A Study to Evaluate the Effect of 1873 
Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial 1874 
Fibrillation) trial, the highest tested dose of a combination of ranolazine (750 mg twice daily) and dronedarone 1875 
(225 mg twice daily) slightly reduced AF burden in 134 subjects with paroxysmal AF and dual-chamber 1876 
pacemakers.680 Small, open-label studies suggest that ranolazine might enhance the antiarrhythmic effect of 1877 
amiodarone for cardioversion,681-683 whereas the results from a controlled trial of ranolazine and the ranolazine–1878 
dronedarone combination to prevent AHRE in pacemaker patients were ambiguous.684 At present, there is 1879 
insufficient evidence to recommend ranolazine as an antiarrhythmic drug, alone or in combination with other 1880 
antiarrhythmic drugs. Of note, the ‘funny channel blocker’ ivabradine, which is used for angina and heart 1881 
failure, increases the risk of AF.685 1882 
 1883 
11.2.4. Antiarrhythmic effects of non-antiarrhythmic drugs 1884 
ACE inhibitors or ARBs appear to prevent new-onset AF in patients with LV dysfunction and in hypertensive 1885 
patients with LV hypertrophy.219, 236, 237, 239, 246, 250, 686 Neprilysin inhibition needs to be studied further, but does 1886 
not seem to enhance this effect.224 A Danish cohort study also suggested that initial treatment of uncomplicated 1887 
hypertension with ACE inhibitors or ARBs reduces incident AF compared with other hypertensive agents.245 1888 
ARB therapy did not reduce the AF burden in patients with AF without structural heart disease.241 Thus, ACE 1889 
inhibitors or ARBs are unlikely to have a relevant direct antiarrhythmic effect. However, it might be justified to 1890 
consider adding ACE inhibitors or ARB therapy to antiarrhythmic drugs to reduce AF recurrences after 1891 
cardioversion.248, 249, 687  1892 
 Compared with placebo, beta-blockers are associated with a reduced risk of new-onset AF in patients 1893 
with reduced ejection fraction and sinus rhythm.23 Beta-blockers have also been reported to reduce symptomatic 1894 
AF recurrences,580, 636, 688 but this finding may be driven by the beneficial effect of rate control, which will 1895 
render AF more often asymptomatic. 1896 
 Perioperative statin therapy appeared to reduce the risk of postoperative AF in a number of small 1897 
RCTs689, 690; however, an adequately powered placebo-controlled trial has shown no effect of perioperative 1898 
rosuvastatin therapy on postoperative AF.691 Statin treatment does not prevent AF in other settings.692, 693 1899 
Similarly, polyunsaturated fatty acids failed to show convincing benefit.241, 694-698 The role of aldosterone 1900 
antagonists in the management of AF has not been extensively investigated in humans; although preliminary 1901 
evidence from trials of eplerenone is encouraging for primary prevention,243 at present there is no robust 1902 
evidence to make any recommendation for the use of aldosterone antagonists for secondary prevention of AF.699-1903 
701 1904 
 1905 
Recommendations for rhythm control therapy 1906 
Recommendations Class a Level b Refs d  
General recommendations 
Management of cardiovascular risk factors and avoidance of AF 
triggers should be pursued in patients on rhythm control therapy to 
facilitate maintenance of sinus rhythm 
IIa B 203, 204, 
296, 312 
Rhythm control therapy is indicated for symptom improvement in 
patients with AF 
I B 120, 586, 
601 
With the exception of AF associated with haemodynamic instability, 
the choice between electrical and pharmacological cardioversion 
IIa C  
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should be guided by patient and physician preferences 
Cardioversion of AF 
Electrical cardioversion of AF is recommended in patients with acute 
haemodynamic instability to acutely restore cardiac output 
I B 612, 702-
704 
Cardioversion of AF (either electrical or pharmacological) is 
recommended in symptomatic patients with persistent or long-
standing persistent AF as part of rhythm control therapy 
I B 584, 601, 
627, 628, 
648, 705 
Pretreatment with amiodarone, flecainide, ibutilide, or propafenone 
should be considered to enhance success of electrical cardioversion 
and prevent recurrent AF 
IIa B 248, 584, 
633 
In patients with no history of ischaemic or structural heart disease, 
flecainide, propafenone, or vernakalant are recommended for 
pharmacological cardioversion of new-onset AF 
I A 602-605, 
614, 618, 
622, 706, 
707 
In patients with no history of ischaemic or structural heart disease, 
ibutilide should be considered for pharmacological conversion of AF 
IIa B  
In selected patients with recent-onset AF and no significant structural 
or ischaemic heart disease, a single oral dose of flecainide or 
propafenone (the ‘pill in the pocket’ approach) should be considered 
for patient-led cardioversion, following safety assessment 
IIa B 620, 621 
In patients with ischaemic and/or structural heart disease, 
amiodarone is recommended for cardioversion of AF 
I A 597-601 
Vernakalant may be considered as an alternative to amiodarone for 
pharmacological conversion of AF in patients without hypotension, 
severe heart failure, or severe structural heart disease (especially 
aortic stenosis) 
IIb B 602-605, 
616, 618 
Stroke prevention in patients designated for cardioversion of AF 
Anticoagulation with heparin or a NOAC should be initiated as soon 
as possible before every cardioversion of AF or atrial flutter 
IIa B 708, 709 
For cardioversion of AF/atrial flutter, effective anticoagulation is 
recommended for a minimum of 3 weeks before cardioversion 
I B 648, 708 
Transoesophageal echocardiography (TOE) is recommended to 
exclude cardiac thrombus, as an alternative to preprocedural 
anticoagulation when early cardioversion is planned 
I B 648, 708 
Early cardioversion can be performed without TOE in patients with a 
definite duration of AF < 48 hours 
IIa B 648 
In patients at risk for stroke (e.g. presence of CHA2DS2-VASc 
factors), anticoagulant therapy should be continued long-term after 
cardioversion according to the long-term anticoagulation 
recommendations, irrespective of the method of cardioversion or the 
apparent maintenance of sinus rhythm. In patients without stroke risk 
factors, anticoagulation is recommended for 4 weeks after 
cardioversion 
I B 353, 710 
In patients where thrombus is identified on TOE, effective 
anticoagulation is recommended for at least 3 weeks 
I C  
A repeat TOE to ensure thrombus resolution should be considered 
before cardioversion 
IIa C  
Antiarrhythmic drugs for the long-term maintenance of sinus rhythm/prevention of recurrent 
AF 
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The choice of antiarrhythmic drug needs to be carefully evaluated, taking 
into account the presence of comorbidities, cardiovascular risk and 
potential for serious proarrhythmia, extracardiac toxic effects, patient 
preferences, and symptom burden 
I A 41, 580 
Dronedarone, flecainide, propafenone, or sotalol are recommended for 
prevention of recurrent symptomatic AF in patients with normal left 
ventricular function and without pathological left ventricular hypertrophy.  
I A 581, 583, 
584, 588, 
601 
Dronedarone is recommended for prevention of recurrent symptomatic 
AF in patients with stable coronary artery disease, and without heart 
failure 
I A 583, 588 
Amiodarone is recommended for prevention of recurrent symptomatic AF 
in patients with heart failure 
I B 596-598 
Amiodarone is more effective in preventing AF recurrences than other 
antiarrhythmic drugs but extracardiac toxic effects are common and 
increase with time. For this reason, other antiarrhythmic drugs should be 
considered first 
IIa C 596-598 
Patients on antiarrhythmic drug therapy should be periodically evaluated 
to confirm their eligibility for treatment 
 
IIa 
 
C 
 
583, 588, 
657, 658, 
660  
ECG recording during the initiation of antiarrhythmic drug therapy should 
be considered to monitor heart rate, detect QRS and QT interval 
prolongation, and the occurrence of atrioventricular block 
 
IIa 
 
B 
 
584 582, 
583, 588, 
601 
Antiarrhythmic drug therapy is not recommended in patients with 
prolonged QT interval (> 0.5 s) or with significant sinoatrial node disease 
or atrioventricular node dysfunction who do not have a functioning 
permanent pacemaker 
 
III 
(harm) 
 
C 
 
Adding atrial-based bradycardia pacing to drug treatment that induces or 
exacerbates sinus node dysfunction should be considered to allow 
continuation of antiarrhythmic drug therapy in patients in whom AF 
ablation is declined or not indicated 
IIa B 711, 712 
Continuation of antiarrhythmic drug therapy beyond the blanking period 
after AF ablation should be considered to maintain sinus rhythm when 
recurrences seem likely 
IIa B 713 
Antiarrhythmic effects of non-antiarrhythmic drugs 
ACE inhibitors, ARBs, and beta-blockers should be considered for 
prevention of new-onset AF in patients with heart failure and reduced 
ejection fraction 
IIa A 23, 219, 236, 
237, 239, 
250, 714 
ACE inhibitors and ARBs should be considered for prevention of new-
onset AF in patients with hypertension, particularly with LV hypertrophy 
IIa B 238, 246, 
686, 714 
Pretreatment with ACE inhibitors or ARBs may be considered in patients 
with recurrent AF undergoing electrical cardioversion and receiving 
antiarrhythmic drug therapy 
IIb B 236, 237, 
248, 249 
ARBs or ACE inhibitors are not recommended for the secondary 
prevention of paroxysmal AF in patients with little or no underlying heart 
disease. 
III (no 
benefit) 
B 241, 697 
ACE = angiotensin-converting enzyme; AF = atrial fibrillation; ARB = angiotensin receptor blocker; CHA2DS2-1907 
VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled), Vascular 1908 
disease, Age 65–74, and Sex (female); ECG = electrocardiogram; NOAC = non-vitamin K antagonist oral 1909 
anticoagulant; TOE = transoesophageal echocardiography. 1910 
aClass of recommendation. 1911 
bLevel of evidence. 1912 
cReference(s) supporting recommendations. 1913 
 1914 
11.3. Catheter ablation 1915 
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Since the initial description of triggers in the pulmonary veins that initiate paroxysmal AF,108 catheter ablation 1916 
of AF has developed from a specialized, experimental procedure into a common treatment to prevent recurrent 1917 
AF.587, 715 This is primarily achieved through isolation of the pulmonary veins, probably requiring complete 1918 
isolation for full effectiveness,716 and additional ablation in the posterior left atrial wall. AF ablation, when 1919 
performed in experienced centres by adequately trained teams, is more effective than antiarrhythmic drug 1920 
therapy in maintaining sinus rhythm, and the complication rate, though not negligible, is similar to the 1921 
complication rate for antiarrhythmic drugs.585, 717, 1042 1922 
 1923 
11.3.1. Indications 1924 
Catheter ablation of AF is effective in restoring and maintaining sinus rhythm in patients with symptomatic 1925 
paroxysmal, persistent, and probably long-standing persistent AF – in general as second-line treatment after 1926 
failure of or intolerance to antiarrhythmic drug therapy. In such patients, catheter ablation is more effective than 1927 
antiarrhythmic drug therapy.185, 586, 713, 717-720 As first-line treatment for paroxysmal AF, randomized trials 1928 
showed only modestly improved rhythm outcome with catheter ablation compared to antiarrhythmic drug 1929 
therapy.585, 721-723 Complication rates were similar, but ablation was performed in expert centres, justifying 1930 
catheter ablation as first-line therapy in selected patients with paroxysmal AF who ask for interventional 1931 
therapy. Fewer data are available reporting the effectiveness and safety of catheter ablation in patients with 1932 
persistent or long-standing persistent AF, but all point to lower recurrence rates after catheter ablation compared 1933 
to antiarrhythmic drug therapy with or without cardioversion.185, 717, 723-726, 1039 In patients who experience 1934 
symptomatic recurrences of AF despite antiarrhythmic drug therapy, all RCTs showed better sinus rhythm 1935 
maintenance with catheter ablation than on antiarrhythmic drugs.586, 713, 727, 728 There is no current indication for 1936 
catheter ablation to prevent cardiovascular outcomes (or desired withdrawal of anticoagulation), or to reduce 1937 
hospitalization.40, 594 1938 
 1939 
11.3.2. Techniques and technologies 1940 
Complete pulmonary vein isolation (PVI) on an atrial level is the best documented target for catheter 1941 
ablation,716, 729-731 achievable by point-by-point radiofrequency ablation, linear lesions encircling the pulmonary 1942 
veins, or cryoballoon ablation, with similar outcomes.732-734 Complete isolation of the pulmonary veins has 1943 
better rhythm outcomes than incomplete isolation.716 PVI was initially tested in patients with paroxysmal AF, 1944 
but appears to be non-inferior to more extensive ablation in persistent AF as well.729, 735 More extensive 1945 
ablations have been used in patients with persistent AF, but there are insufficient data to guide the use of these at 1946 
present.117, 718, 719, 735-737 Extended ablation procedures (beyond PVI) consistently require longer procedures and 1947 
more ionizing radiation, potentially creating risk for patients. Left atrial macro-reentrant tachycardia is relatively 1948 
uncommon after PVI (≈ 5%). It also seems even less common after cryoballoon ablation,734 but may occur in up 1949 
to 25% of patients after left atrial substrate modification ablation, often due to incomplete ablation lines. Thus, 1950 
for patients with persistent AF, ablation of complex fractionated electrograms, ablation of rotors, or routine 1951 
deployment of linear lesions or other additional ablations does not seem justified in the first procedure.735, 738, 739 1952 
However, additional ablation on top of complete PVI716 may be considered in patients with recurrent AF after 1953 
the initial ablation procedure.719, 740, 741 In patients with documented right atrial isthmus-dependent flutter 1954 
undergoing AF ablation, right atrial isthmus ablation is recommended. Adenosine testing to identify patients in 1955 
need of additional ablation remains controversial after evaluation in several reports.739, 742-744 Ablation of so-1956 
called ‘rotors’ guided by body surface mapping or endocardial mapping is under evaluation and cannot be 1957 
recommended for routine clinical use at present.  1958 
 1959 
11.3.3. Outcome and complications 1960 
The rhythm outcome after catheter ablation of AF is difficult to predict in individual patients.173, 227, 713, 728 Most 1961 
patients require more than one procedure to achieve symptom control.713, 726, 728 In general, better rhythm 1962 
outcome and lower procedure-related complications can be expected in younger patients with a short history of 1963 
AF and frequent, short AF episodes in the absence of significant structural heart disease.745 Catheter ablation is 1964 
more effective than antiarrhythmic drug therapy in maintaining sinus rhythm (Web Addenda Figure 2).746, 1039  1965 
Sinus rhythm without severely symptomatic recurrences of AF is found in up to 70% of patients with 1966 
paroxysmal AF, and around 50% in persistent AF.713, 728, 735, 1042 Very late recurrence of AF after years of sinus 1967 
rhythm is not uncommon and may reflect disease progression, with important implications for continuation of 1968 
AF therapies.728 Multiple variables have been identified as risk factors for recurrence after catheter ablation of 1969 
AF, but their predictive power is weak. The decision for catheter ablation thus should be based on a shared 1970 
decision-making process747 (see Chapter 7), following thorough explanation of the potential benefits and risks, 1971 
and of the alternatives such as antiarrhythmic drug or acceptance of current symptoms without rhythm control 1972 
therapy.175  1973 
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Complications of catheter ablation for AF 1974 
There is a clear need to systematically capture complications in clinical practice to improve the quality of AF 1975 
ablation procedures.175 The median length of hospital stay in AF patients undergoing their first ablation as part 1976 
of the EURObservational Research Programme (EORP) was 3 days (interquartile range 2–4 days), based on 1977 
data from 1391 patients from hospitals performing at least 50 ablations per year. Five to seven per cent of 1978 
patients will suffer severe complications after catheter ablation of AF, and 2–3% will experience life-threatening 1979 
but usually manageable complications.727, 748-750 Intraprocedural death has been reported, but is rare (< 0.2%).751 1980 
The most important severe complications are stroke/TIA (< 1%), cardiac tamponade (1–2%), pulmonary vein 1981 
stenosis, and severe oesophageal injury leading to atrio-oesophageal fistula weeks after ablation (Table 18). 1982 
‘Silent strokes’ (i.e. white matter lesions detectable by brain MRI), have been observed in around 10% of 1983 
patients treated with radiofrequency and cryoballoon ablation.752 The clinical relevance of this observation is 1984 
unclear.749 Post-procedure complications include stroke, with the highest risk within the first week,753 late 1985 
pericardial tamponade several days after catheter ablation,751 and oesophageal fistulas, which usually become 1986 
apparent 7–30 days after ablation. Timely detection of atrio-oesophageal fistulas can be life-saving and should 1987 
be based on the typical triad of infection without a clear focus, retrosternal pain, and stroke or TIA.748 1988 
 1989 
Table 18 Complications related to catheter ablation of AF 1990 
Complication severity Complication type Rate727, 748, 750, 754-759 
Life-threatening complications 
Periprocedural death < 0.2% 
Oesophageal injury (perforation/fistula)a < 0.5% 
Periprocedural stroke (including TIA/air 
embolism) < 1% 
Cardiac tamponade 1–2% 
Severe complications 
Pulmonary vein stenosis < 1% 
Persistent phrenic nerve palsy 1–2% 
Vascular complications 2–4% 
Other severe complications ≈ 1% 
Other moderate or minor 
complications  1–2% 
Unknown significance Asymptomatic cerebral embolism (silent stroke)b 5–20% 
 Radiation exposure  
AF = atrial fibrillation; TIA = transient ischaemic attack. 1991 
aOesophageal fistula should be suspected in patients presenting with the triad of unspecific signs of infection, 1992 
chest pain, and stroke or TIA in the first weeks after an ablation procedure. It requires immediate therapy. 1993 
b< 10% for cryoablation or radiofrequency ablation, > 20% for phased radiofrequency ablation 1994 
 1995 
11.3.4. Anticoagulation – before, during, and after ablation 1996 
Patients anticoagulated with VKAs should continue therapy during ablation (with an INR of 2–3).760 1997 
Anticoagulation with NOACs is an alternative to warfarin.478, 761-765 There is no safety signal from observational 1998 
cohorts treated with uninterrupted NOAC therapy undergoing catheter ablation in experienced centres.761, 763, 766, 1999 
767 The first controlled trial, enrolling around 200 patients, has recently been published,768 as well as several 2000 
observational data sets.761, 769, 770 Ongoing studies compare uninterrupted VKA with NOAC therapy in AF 2001 
patients undergoing ablation (e.g. AXAFA – AFNET 5 [Apixaban During Atrial Fibrillation Catheter Ablation: 2002 
Comparison to Vitamin K Antagonist Therapy – Anticoagulation using the direct factor Xa inhibitor apixaban 2003 
during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy; NCT02227550] and 2004 
RE-CIRCUIT [Randomized Evaluation of dabigatran etexilate Compared to warfarin in pulmonaRy vein 2005 
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ablation: assessment of different peri-proCedUral anticoagulation sTrategies; NCT02348723]). During ablation, 2006 
heparin should be given to maintain an activated clotting time > 300 seconds. Anticoagulation should be 2007 
maintained for at least 8 weeks after ablation for all patients. The true incidence of thromboembolic events after 2008 
catheter ablation has never been systematically studied and the expected stroke risk has been adopted from non-2009 
ablation AF cohorts. Although observational studies suggest a relatively low stroke rate in the first few years 2010 
after catheter ablation of AF,737, 771-776 the long-term risk of recurrent AF and the safety profile of 2011 
anticoagulation in ablated patients need to be considered. In the absence of controlled trial data, OAC after 2012 
catheter ablation should follow general anticoagulation recommendations, regardless of the presumed rhythm 2013 
outcome. 2014 
 2015 
11.3.5. Ablation of atrial fibrillation in heart failure patients 2016 
Catheter ablation, compared with amiodarone therapy, significantly reduces recurrent AF in AF patients with 2017 
HFrEF.777 Selected patients with HFrEF and AF can achieve recovery of LV systolic function after catheter 2018 
ablation (probably reflecting tachycardiomyopathy). Several smaller trials suggest improved LV function after 2019 
catheter ablation in HFrEF patients185, 226-228, 778, 779 and reduced hospitalizations,720, 777 especially in patients 2020 
without a previous myocardial infarction.780 Larger trials are warranted to confirm these findings. Catheter 2021 
ablation can be demanding in these patients. Thus, indications for catheter ablation in HFrEF patients should be 2022 
carefully balanced, and the procedures performed in experienced centres.  2023 
 2024 
11.3.6. Follow-up after catheter ablation 2025 
Patients and physicians involved in the follow-up after catheter ablation should know the signs and symptoms of 2026 
late complications to allow swift referral for treatment. Patient should also be aware that symptomatic and 2027 
asymptomatic AF recurrences are frequent after catheter ablation.119, 781, 782 In line with the primary goal of 2028 
rhythm control therapy, asymptomatic episodes should generally not trigger further rhythm control therapy. 2029 
Patients should be seen at least once by a rhythm specialist in the first 12 months after ablation. Further rhythm 2030 
control options should be considered in patients with symptomatic recurrences, including discussion in a Heart 2031 
Team (Figure 17). 2032 
 2033 
11.4. Atrial fibrillation surgery 2034 
11.4.1. Concomitant atrial fibrillation surgery 2035 
The Cox maze procedure was first performed 30 years ago as a ‘cut-and-sew’ technique, including isolation of 2036 
the posterior left atrium, a connection to the posterior mitral annulus, a cavotricuspid connection, a cavocaval 2037 
connection, and exclusion of the LAA (Figure 18).783 Thereby, the Cox maze procedure creates an electrical 2038 
labyrinth (maze) of passages through which the sinoatrial node impulse finds a route to the atrioventricular node 2039 
while preventing fibrillatory conduction. The Cox maze procedure and other, often simpler, forms of AF surgery 2040 
have mainly been used in patients undergoing other open heart surgical procedures.461, 466, 784-798 In a systematic 2041 
review commissioned for these guidelines, concomitant AF surgery resulted in greater freedom from AF, atrial 2042 
flutter, and atrial tachycardia (RR 1.94, 95% CI 1.51–2.49; n = 554 from seven RCTs) (Web Addenda Figure 2043 
3).1040 Patients undergoing the Cox maze procedure required pacemaker implantation more often (RR 1.69, 95% 2044 
CI 1.12–2.54; n = 1631 from 17 RCTs), without a detectable difference in other outcomes or complications. 2045 
These findings are underpinned by an analysis of Society of Thoracic Surgeons database comprising 67,389 2046 
patients in AF: mortality or major morbidity was not affected by concomitant AF surgery (adjusted OR 1.00; 2047 
95% CI 0.83–1.20), but pacemaker implantation was more frequent (adjusted OR 1.26; 95% CI 1.07–1.49).799 2048 
Predictors of AF recurrence after surgery include left atrial dilatation, older age, > 10-year history of AF, and 2049 
non-paroxysmal AF.800-804 Regarding AF type, surgical PVI seems effective in paroxysmal AF.805 Biatrial lesion 2050 
patterns may be more effective in persistent and long-standing persistent AF.797, 803, 806 The suggested 2051 
management of patients with AF-related symptoms undergoing cardiac surgery is displayed in Figure 19, with 2052 
an important contribution of the AF Heart Team to advise and inform patient choice. 2053 
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 2054 
Figure 18 A. Surgical lesion sets for the biatrial Cox maze procedure. Left and middle panel: right atrial lesions. 2055 
Right panel: left atrial lesions.  2056 
B: Left atrial lesions in a thoracoscopic minimally invasive surgical procedure (dashed lines), including left 2057 
appendage exclusion (double line). 2058 
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 2059 
Figure 19 Surgical rhythm control in patients undergoing cardiac surgery. 2060 
AF = atrial fibrillation; CABG = coronary artery bypass graft; LAA = left atrial appendage; PVI = pulmonary 2061 
vein isolation. 2062 
aAF surgery may be PVI in paroxysmal AF and biatrial maze in persistent or long-standing persistent AF.  2063 
bOral anticoagulation should be continued in patients at risk of stroke irrespective of AF surgery or LAA 2064 
exclusion. 2065 
 2066 
 2067 
11.4.2. Stand-alone rhythm control surgery  2068 
Current technology (e.g. bipolar radiofrequency or cryothermy) renders the procedure easier and more 2069 
reproducible and feasible via a mini-thoracotomy.786, 807, 808 Thoracoscopic PVI with bipolar radiofrequency 2070 
prevents recurrence of paroxysmal AF (69–91% freedom from arrhythmias at 1 year, see Figure 18B for lesion 2071 
set),468, 809, 810 and seems effective in patients refractory to catheter ablation.811 The average length of hospital 2072 
stay for thoracoscopic ablation varies from 3.6 to 6.0 days.468, 812, 813 The FAST (Atrial Fibrillation Catheter 2073 
Ablation vs Surgical Ablation Treatment) trial,468 and another smaller trial,814 suggested that thoracoscopic AF 2074 
surgery could be more effective than catheter ablation for the maintenance of sinus rhythm,468, 814 while also 2075 
causing more complications (Table 19).815 To improve results,468, 816-818 more extensive lesion sets have been 2076 
performed, connecting lines between the PVI encircling and towards the mitral annulus.812, 819-822 To improve the 2077 
generation of transmural lesions,716 endo-epicardial ablation strategies have recently been proposed.812, 823-825 2078 
Although preliminary experience with hybrid simultaneous ablation shows promise, procedural time and rates of 2079 
bleeding complications are higher.812, 823  2080 
 2081 
Table 19 Complications of thoracoscopic AF surgery 2082 
Complication Rate468, 815, 822, 826 
Conversion to sternotomy 0–1.6% 
Pacemaker implantation 0–3.3% 
Drainage for pneumothorax 0–3.3% 
Pericardial tamponade 0–6.0% 
Transient ischaemic attack a 0–3.0% 
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AF = atrial fibrillation. 2083 
aThe rate of asymptomatic cerebral embolism is unknown 2084 
 2085 
11.5. Choice of rhythm control following treatment failure 2086 
There is insufficient evidence on which to base clear recommendations on how to treat patients with recurrent 2087 
AF after catheter ablation. Early recurrences of AF or atrial tachycardias after ablation (occurring within 8 2088 
weeks) may be treated with cardioversion. Many of the published series of patients undergoing AF ablation 2089 
included those who failed antiarrhythmic drug therapy. Thus, considering ablation therapy in patients who have 2090 
symptomatic recurrences on antiarrhythmic drug therapy is often reasonable. Alternatively, trialling another 2091 
antiarrhythmic drug can be considered. Combining antiarrhythmic drug with ablation (‘hybrid therapy’, see 2092 
Section 11) should be considered based on the different and possibly synergistic effects of these drugs with AF 2093 
ablation, possibly benefitting patients in whom either treatment alone was previously ineffective. Rate control 2094 
without rhythm control, surgical ablation, or repeat catheter ablation should be considered as well as third-line 2095 
options (Figure 20). Patient preferences and local access to therapy are important considerations to inform the 2096 
therapy choice in patients who are in need of further rhythm control therapy after an initial therapy failure.  2097 
 2098 
Figure 20 Choice of rhythm control approaches following treatment failure. 2099 
AAD = antiarrhythmic drug; AF = atrial fibrillation; PVI = pulmonary vein isolation. 2100 
a catheter ablation should target PVI. Class I level B for paroxysmal AF and Class IIa level B for persistent AF.  2101 
b AF surgery may be PVI (e.g. in paroxysmal AF) or maze surgery (e.g. in therapy-refractory or long-standing 2102 
persistent AF).  2103 
c Hybrid therapy involves combination of antiarrhythmic drugs, catheter ablation, and/or AF surgery. 2104 
 2105 
11.6. The atrial fibrillation Heart Team 2106 
In view of the complexity of the different treatment options in patients with failed rhythm control therapy but 2107 
who still require or demand further rhythm control therapy, this Task Force proposes that decisions involving 2108 
AF surgery or extensive AF ablation should be based on advice from an AF Heart Team. This will also apply to 2109 
reversal to a rate control strategy in patients with severe (EHRA III or IV) AF symptoms. An AF Heart Team 2110 
should consist of a cardiologist with expertise in antiarrhythmic drug therapy, an interventional 2111 
electrophysiologist, and a cardiac surgeon with expertise in appropriate patient selection, techniques, and 2112 
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technologies for interventional or surgical AF ablation. Such AF Heart Teams – and a collaborative 2113 
infrastructure supporting a continued interaction between physicians delivering continued care, AF 2114 
cardiologists, interventional electrophysiologists, and AF surgeons – should be established to provide optimal 2115 
advice and ultimately to improve rhythm outcomes for patients in need of advanced and complex rhythm control 2116 
interventions.  2117 
 2118 
Recommendations for catheter ablation of AF and AF surgery 2119 
Minimally invasive surgery with epicardial pulmonary vein 
isolation should be considered in patients with symptomatic AF 
when catheter ablation has failed. Decisions on such patients 
should be supported by an AF Heart Team 
IIa B 468 812, 819, 
823 
Maze surgery, possibly via a minimally invasive approach, 
performed by an adequately trained operator in an experienced 
centre, should be considered by an AF Heart Team as a 
treatment option for patients with symptomatic refractory 
persistent AF or post-ablation AF to improve symptoms 
IIa C 808, 832 
Recommendations Class a Level b Refs c 
Catheter ablation of symptomatic paroxysmal AF is 
recommended to improve AF symptoms in patients who have 
symptomatic recurrences of AF on antiarrhythmic drug therapy 
(amiodarone, dronedarone, flecainide, propafenone, sotalol) and 
who prefer further rhythm control therapy, when performed by an 
electrophysiologist who has received appropriate training and is 
performing the procedure in an experienced centre 
I A 585-587, 713, 
727 
Ablation of common atrial flutter should be considered to prevent 
recurrent flutter as part of an AF-ablation procedure if previously 
documented or occurring during the AF ablation 
IIa B 827 
Catheter ablation of AF should be considered as first-line therapy 
to prevent recurrent AF and to improve symptoms in selected 
patients with symptomatic paroxysmal AF as an alternative to 
antiarrhythmic drug therapy, considering patient choice, benefit, 
and risk 
IIa B 585 
All patients should receive oral anticoagulation for stroke 
prevention for at least 8 weeks after catheter (IIaB) or surgical 
(IIaC) ablation. 
IIa B/C 727 
Anticoagulation for stroke prevention should be continued 
indefinitely after apparently successful catheter or surgical 
ablation of AF in patients at high risk of stroke 
IIa C  
When catheter ablation of AF is planned, continuation of oral 
anticoagulation with VKA (IIaB) or NOAC (IIaC) should be 
considered during the procedure, maintaining effective 
anticoagulation 
IIa B/C 760, 768 
Catheter ablation should target complete isolation of the 
pulmonary veins using radiofrequency ablation or cryothermy 
balloon catheters 
IIa B 585, 715, 716, 
734, 735 
AF ablation should be considered in symptomatic patients with AF 
and heart failure with reduced ejection fraction to improve 
symptoms and cardiac function when tachycardiomyopathy is 
suspected 
IIa C 185, 226-228, 
720, 777-779, 
828 
AF ablation should be considered as a strategy to avoid 
pacemaker implantation in patients with AF-related bradycardia 
IIa C 829, 830 
Catheter or surgical ablation should be considered in patients with 
symptomatic persistent or long-standing persistent AF refractory 
to antiarrhythmic drug therapy to improve symptoms, considering 
patient choice, benefit and risk, supported by an AF Heart Team 
IIa C 468, 735, 777, 
831, 832, 
1040 
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Maze surgery, preferably biatrial, should be considered in 
patients undergoing cardiac surgery to improve symptoms 
attributable to AF, balancing the added risk of the procedure and 
the benefit of rhythm control therapy 
IIa A 461, 466, 
790, 791, 
796, 797 
Concomitant biatrial maze or pulmonary vein isolation surgery 
may be considered in asymptomatic AF patients undergoing 
cardiac surgery 
IIb C 796, 797, 833 
AF = atrial fibrillation; NOAC = non-vitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist.  2120 
aClass of recommendation. 2121 
bLevel of evidence. 2122 
cReference(s) supporting recommendations. 2123 
 2124 
12 Hybrid rhythm control therapy 2125 
AF has many different drivers, which are only partially targeted by antiarrhythmic drug or catheter ablation.96 2126 
Hence, combination or ‘hybrid’ rhythm control therapy seems reasonable, although there is little evidence 2127 
supporting its use. 2128 
 2129 
12.1. Combining antiarrhythmic drugs and catheter ablation 2130 
Antiarrhythmic drug therapy is commonly given for 8–12 weeks after ablation to reduce early recurrences of AF 2131 
after catheter ablation, supported by a recent controlled trial where amiodarone halved early AF recurrences 2132 
compared with placebo.650 Prospective studies have not been done, but a meta-analysis of the available (weak) 2133 
evidence suggests slightly better prevention of recurrent AF in patients treated with antiarrhythmic drugs after 2134 
catheter ablation.713 Many patients are treated with antiarrhythmic drug therapy after catheter ablation (most 2135 
often amiodarone or flecainide),587 and this seems a reasonable option in patients with recurrent AF after 2136 
ablation. It seems common sense to consider antiarrhythmic drug therapy in patients who are in need of further 2137 
rhythm control therapy after catheter ablation, but controlled trials to confirm this are desirable. 2138 
 Combining cavotricuspid isthmus ablation and antiarrhythmic drugs may lead to improved rhythm 2139 
control without the need for left atrial ablation in patients who develop ‘drug-induced atrial flutter’ on therapy 2140 
with flecainide, propafenone, or amiodarone,834-836 although recurrent AF is a concern in the long term.837, 838  2141 
 2142 
12.2. Combining antiarrhythmic drugs and pacemakers 2143 
In selected patients with sick sinus syndrome and fast ventricular response during AF paroxysms requiring rate 2144 
control therapy, the addition of a pacemaker not only optimizes rate control but may also help to control 2145 
rhythm.711, 712 Moreover, when antiarrhythmic drug treatment leads to sinus node dysfunction and bradycardia, 2146 
pacing may permit uptitration of the antiarrhythmic drug dose. Such strategies have never been prospectively 2147 
investigated and the existing populations studied are highly selected.839, 840 Some patients with AF-induced 2148 
bradycardia may benefit from catheter ablation of AF, obviating the need for antiarrhythmic drugs and 2149 
pacemaker implantation.829, 830 2150 
 2151 
13 Specific situations 2152 
13.1. Frail and ‘elderly’ patients 2153 
Many AF patients present at an older age (e.g. > 75 or > 80 years). There are no studies suggesting that 2154 
cardiovascular risk reduction is less effective in these ‘elderly’ AF patients than in younger patients. Rather, age 2155 
is one of the strongest predictors/risk factors for ischaemic stroke in AF (Table 11).382 Good data are available to 2156 
support the use of anticoagulants in older patients from BAFTA (Birmingham Atrial Fibrillation Treatment of 2157 
the Aged Study),362 the NOAC trials,39 and from analyses in elderly Americans (Medicare).396 Elderly AF 2158 
patients are at higher risk of stroke and thus are more likely to benefit from OAC than younger patients,841 and 2159 
yet OAC is still underutilized in the elderly.220, 842 Although the evidence base is smaller for other treatment 2160 
options in AF, the available data support the use of available rate and rhythm control interventions, including 2161 
pacemakers and catheter ablation, without justification to discriminate by age group. Individual patients at older 2162 
age may present with multiple comorbidities including dementia, a tendency to falls, CKD, anaemia, 2163 
hypertension, diabetes, and cognitive dysfunction. Such conditions may limit quality of life more than AF-2164 
related symptoms. Impairment of renal and hepatic function and multiple simultaneous medications make drug 2165 
interactions and adverse drug reactions more likely. Integrated AF management and careful adaptation of drug 2166 
dosing seem reasonable to reduce complications of AF therapy in such patients.843 2167 
 2168 
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13.2. Inherited cardiomyopathies, channelopathies, and accessory pathways 2169 
Several inherited cardiac conditions are associated with early-onset AF (Table 20). Treatment of the underlying 2170 
cardiac condition is an important contribution to AF management in these young patients (see also ESC 2171 
guidelines on the sudden cardiac death844 and hypertrophic cardiomyopathy845).  2172 
 2173 
Table 20 Inherited cardiomyopathies, channelopathies, and pathways associated with AF 2174 
 2175 
Syndrome Gene Functional alteration AF 
prevalence 
References 
Long QT syndrome KCNQ1 
KCNH2 
SCN5A 
ANK2 
others 
IKs  
IKr  
INa  
INa,K  
Various effects 
5–10% 846-850 
Brugada syndrome SCN5A 
GPDIL 
SCN1B 
CACNA1C 
CACNB2b 
others 
INa  
INa  
INa  
ICa  
ICa  
others 
10–20% 851-855 
Short QT syndrome KCNH2 
KCNQ1 
KCNJ2 
CACNA1C 
CACNB2b 
 
IKr  
IKs  
IK1  
ICa  
ICa  
 
Up to 70% 853, 856-858 
Catecholaminergic 
ventricular tachycardia 
RYR2 
CASQ2 
Abnormal Ca2+ release from 
sarcoplasmic reticulum 
Variable but 
significant 
859-861 
 
Hypertrophic 
cardiomyopathy 
Sarcomeric 
genes 
 5–15% 862-864 
Wolff–Parkinson–White 
syndrome 
PRKAG  Variable 865 
Holt–Oram syndrome TBX5  Variable 866 
Arrhythmogenic right 
ventricular 
cardiomyopathy 
Several 
desmosomal 
genes, 
unknown gene 
loci 
 
 >40% in 
patients with 
VTs 
867, 868 
AF = atrial fibrillation. 2176 
 2177 
13.2.1. Wolff–Parkinson–White syndrome 2178 
Patients with pre-excitation and AF are at risk of rapid conduction across the accessory pathway, resulting in a 2179 
fast ventricular rate, possibly ventricular fibrillation, and sudden death. In AF patients with evidence of an 2180 
antegrade accessory pathway, catheter ablation of the pathway is recommended.869, 870 This procedure is safe and 2181 
effective and may be considered as a prophylactic treatment strategy.871, 872 In AF patients surviving a sudden 2182 
death event with evidence of an accessory pathway, urgent catheter ablation of the pathway is recommended.869 2183 
A documented short pre-excited RR interval (< 250 ms) during spontaneous or induced AF is one of the risk 2184 
markers for sudden death in Wolff–Parkinson–White syndrome (WPW) syndrome, in addition to a history of 2185 
symptomatic tachycardia, the presence of multiple accessory pathways, and Ebstein’s anomaly. Intravenous 2186 
procainamide, propafenone, or ajmaline can be used to acutely slow ventricular rate,873, 874 whereas digoxin, 2187 
verapamil, and diltiazem are contraindicated.875 Intravenous amiodarone should be used with caution, as there 2188 
are case reports of accelerated ventricular rhythms and ventricular fibrillation in patients with pre-excited AF 2189 
receiving intravenous amiodarone infusion.876  2190 
 2191 
13.2.2. Hypertrophic cardiomyopathy  2192 
AF is the most common arrhythmia in patients with hypertrophic cardiomyopathy, affecting approximately one-2193 
quarter of this population.877 Observational data highlight a high stroke risk in hypertrophic cardiomyopathy 2194 
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patients with AF, confirming the need for OAC.878 While there is more experience with VKAs, there are no data 2195 
to suggest that NOACs cannot be used in these patients.845 Studies of rate or rhythm control medications in 2196 
patients with hypertrophic cardiomyopathy are relatively scarce. Beta-blockers and diltiazem or verapamil seem 2197 
reasonable treatment options for rate control in these patients. In the absence of signiﬁcant LV outflow tract 2198 
obstruction, digoxin can be used alone or in combination with beta-blockers.845 Amiodarone seems a safe 2199 
antiarrhythmic drug in AF patients with hypertrophic cardiomyopathy,879 and expert opinion suggests that 2200 
disopyramide may be beneficial in those with outflow tract obstruction. AF ablation is effective to suppress 2201 
symptomatic AF recurrences.880-884 Surgical treatment of AF may be appropriate in patients with hypertrophic 2202 
cardiomyopathy undergoing surgery (e.g. for LV outflow tract obstruction or mitral valve surgery), but 2203 
experience is limited.  2204 
 2205 
13.2.3. Channelopathies and arrhythmogenic right ventricular cardiomyopathy  2206 
Many channelopathies and inherited cardiomyopathies are associated with AF. AF prevalence ranges from 5% 2207 
to 20% in patients with long QT syndrome or Brugada syndrome, and is up to 70% in short QT syndrome 2208 
(Table 20).853, 856-858 Penetrance of disease phenotype including AF is variable.61, 852, 885, 886 Both shortening as 2209 
well as prolongation of the atrial action potential have been demonstrated as likely mechanisms underlying AF 2210 
in these diseases. It seems reasonable to consider antiarrhythmic drugs that reverse the suspected channel defect 2211 
in AF patients with inherited cardiomyopathies (e.g. a sodium channel blocker in LQT3852 and quinidine in 2212 
Brugada syndrome887). More importantly, new-onset AF in young, otherwise healthy individuals should trigger 2213 
a careful search for such inherited conditions, including clinical history, family history, ECG phenotype, and 2214 
echocardiography and/or other cardiac imaging. 2215 
 Monogenic defects only account for 3–5% of all patients with AF, even in younger populations.846, 848, 2216 
888-890 Furthermore, there is no clear link between detected mutations and specific outcomes or therapeutic needs. 2217 
For these reasons, genetic testing is not recommended in the general AF population.77 Other guidelines have 2218 
described the indications for genetic testing in patients with inherited arrhythmogenic diseases.844, 891  2219 
 2220 
Recommendations for inherited cardiomyopathies 2221 
 2222 
Recommendations  Class a Level b Refs c 
WPW syndrome    
Catheter ablation of the accessory pathway in WPW patients with AF 
and rapid conduction over the accessory pathway is recommended to 
prevent sudden cardiac death 
I B 892-894 
Catheter ablation of the accessory pathway is recommended without 
delay in WPW patients who survive sudden cardiac death I C 
869 
Asymptomatic patients with overt pre-excitation and AF should be 
considered for accessory pathway ablation after careful counselling IIa B 
872, 895 
Hypertrophic cardiomyopathy    
Lifelong oral anticoagulation to prevent stroke is recommended in 
hypertrophic cardiomyopathy patients who develop AF I B 
878 
Restoration of sinus rhythm by electrical or pharmacological 
cardioversion to improve symptoms is recommended in hypertrophic 
cardiomyopathy patients with symptomatic new-onset AF 
I B 845 
In haemodynamically stable hypertrophic cardiomyopathy patients 
with AF, ventricular rate control using beta-blockers and 
diltiazem/verapamil is recommended 
I C 845 
Treatment of LV outflow tract obstruction should be considered in 
AF patients with hypertrophic cardiomyopathy to improve symptoms IIa B 
896 
Amiodarone should be considered to achieve rhythm control and 
maintain sinus rhythm in hypertrophic cardiomyopathy patients IIa C 
845, 897 
Inherited cardiomyopathies and channelopathies     
Targeted genetic testing should be considered in patients with AF and 
a suspicion of inherited cardiomyopathies or channelopathies based 
on clinical history, family history, or electrocardiographic phenotype 
IIa A 852 
AF = atrial fibrillation; LV = left ventricular; WPW = Wolff–Parkinson–White syndrome. 2223 
aClass of recommendation. 2224 
bLevel of evidence. 2225 
cReference(s) supporting recommendations. 2226 
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 2227 
13.3. Sports and atrial fibrillation 2228 
Physical activity improves cardiovascular health, which translates into a lower risk of AF.898 Therefore, physical 2229 
activity is a cornerstone of preventing AF. Intensive sports practice, especially endurance sports (> 1500 h of 2230 
endurance sports practice),899 increases the risk of AF later in life,900-902 probably mediated by altered autonomic 2231 
tone, volume load during exercise, atrial hypertrophy, and dilatation.903, 904 This results in a U-shaped 2232 
relationship of physical activity and incident AF.214, 898, 902, 905, 906 Detraining can reduce AF in models904 and 2233 
reduces ventricular arrhythmias in athletes,907 but the role of detraining for AF in human athletes is unknown. 2234 
The management of athletes with AF is similar to general AF management, but requires a few special 2235 
considerations. Clinical risk factors will determine the need for anticoagulation. Sports with direct bodily 2236 
contact or prone to trauma should be avoided in patients on OAC. Beta-blockers are not well tolerated and at 2237 
times prohibited, and digoxin, verapamil, and diltiazem are often not potent enough to slow heart rate during 2238 
exertional AF. Catheter ablation for AF probably has similar outcomes in athletes as in non-athletes,908, 909 but 2239 
further data are needed. Pill-in-the-pocket therapy has been used as well.620 After ingestion of flecainide or 2240 
propafenone as pill-in-the-pocket, patients should refrain from sports as long as AF persists and until two half-2241 
lives of the antiarrhythmic drug have elapsed. Prophylactic ablation of the flutter circuit may be considered in 2242 
athletes treated with sodium channel blockers.910 2243 
 2244 
Recommendations for physical activity in patients with AF 2245 
Recommendations Class a Level b Refsc 
Moderate regular physical activity is recommended to prevent AF, while 
athletes should be counselled that long-lasting, more intense sports 
participation can promote AF 
I A 
214, 898, 900-
902, 905, 906 
AF ablation should be considered to prevent recurrent AF in athletes IIa B 908, 909 
The ventricular rate while exercising with AF should be evaluated in 
every athlete (by symptoms and/or by monitoring), and titrated rate 
control should be instituted 
IIa C  
After ingestion of pill-in-the-pocket Class I antiarrhythmic drugs, 
patients should refrain from sports as long as AF persists and until two 
half-lives of the antiarrhythmic drug have elapsed 
IIa C 620 
AF = atrial fibrillation. 2246 
aClass of recommendation. 2247 
bLevel of evidence. 2248 
cReference(s) supporting recommendations. 2249 
 2250 
13.4. Pregnancy 2251 
AF in pregnant women is rare and is usually associated with pre-existing heart disease. AF is associated with 2252 
increased complications for the mother and foetus.911, 912 Better treatment of congenital heart diseases will 2253 
probably increase the incidence of AF during pregnancy in the future.913 Pregnant women with AF should be 2254 
managed as high-risk pregnancies in close collaboration with cardiologists, obstetricians, and neonatologists. 2255 
 2256 
13.4.1. Rate control 2257 
Owing to a lack of specific data, beta-blockers, verapamil, diltiazem, and digoxin all carry a US Food and Drug 2258 
Administration pregnancy safety category of C (benefits may outweigh risk), except for atenolol (category D: 2259 
positive evidence of risk). Their use should be at the lowest dose and for the shortest time required. None of the 2260 
agents are teratogenic, but they readily cross the placenta.914 Beta-blockers are commonly used in clinical 2261 
practice (e.g. for management of gestational hypertension and pre-eclampsia), but may be associated with 2262 
intrauterine growth retardation,915 and hence growth scans after 20 weeks gestation are recommended. Digoxin 2263 
is considered safe for maternal and foetal arrhythmias.916 There are insufficient data to comment on verapamil or 2264 
diltiazem, hence rate control using beta-blockers and/or digoxin is recommended.917 With regards to 2265 
breastfeeding, all rate control agents are present in breast milk, although levels of beta-blockers, digoxin, and 2266 
verapamil are too low to be considered harmful. Diltiazem will be present at high levels and should be 2267 
considered second-line treatment.918  2268 
 2269 
13.4.2. Rhythm control 2270 
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Rhythm control therapy in pregnant patients with AF has only been reported in case studies. Amiodarone is 2271 
associated with severe adverse foetal side-effects and should only be considered for emergency situations.919 2272 
Flecainide and sotalol can both be used for conversion of foetal arrhythmias without major adverse effects,920 2273 
and thus are likely to be safe to treat maternal symptomatic AF. Electrical cardioversion can be effective for 2274 
restoration of sinus rhythm when tachyarrhythmia is causing haemodynamic instability, with low rates of 2275 
adverse outcomes for both mother and foetus.921 However, in view of the risk of foetal distress, electrical 2276 
cardioversion should only be carried out where facilities are available for foetal monitoring and emergency 2277 
caesarean section. As with other emergencies during pregnancy, patients should receive 100% oxygen, 2278 
intravenous access should be established early, and the mother should be positioned in the left lateral position to 2279 
improve venous return.922 2280 
 2281 
13.4.3. Anticoagulation 2282 
VKAs should be avoided in the first trimester because of teratogenic effects, and in the 2–4 weeks preceding 2283 
delivery to avoid foetal bleeding. Low-molecular-weight heparins are a safe substitute, as they do not cross the 2284 
placenta.923 In the third trimester, frequent laboratory checks for adequate anticoagulation (e.g. every 10–14 2285 
days) and corresponding dose adjustments are advised, given that in some women high doses of both VKA and 2286 
heparin may be needed to maintain adequate anticoagulation. Pregnant patients with AF and mechanical 2287 
prosthetic valves who elect to stop VKA treatment in consultation with their specialist team between 6 and 12 2288 
weeks of gestation, should receive continuous, dose-adjusted unfractionated heparin or dose-adjusted 2289 
subcutaneous low-molecular-weight heparin. As only limited data are available about teratogenesis for NOACs, 2290 
these drugs should be avoided during pregnancy. 2291 
 2292 
Recommendations during pregnancy 2293 
Recommendations Class a Level b Refs c 
Electrical cardioversion can be performed safely at all stages of 
pregnancy, and is recommended in patients who are 
haemodynamically unstable due to AF, and whenever the risk of 
ongoing AF is considered high, for the mother or the foetus 
I C  
Anticoagulation is recommended in pregnant patients with AF at risk 
of stroke. To minimize teratogenic risk and intrauterine bleeding, 
dose-adjusted heparins are recommended during the first trimester 
of pregnancy and in the 2–4 weeks before delivery. Vitamin K 
antagonists or heparin can be used in the remaining parts of the 
pregnancy 
I  B 923 
NOACs should be avoided in pregnancy and in women planning a 
pregnancy 
III 
(harm) C 
 
NOAC =  non-vitamin K antagonist oral anticoagulants  2294 
aClass of recommendation. 2295 
bLevel of evidence. 2296 
cReference(s) supporting recommendations. 2297 
 2298 
13.5. Postoperative atrial fibrillation 2299 
AF is common after cardiac surgery (occurring in 15–45% of patients),924-926 and is associated with increased 2300 
length of hospital stay and higher rates of complications and mortality.927 Postoperative AF is also not 2301 
uncommon after other major surgery, especially in elderly patients. The treatment of postoperative AF is mainly 2302 
based on studies of patients undergoing cardiac surgery, with much less evidence in the non-cardiac surgery 2303 
setting.  2304 
 2305 
13.5.1. Prevention of postoperative atrial fibrillation 2306 
Beta-blockers reduce postoperative AF and supraventricular tachycardias, albeit with high heterogeneity and 2307 
moderate risk of bias in a systematic review of published studies (the most commonly studied drug was 2308 
propranolol, with AF in 16.3% of the treatment group vs. 31.7% in the control group).925 In the majority of these 2309 
studies, beta-blockers were administered postoperatively, a regimen supported in a recent meta-analysis.928 2310 
Amiodarone reduced the incidence of postoperative AF compared to a beta-blocker regimen in several meta-2311 
analyses, also reducing hospital stay.925, 929-931  2312 
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 Despite initial reports from meta-analyses,689, 932, 933 preoperative treatment with statins did not prevent 2313 
postoperative AF in a prospective controlled trial.934 Other therapies have also been studied in small, hypothesis-2314 
generating trials, but have not demonstrated clear beneficial effects. These include magnesium,925, 935, 936 n-3 2315 
polyunsaturated fatty acids,937-945 colchicine,946 corticosteroids,947, 948 and posterior pericardectomy.949 2316 
Postoperative overdrive biatrial pacing has not gained widespread use despite some suggestion of prophylactic 2317 
effects.925, 950 2318 
 2319 
13.5.2. Anticoagulation 2320 
Postoperative AF is associated with an increased early stroke risk, increased morbidity, and 30-day mortality.927, 2321 
951, 952 In the long term, patients with an episode of postoperative AF have a twofold increase in cardiovascular 2322 
mortality and a substantially increased risk of future AF and ischaemic stroke compared with patients that 2323 
remain in sinus rhythm after surgery.952-958 OAC at discharge has been associated with a reduced long-term 2324 
mortality in patients with postoperative AF,959 without evidence from controlled trials. Good quality data are 2325 
needed to determine whether long-term anticoagulation can prevent strokes in patients with postoperative AF at 2326 
high stroke risk,368, 386 and to assess whether short episodes of postoperative AF (e.g. < 48 h) carry a similar risk 2327 
as longer episodes.960 The indication and timing of OAC in postoperative AF patients should take into 2328 
consideration the risk of postoperative bleeding.  2329 
 2330 
13.5.3. Rhythm control therapy in postoperative atrial fibrillation 2331 
In haemodynamically unstable patients, cardioversion and consideration of antiarrhythmic drugs is 2332 
recommended. Amiodarone or vernakalant have been efficient in converting postoperative AF to sinus 2333 
rhythm.603, 950, 961 A recent medium-sized trial randomizing patients with postoperative AF to either rhythm 2334 
control therapy with amiodarone or to rate control did not find a difference in hospital admissions during a 60-2335 
day follow-up,962 underpinning that the aim of rhythm control therapy should be to improve AF-related 2336 
symptoms in postoperative AF. In asymptomatic patients and in those with acceptable symptoms, rate control or 2337 
deferred cardioversion preceded by anticoagulation is a reasonable approach.  2338 
 2339 
Recommendations for preventing postoperative AF 2340 
Recommendations Class a Level b Refs c 
Perioperative oral beta-blocker therapy is recommended for the 
prevention of postoperative AF after cardiac surgery I B 
925, 928 
Restoration of sinus rhythm by electrical cardioversion or 
antiarrhythmic drugs is recommended in postoperative AF with 
haemodynamic instability 
I C  
Long-term anticoagulation should be considered in patients 
with AF after cardiac surgery at risk for stroke, considering 
individual stroke and bleeding risk 
IIa B 368, 386 
Antiarrhythmic drugs should be considered for recurrent or 
symptomatic postoperative AF after cardiac surgery in an 
attempt to restore sinus rhythm 
IIa C  
Perioperative amiodarone should be considered for 
prophylactic therapy to prevent AF after cardiac surgery IIa  A 
925 
Intravenous vernakalant may be considered for cardioversion 
of postoperative AF in patients without severe heart failure, 
hypotension, or severe structural heart disease (especially 
aortic stenosis) 
IIb B 603 
Asymptomatic postoperative AF should initially be managed 
with rate control and anticoagulation IIa B 
962 
AF = atrial fibrillation. 2341 
aClass of recommendation. 2342 
bLevel of evidence. 2343 
cReference(s) supporting recommendations. 2344 
 2345 
13.6. Atrial arrhythmias in grown-up patients with congenital heart disease 2346 
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Atrial arrhythmias (AF, atrial flutter, atrial tachycardias) often occur late after surgical repair of congenital heart 2347 
defects, occurring in 15–40% of grown-up patients with congenital heart disease (GUCH). They are associated 2348 
with heart failure, syncope, thromboembolic events, and sudden death.963-967 The pathophysiological substrate is 2349 
complex, associated with hypertrophy, fibrosis, hypoxaemia, chronic haemodynamic overload, and surgical 2350 
scars and patches. Additionally, related primary anomalies in the conduction pathways can lead to reentrant 2351 
atrial and ventricular tachycardia, heart block, and sinus node dysfunction.963 Macro-reentrant atrial tachycardia 2352 
or atypical atrial flutter may be seen after nearly any surgical procedure involving atriotomy or atrial patches.  2353 
 2354 
13.6.1. General management of atrial arrhythmias in grown-up patients with 2355 
congenital heart disease 2356 
The conventional stroke risk factors should be used to inform decisions on long-term anticoagulation in GUCH 2357 
patients with AF. In addition, anticoagulation should be considered in GUCH patients with atrial arrhythmias 2358 
when they present with intracardial repair, cyanosis, Fontan palliation, or systemic right ventricle, in addition to 2359 
those with conventional stroke risk factors.968 Beta-blockers, verapamil, diltiazem, and digitalis can be used. 2360 
Care should be taken to avoid bradycardia and hypotension. 2361 
 Sodium channel blockers suppress approximately half of atrial arrhythmias in Fontan patients.969 2362 
Amiodarone is more effective, but long-term treatment with an antiarrhythmic drugs carries a high risk of 2363 
extracardiac side-effects in this relatively young population. Intracardiac thrombi are common in GUCH 2364 
patients undergoing cardioversion for AF, but also in patients with atrial tachycardias or atrial flutter.970 2365 
Therefore, both a TOE and anticoagulation for a few weeks before the planned cardioversion should be 2366 
considered.964 Radiofrequency ablation may be a good option for symptomatic GUCH patients with atrial 2367 
arrhythmias, especially in those with atrial flutter and other macro-reentrant tachycardias. Interventions should 2368 
be performed in adequately qualified centres by specialized teams.  2369 
 2370 
13.6.2. Atrial tachyarrhythmias and atrial septal defects 2371 
Atrial flutter and fibrillation occur in 14–22% of adults with unoperated atrial septal defects, especially in older 2372 
patients,971 and can lead to heart failure.972 Early repair can reduce but not eliminate the risk of AF.973 Biatrial 2373 
volume overload,974 pulmonary hypertension,975 and possibly the arrhythmogenic effect of atrial patches can 2374 
contribute to these arrhythmias.976 Anticoagulation should be decided based on stroke risk factors. In patients 2375 
with a history of paroxysmal or persistent AF, AF surgery could be considered at the time of surgical closure, or 2376 
catheter ablation in patients undergoing interventional atrial septal defect closure. Catheter ablation of late atrial 2377 
arrhythmias has shown to be effective in 46 consecutive patients after surgical atrial septal defect.977 2378 
 2379 
13.6.3. Atrial tachyarrhythmias after Fontan operation 2380 
Atrial arrhythmias occur in up to 40% of patients with a Fontan circulation, and can manifest as atrial flutter, 2381 
primary atrial tachycardia, AF, and accelerated junctional rhythm or junctional tachycardia978 with or without 2382 
sinoatrial node dysfunction.979 Patients with atriopulmonary anastomoses (possibly due to higher atrial volume 2383 
and pressure load) and those with early postoperative atrial arrhythmias are more likely to develop long-term 2384 
atrial arrhythmias.980 Atrial arrhythmias can also be the first manifestation of obstruction of the atriopulmonary 2385 
anastomosis, a complication that must be identified. Right atrial thrombus formation is common in Fontan 2386 
patients with atrial arrhythmias and requires oral anticoagulation.981 Operative conversion to total 2387 
cavopulmonary artery connection with concomitant arrhythmia surgery can in some patients improve heart 2388 
failure symptoms and reduce recurrent arrhythmias,969, 982 with low recurrence rates of clinically apparent atrial 2389 
arrhythmias in the first few years after repeat surgery.983-985 Catheter ablation of atrial arrhythmia in Fontan 2390 
patients has been successful in selected patients.986 2391 
 2392 
13.6.4. Atrial tachyarrhythmias after tetralogy of Fallot correction  2393 
Approximately one-third of patients after repair of tetralogy of Fallot develop atrial arrhythmias, including intra-2394 
atrial reentrant tachycardia, focal atrial tachycardia, and AF.987 Circuits involving the cavotricuspid isthmus and 2395 
areas of presumed surgical right atrial scaring have been described as responsible for atrial arrhythmias.  2396 
 2397 
Recommendations in patients with GUCH 2398 
Recommendations Class a Level b Refs c 
Atrial septal defect closure should be considered before 
the fourth decade of life to diminish the chance of atrial 
flutter and fibrillation 
IIa C 971, 972, 974 
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In patients who need surgical closure of an atrial septal 
defect and who have a history of symptomatic atrial 
arrhythmia, atrial ablation should be considered at the 
time of surgical closure 
IIa C 204, 988, 989 
Cox maze surgery should be considered in patients with 
symptomatic AF and an indication for corrective repair of 
congenital heart defects. All such surgery should be done 
in experienced centres 
IIa C 988, 990 
Oral anticoagualtion should be considered in all adult 
patients with intracardiac repair, cyanosis, Fontan 
palliation, or systemic right ventricle and a history of AF, 
atrial flutter, or intra-atrial reentrant tachycardia. In all 
other congenital heart disease patients with AF, 
anticoagulation should be considered if the CHA2DS2-
VASC score is ≥ 1 
IIa C  968 
Catheter ablation of atrial arrhythmias associated with 
congenital heart defects may be considered when 
performed in experienced centres 
IIb C 991 
In patients with congenital heart disease, 
transoesophageal echocardiography may be considered 
together with 3-week anticoagulation therapy before 
cardioversion 
IIb C 964, 970, 988, 990 
AF = atrial fibrillation; CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), 2399 
Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); GUCH = grown-up patients with 2400 
congenital heart disease; OAC = oral anticoagulation; TOE = transoesophageal echocardiography. 2401 
aClass of recommendation.  2402 
bLevel of evidence. 2403 
cReference(s) supporting recommendations. 2404 
 2405 
13.7. Management of atrial flutter 2406 
The goals for the management of atrial flutter are similar to those for AF.992 Based on the available evidence, the 2407 
stroke risk in patients with atrial flutter is not much different from that in AF.827 Furthermore, many patients 2408 
diagnosed with atrial flutter develop AF.993-995 Thus, anticoagulation should be used in patients with atrial flutter 2409 
similar to that in patients with AF. Rate control in atrial flutter is achieved with the same medications as in AF, 2410 
but is often more difficult to achieve. Flecainide, propafenone, dofetilide, and intravenous ibutilide are useful for 2411 
cardioversion of atrial flutter. They should be combined with a rate-controlling agent to avoid 1:1 conduction of 2412 
slowing flutter waves to the ventricles. Ibutilide is more effective for conversion of atrial flutter than AF, 2413 
whereas vernakalant is less effective in converting typical atrial flutter.996, 997 Electrical cardioversion of atrial 2414 
flutter can be performed using lower energies (50–100 J) than for AF.998, 999 Atrial overdrive pacing through 2415 
pacemaker leads or endocardial or transesophageal catheters can convert atrial flutter to sinus rhythm.1000, 1001 2416 
Anticoagulation and transoesophageal echocardiography around cardioversion or overdrive pacing should be 2417 
used similar to that in AF.  2418 
 Ablation of the cavotricuspid isthmus for isthmus-dependent right atrial flutter (either the common 2419 
counter-clockwise atrial flutter or the less-common clockwise atrial flutter) restores and maintains sinus rhythm 2420 
with a success rate of 90–95%.1002 It may also reduce AF recurrences in selected patients,1003, 1004 and help to 2421 
prevent hospitalizations.1004, 1005 Isthmus ablation is comparably safe and more effective than antiarrhythmic 2422 
drug therapy, and is recommended for recurrent atrial flutter.585-587, 713 Catheter ablation of left atrial macro-2423 
reentrant tachycardia is more complex, with lower success rates and higher recurrence rates.1006, 1007  2424 
 2425 
Recommendations for management of atrial flutter 2426 
Recommendations Class a Level b Refs c 
For patients with atrial flutter, antithrombotic therapy is recommended 
according to the same risk profile used for AF 
I B 827 
Overdrive atrial pacing of atrial flutter should be considered as an 
alternative to electrical cardioversion, depending on local availability and 
experience 
IIa B 1000, 1001 
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Management of typical atrial flutter with ablation of the cavotricuspid 
isthmus is recommended for patients failing antiarrhythmic drug therapy or 
as first-line treatment considering patient preference 
I B 158 
If atrial flutter has been documented before AF ablation, ablation of the 
cavotricuspid isthmus should be considered as part of the AF ablation 
procedure 
IIa C  
AF = atrial fibrillation. 2427 
aClass of recommendation. 2428 
bLevel of evidence. 2429 
cReference(s) supporting recommendations. 2430 
 2431 
14 Patient involvement, education and self-management 2432 
A fundamental aspect of a structured AF management programme is the focus on patient-centred care.  2433 
 2434 
14.1. Patient-centred care 2435 
Autonomous, informed patients are better placed to adhere to long-term therapy, and it is very likely that long-2436 
term management of chronic conditions such as AF will benefit from informed patients involved in the disease 2437 
management who are aware of their own responsibilities.328 Shared decision-making747 and patient-centred 2438 
organization of care can help to ensure adherence to management and empower patients, and respect individual 2439 
patient preferences, needs, and values (see Chapter 7.2).326, 1008, 1009 Patients in an active role tend to have better 2440 
health outcomes and care experiences, and engagement itself can be considered as an intermediate outcome, 2441 
particularly where related to improved clinical outcomes.1010 2442 
 2443 
14.2. Integrated patient education  2444 
Education is a prerequisite for informed, involved patients and patient-centred care. However, lack of AF-2445 
related knowledge in patients is common, even in those who have received verbal and written information,32, 1011, 2446 
1012 indicating the need to further develop structured patient education. Several patient-information tools have 2447 
been developed, largely focusing on oral anticoagulation.1013-1016 Understanding patients’ perceptions and 2448 
attitudes towards AF and its management can improve AF management and related outcomes.1017 This includes 2449 
tailored patient education focusing on the disease, symptom recognition, therapy, modifiable risk factors for AF, 2450 
and self-management activities.1018, 1019  2451 
 2452 
14.3. Self-management and shared decision-making  2453 
Self-management is primarily focused on tasks to manage the condition, such as adhering to a therapeutic 2454 
regimen or modifying behaviour (e.g. resulting in smoking cessation or weight loss).1020 It requires 2455 
understanding of the treatment modalities and goals.350 Within a multidisciplinary team, allied health 2456 
professionals can guide this interactive process in which communication, trust, and reciprocal respect foster 2457 
patient engagement.1021 Shared decision-making should be considered as a routine part of the decision-making 2458 
process,747 supported by decision aids where applicable.1022 Models of care that integrate education, 2459 
engagement, and shared decision making are now available,1023 and may be of particular value in the 2460 
management of AF. 2461 
 2462 
Recommendations for patient involvement, education, and self-management 2463 
Recommendations Class a Level b Refs c 
Tailored patient education is recommended in all phases of AF 
management to support patients’ perception of AF and to 
improve management 
I C 
1014, 1017 
Patient involvement in the care process should be considered to 
encourage self-management and responsibility for lifestyle 
changes 
IIa C 
328, 1010 
Shared decision-making should be considered to ensure that 
care is based on the best available evidence and fits the needs, 
values, and preferences of the patient 
IIa C 
747 
AF = atrial fibrillation. 2464 
aClass of recommendation. 2465 
bLevel of evidence. 2466 
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cReference(s) supporting recommendations. 2467 
 2468 
15 Gaps in evidence 2469 
There are some areas of AF management that are supported by excellent evidence from multiple, adequately 2470 
powered randomized trials (e.g. oral anticoagulation. Other areas, such as rhythm control therapy, integrated AF 2471 
management, and lifestyle modifications are clearly developing the required evidence, while areas such as rate 2472 
control are in dire need of better studies to underpin future guidelines. Here we identify areas in need of further 2473 
research.  2474 
 2475 
15.1. Major health modifiers causing atrial fibrillation 2476 
Atrial fibrillation has different causes in different patients. More research is needed into the major causes (and 2477 
electrophysiological mechanisms) of AF in different patient groups.176, 1024 Such research should consider the 2478 
major comorbidities associated with AF, and characterize the response to AF therapy in patients with different, 2479 
pathophysiologically distinct types of AF.  2480 
 2481 
15.2. How much atrial fibrillation constitutes a mandate for therapy? 2482 
Technological advances allow screening for an irregular pulse using patient-operated ECG devices, 2483 
smartphones, and a variety of other technologies. These may be very useful to detect silent, undiagnosed AF.157 2484 
Adequately powered studies evaluating the diagnostic accuracy of such technologies, the diagnostic yield in 2485 
different populations, the shortest duration of atrial arrhythmias conveying a stroke risk, and ideally the effect of 2486 
ECG screening on outcomes are needed. 2487 
 2488 
15.3. Atrial high-rate episodes and need for anticoagulation 2489 
All of the information on the benefit of OAC has been in patients with AF diagnosed by ECG. Technological 2490 
advances allow ready detection of AHRE in patients with implanted devices and an atrial lead. Such patients are 2491 
at increased stroke risk, but it is unclear whether they benefit from OAC. Controlled trials evaluating OAC in 2492 
AHRE patients are ongoing and will provide evidence on the best antithrombotic therapy in these patients. 2493 
 2494 
15.4. Stroke risk in specific populations 2495 
Several specific AF groups should be studied to better characterize their risk for AF, stroke, and other AF-2496 
related complications (e.g. patients with one stroke risk factor, and non-Caucasian patients). Confounding 2497 
factors (e.g. different therapy of concomitant cardiovascular diseases) may help to explain the variability in the 2498 
reported rates of incident AF, prevalent AF, and AF complications. This also applies to the effect of gender in 2499 
AF patients.47 2500 
 2501 
15.5. Anticoagulation in patients with severe chronic kidney disease 2502 
The use of NOACs has not been tested in patients with creatinine clearance < 30 mL/min, and there is very little 2503 
evidence on the effects of OAC in patients on haemodialysis or on other forms of renal-replacement therapy. 2504 
Studies evaluating OAC in patients with severe chronic kidney disease are needed to inform the best 2505 
management in this patient group at high risk for stroke and bleeding.  2506 
 2507 
15.6. Left atrial appendage occlusion for stroke prevention 2508 
The most common justification for LAA occlusion devices in clinical practice is a perceived high bleeding risk 2509 
and, less often, contraindications for OAC.459 Unfortunately, LAA occluders have not been tested in such 2510 
populations. Furthermore, LAA occluders have not been compared with NOAC therapy in patients at risk for 2511 
bleeding, or with thoracoscopic LAA clipping. There is a clear need to conduct adequately designed and 2512 
powered trials to define the clinical role of LAA occluders compared with NOAC therapy in patients with 2513 
relative or absolute contraindications for anticoagulation, and/or in those suffering from an ischaemic stroke on 2514 
anticoagulant therapy. 2515 
 2516 
15.7. Anticoagulation in atrial fibrillation patients after a bleeding or stroke event 2517 
At least 2% of anticoagulated patients with AF will experience a serious bleeding event per year. Observational 2518 
data suggest that OAC can be reinitiated even after an intracerebral bleeding event.460, 484 Controlled studies 2519 
evaluating different anticoagulation and stroke prevention interventions are urgently needed to provide evidence 2520 
on the best management of patients who have suffered a bleeding event that would usually lead to withholding 2521 
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OAC. Some studies (e.g. APACHE II1025) are ongoing, but adequately powered trials are needed. Similarly, 2522 
prospectively collected data are needed on the efficacy and bleeding risk following (re-)initiation of OAC after 2523 
stroke or intracranial bleeding.  2524 
 2525 
15.8. Anticoagulation and optimal timing of non-acute cardioversion 2526 
Based on retrospective data, previous recommendations on the safe time-window in which a cardioversion can 2527 
be performed in new-onset AF used ≤ 48 hours as the ‘gold standard’ for non-protected cardioversion. However, 2528 
new evidence has emerged that initiating precardioversion anticoagulation in patients with AF episodes of < 24 2529 
hours or even < 12 hours would provide even better safety.642, 647, 1026-1028 Further research is needed to establish 2530 
a clear safety margin in this clinical situation.  2531 
 2532 
15.9. Competing causes of stroke or transient ischaemic attack in atrial fibrillation 2533 
patients 2534 
Prospective RCTs have demonstrated the superiority of carotid endarterectomy compared to stenting in patients 2535 
with symptomatic high-degree stenosis of the internal carotid artery.1029 As endartectomy minimizes the need 2536 
for combination therapy with OAC and antiplatelets,1030 this approach has appeal in patients with AF to reduce 2537 
bleeding risk. However, few of these studies included patients with AF. In a large observational study, the 2538 
composite of in-hospital mortality, post-procedural stroke, and cardiac complications was higher in AF patients 2539 
undergoing carotid stenting (457/7668; 6.0%) compared with endarterectomy (4438/51320; 8.6%; P < 2540 
0.0001).1031 Despite adjustment for baseline risk, this may just reflect the type of patients referred for each 2541 
procedure, and further randomized studies are needed to confirm the optimal treatment strategy in AF patients 2542 
with carotid disease.  2543 
 2544 
15.10. Anticoagulation in patients with biological heart valves (including transcatheter 2545 
aortic valve implantation) and non-rheumatic valve disease 2546 
The optimal antithrombotic therapy in the first months after biological valve replacement (including after 2547 
catheter-based valve replacement) is not known. VKAs remain the mainstay during the initial postoperative 2548 
period; NOACs probably deliver the same protection. In patients without AF, many centres use platelet 2549 
inhibitors only. NOACs appear to be equally effective as VKAs in patients with moderate aortic stenosis, based 2550 
on a subanalysis from the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared 2551 
with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial1032 as well 2552 
as the Loire Valley AF project.1033 Further data would be helpful to confirm these observations.1034 The safety 2553 
and efficacy of NOACs in patients with rheumatic mitral valve disease has not been evaluated and should be 2554 
studied. 2555 
 2556 
15.11. Anticoagulation after ‘successful’ catheter ablation 2557 
In view of the long-term recurrence rates of AF, this Task Force recommends to continue OAC in AF patients 2558 
after ‘successful’ catheter ablation. Nonetheless, observational data suggest that the stroke risk may be lower 2559 
after catheter ablation of AF compared with other AF patients. The ongoing EAST (Early treatment of Atrial 2560 
fibrillation for Stroke prevention Trial) trial will inform in a more general way whether rhythm control therapy 2561 
can reduce stroke rates in anticoagulated AF patients. If confirmed, there may be a place for a controlled trial 2562 
evaluating the termination of OAC therapy at an interval after ‘successful’ catheter ablation.  2563 
 2564 
15.12. Comparison of rate control agents 2565 
Although the use of rate control therapy is very common in AF patients, robust data comparing rate control 2566 
therapies are scant, with the majority of studies being small uncontrolled trials over short periods of follow-up. 2567 
Some studies are funded (e.g. RATE-AF [Rate Control Therapy Evaluation in Permanent Atrial Fibrillation]559) 2568 
and will investigate the potential benefits of different rate controlling agents, characteristics, or biomarkers that 2569 
can help to personalize the use of rate control, and the adverse-event profile of specific drugs in defined groups 2570 
of patients (e.g. AF with HFrEF). 2571 
 2572 
15.13. Catheter ablation in persistent and long-standing persistent AF 2573 
While a few recent randomized studies support the use of catheter or surgical ablation in patients with persistent 2574 
AF and long-standing persistent AF, there is a clear need for more data evaluating this intervention in 2575 
adequately powered randomized trials.  2576 
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 2577 
15.14. Optimal technique for repeat catheter ablation 2578 
PVI emerges as the most important target for catheter ablation of AF. Although a plethora of different additional 2579 
ablation techniques have been published, their added value is questionable in patients undergoing a first catheter 2580 
ablation, including those with persistent AF.735 Many patients are in need of multiple catheter-ablation 2581 
procedures, and such interventions often follow local or operator-specific protocols without clear evidence to 2582 
support the choice of ablation target or intervention. There is a clear clinical need to define the best approach in 2583 
patients who are in need of a second ablation procedure. 2584 
 2585 
15.15. Combination therapy for maintenance of sinus rhythm  2586 
In the follow-up after initially successful catheter ablation, even when done in experienced centres, many 2587 
patients will experience symptomatic recurrences of AF. These patients are often managed with antiarrhythmic 2588 
drugs. There is a surprising paucity of data evaluating different rhythm control interventions in patients with 2589 
recurrent AF after catheter ablation. Such studies seem reasonable and feasible. 2590 
 2591 
15.16. Can rhythm control therapy convey a prognostic benefit in atrial fibrillation 2592 
patients? 2593 
The progress in rhythm control therapy (catheter ablation, new antiarrhythmic drugs) and observational long-2594 
term analyses suggest that rhythm control therapy may have a prognostic benefit. Ongoing trials such as 2595 
CABANA and EAST – AFNET 4 will provide initial answers to this important question, but more data are 2596 
needed, in addition to trials of surgical ablation techniques.  2597 
 2598 
15.17. Thoracoscopic ‘stand-alone’ atrial fibrillation surgery 2599 
Minimally invasive epicardial ablation surgery for the treatment of stand-alone AF was reported a decade 2600 
ago.1035 The procedure has since evolved towards a totally thoracoscopic procedure,1036 and lesion sets were 2601 
extended to a complete left atrial maze.822 With such rapid development and the coexistence of different 2602 
techniques and lesion sets, scientific evidence on long-term results is still limited. Randomized trials using a 2603 
standardized procedure are urgently needed to clearly define the benefits and risks of thoracoscopic AF ablation, 2604 
and to further support decisions of the AF Heart Team. 2605 
  2606 
15.18. Surgical exclusion of the left atrial appendage 2607 
Exclusion of the LAA has been performed by cardiothoracic surgeons for decades, but prospective randomized 2608 
studies comparing the rate of ischaemic stroke with or without left appendage exclusion are presently lacking. 2609 
The LAAOS (Left Atrial Appendage Occlusion Study) III is currently randomizing cardiac surgery patients with 2610 
AF to undergo concomitant occlusion or no occlusion of the appendage.467 More data are also needed to confirm 2611 
the safety and efficacy of thoracoscopic exclusion, following early positive observational data.1037 2612 
  2613 
15.19. Concomitant atrial fibrillation surgery 2614 
Adequately powered randomized trials are needed, employing systematic follow-up, uniform lesion sets and 2615 
energy sources to evaluate the benefits and risks of concomitant AF surgery in symptomatic AF patients. An 2616 
RCT on non-uniform lesion sets with long-term follow-up is due to publish shortly.1038 These will assist the AF 2617 
Heart Team to decide on optimal therapy for individual patients, including the full repertoire of medical and 2618 
surgical options for the treatment of AF. 2619 
2620 
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16 To do and not to do messages from the Guidelines 2621 
 2622 
Recommendations for diagnosis and screening of AF Class Level 
ECG documentation is required to establish the diagnosis of AF I B 
Opportunistic screening for AF is recommended by pulse taking or ECG rhythm 
strip in patients > 65 years of age I B 
In patients with TIA or ischaemic stroke, screening for AF is recommended by 
short-term ECG recording followed by continuous ECG monitoring for at least 
72 hours 
I B 
It is recommended to interrogate pacemakers and ICDs on a regular basis for 
atrial high rate episodes (AHRE). Patients with AHRE should undergo further 
ECG monitoring to document AF before initiating AF therapy 
I B 
Recommendations for general management of AF Class Level 
Tailored patient education is recommended in all phases of AF management to 
support patients’ perception of AF and to improve management I C 
A full cardiovascular evaluation, including an accurate history, careful clinical 
examination, and assessment of concomitant conditions, is recommended in all 
AF patients 
I C 
Use of the modified EHRA symptom scale is recommended in clinical practice 
and research studies to quantify AF-related symptoms I C 
Transthoracic echocardiography is recommended in all AF patients to guide 
management I C 
The assessment of kidney function by serum creatinine or creatinine clearance is 
recommended in all AF patients to detect kidney disease and to support correct 
dosing of AF therapy 
I A 
Recommendations for stroke prevention in AF Class Level 
The CHA2DS2-VASc score is recommended for stroke risk prediction in patients 
with AF I A 
Oral anticoagulation therapy to prevent thromboembolism is recommended for 
all male AF patients with a CHA2DS2-VASc score of 2 or more 
I A 
Oral anticoagulation therapy to prevent thromboembolism is recommended in all 
female AF patients with a CHA2DS2-VASc score of 3 or more 
I 
 A 
When oral anticoagulation is initiated in a patient with AF who is eligible for a 
non vitamin-K-antagonist oral anticoagulant (NOAC, apixaban, dabigatran, 
edoxaban, or rivaroxaban), a NOAC is recommended in preference to a Vitamin 
K antagonist 
I A 
Vitamin K antagonist therapy (INR 2.0–3.0 or higher) is recommended for stroke 
prevention in AF patients with moderate-to-severe mitral stenosis or mechanical 
heart valves 
I B 
NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are not recommended 
in patients with mechanical heart valves (Level of evidence B) or moderate-to-
severe mitral stenosis (Level of evidence C) 
III (harm) B/C 
When patients are treated with a vitamin K antagonist, time in therapeutic range 
(TTR) should be kept as high as possible and closely monitored I A 
Combinations of oral anticoagulants and platelet inhibitors increase bleeding risk 
and should be avoided in AF patients without another indication for platelet III (harm) B 
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inhibition 
In male or female AF patients without additional stroke risk factors, 
anticoagulant or antiplatelet therapy is not recommended for stroke prevention III (harm) B 
Antiplatelet monotherapy is not recommended for stroke prevention in AF 
patients, regardless of stroke risk III (harm) A 
After surgical occlusion or exclusion of the left atrial appendage, it is 
recommended to continue anticoagulation in at-risk patients with AF for stroke 
prevention 
I B 
Genetic testing before the initiation of vitamin K antagonist therapy is not 
recommended. 
III (no 
benefit) B 
In AF patients with severe active bleeding events, it is recommended to interrupt 
oral anticoagulation therapy until the underlying cause is resolved I C 
NOACs should be avoided in pregnancy and in women planning a pregnancy III (harm) C 
For patients with atrial flutter, antithrombotic therapy is recommended according 
to the same risk profile used for AF I B 
Management of typical atrial flutter with ablation of the cavotricuspid isthmus is 
recommended for patients failing antiarrhythmic drug therapy or as first-line 
treatment considering patient preference 
I B 
Lifelong oral anticoagulation to prevent stroke is recommended in hypertrophic 
cardiomyopathy patients who develop AF I B 
Anticoagulation with heparin or low-molecular-weight heparin immediately after 
ischaemic stroke is not recommended in AF patients III (harm) A 
Systemic thrombolysis with a recombinant tissue plasminogen activator is not 
recommended if the INR is above 1.7 (or, for patients on dabigatran, if activated 
partial thromboplastin time is outside the normal range) 
III (harm) C 
After TIA or stroke, combination therapy of OAC and an antiplatelet is not 
recommended III (harm) B 
Recommendations for rate control of AF Class Level 
Beta-blocker, digoxin, diltiazem, or verapamil is recommended to control heart 
rate in AF patients with LVEF ≥ 40% I B 
Beta-blocker and/or digoxin is recommended to control heart rate in AF patients 
with LVEF < 40%  I B 
In patients with permanent AF (i.e. where no attempt to restore sinus rhythm is 
planned), antiarrhythmic drugs should not routinely be used for rate control III (harm) A 
Recommendations for rhythm control of AF Class Level  
Rhythm control therapy is indicated for symptom improvement in patients with 
AF I B 
Cardioversion of AF (either electrical or pharmacological) is recommended in 
symptomatic patients with persistent or long-standing persistent AF as part of 
rhythm control therapy 
I B 
In patients with no history of ischaemic or structural heart disease, flecainide, 
propafenone, or vernakalant is recommended for pharmacological cardioversion 
of new-onset AF 
I A 
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In patients with ischaemic and/or structural heart disease, amiodarone is 
recommended for cardioversion of AF I A 
For cardioversion of AF/atrial flutter, effective anticoagulation is recommended 
for a minimum of 3 weeks before cardioversion I B 
Transoesophageal echocardiography (TOE) is recommended to exclude cardiac 
thrombus, as an alternative to preprocedural anticoagulation when early 
cardioversion is planned 
I B 
The choice of antiarrhythmic drug needs to be carefully evaluated, taking into 
account the presence of comorbidities, cardiovascular risk and potential for 
serious proarrhythmia, extracardiac toxic effects, patient preferences, and 
symptom burden 
I A 
Dronedarone, flecainide, propafenone, or sotalol is recommended for prevention 
of recurrent symptomatic AF in patients with normal left ventricular function and 
without pathological left ventricular hypertrophy.  
I A 
Dronedarone is recommended for prevention of recurrent symptomatic AF in 
patients with stable coronary artery disease, and without heart failure I A 
Amiodarone is recommended for prevention of recurrent symptomatic AF in 
patients with heart failure I B 
Antiarrhythmic drug therapy is not recommended in patients with prolonged QT 
interval (> 0.5 s) or with significant sinoatrial node disease or atrioventricular 
node dysfunction who do not have a functioning permanent pacemaker 
 
III (harm) 
 
C 
Catheter ablation of symptomatic paroxysmal AF is recommended to improve 
AF symptoms in patients who have symptomatic recurrences of AF on 
antiarrhythmic drug therapy (amiodarone, dronedarone, flecainide, propafenone, 
sotalol) and who prefer further rhythm control therapy, when performed by an 
electrophysiologist who has received appropriate training and is performing the 
procedure in an experienced centre 
I A 
ARBs or ACE inhibitors are not recommended for the secondary prevention of 
paroxysmal AF in patients with little or no underlying heart disease. 
III (no 
benefit) B 
Moderate regular physical activity is recommended to prevent AF, while athletes 
should be counselled that long-lasting, more intense sports participation can 
promote AF 
I A 
 2623 
 2624 
  2625 
Page 88 of 148 ESC AF Guidelines 
 
17 A short summary of the management of AF patients 2626 
 2627 
Here, we provide 17 simple rules to guide diagnosis and management of AF patients according to the 2016 2628 
ESC/EACTS/ESO Guidelines for the management of atrial fibrillation 2629 
 2630 
1. Use ECG screening in at risk populations for atrial fibrillation, especially stroke survivors and the 2631 
Elderly. 2632 
2. Document AF by ECG before starting treatment. 2633 
3. Evaluate all AF patients by clinical evaluation, ECG, and echocardiogram for underlying 2634 
cardiovascular conditions such as hypertension, heart failure, valvular heart disease, and others. 2635 
4. Provide tailored information and education to AF patients to empower them to support AF 2636 
management. 2637 
5. Propose life style changes to all suitable AF patients to make their management more effective. 2638 
6. Treat underlying cardiovascular conditions adequately, e.g. valve repair or replacement in AF patients 2639 
with significant valvular heart disease, treatment of heart failure, or management of hypertension, 2640 
among others. 2641 
7. Use oral anticoagulation in all AF patients unless they are at low risk for stroke based on the 2642 
CHA2DS2VASc score or have true contraindications for anticoagulant therapy. 2643 
8. Anticoagulate patients with atrial flutter similar to atrial fibrillation. Offer isthmus ablation to 2644 
symptomatic flutter patients. 2645 
9. Reduce all modifiable bleeding risk factors in all AF patients on oral anticoagulation, e.g. by treating 2646 
hypertension, minimising the duration and intensity of concomitant antiplatelet and NSAID therapy , 2647 
treating anaemia and eliminating causes for blood loss, maintaining stable INR values in patients on 2648 
vitamin K antagonists, and moderating alcohol intake 2649 
10. Check ventricular rate in all AF patients and use rate control medications to achieve lenient rate 2650 
control. 2651 
11. Evaluate AF-related symptoms in all AF patients using the modified EHRA score. Whenever patients 2652 
have AF-related symptoms, aim to improve symptoms by adjustment of rate control therapy and by 2653 
offering antiarrhythmic drugs, cardioversion, or catheter or surgical ablation. 2654 
12. Select antiarrhythmic drugs based on their safety profile and consider catheter or surgical ablation 2655 
when antiarrhythmic drugs fail. 2656 
13. Do not offer routine genetic testing in AF patients unless there is a suspicion for an inherited cardiac 2657 
condition. 2658 
14. Do not use antiplatelet therapy for stroke prevention in AF. 2659 
15. Do not permanently discontinue oral anticoagulation in AF patients at increased risk of stroke unless 2660 
such a decision is taken by a multidisciplinary team. 2661 
16. Do neither use rhythm control therapy in asymptomatic AF patients, nor in patients with permanent 2662 
AF. 2663 
17. Do not perform cardioversion or catheter ablation without anticoagulation unless an atrial thrombus has 2664 
been ruled out by transesophageal echocardiogram. 2665 
 2666 
  2667 
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 2668 
18 Web Addenda 2669 
All Web figures and Web tables are available in the Web addenda, available at European Heart Journal online 2670 
and also via the ESC Website (www.escardio.org/guidelines). 2671 
 2672 
19 Appendix 2673 
ESC Committee for Practice Guidelines (CPG): Jose Luis Zamorano (Chairperson) (Spain), Victor Aboyans 2674 
(France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Lina Badimon (Spain), Gonzalo Barón-2675 
Esquivias (Spain), Helmut Baumgartner (Germany), Jeroen J. Bax (The Netherlands), Héctor Bueno (Spain), 2676 
Scipione Carerj (Italy), Veronica Dean (France), Çetin Erol (Turkey), Donna Fitzsimons (UK), Oliver 2677 
Gaemperli (Switzerland), Paulus Kirchhof (UK/Germany), Philippe Kolh (Belgium), Patrizio Lancellotti 2678 
(Belgium), Gregory Y. H. Lip (UK), Petros Nihoyannopoulos (UK), Massimo F. Piepoli (Italy), Piotr 2679 
Ponikowski (Poland), Marco Roffi (Switzerland), Adam Torbicki (Poland), António Vaz Carneiro (Portugal), 2680 
Stephan Windecker (Switzerland). 2681 
 2682 
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management of atrial fibrillation developed in collaboration with EACTS  2684 
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